

Please type a plus (+) inside this box - ☒

04-04-00

88 Listing

PTO/SB/29 (12/97)

Approved for use through 09/30/00. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

04/03/00
JC781 U.S. PTO

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	7969-076-999	Total Pages	105
First Named Inventor or Application Identifier			
Jackson			
Express Mail Label No.	EL 394 218 095 US		

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ Fee Transmittal Form
Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages 92]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description of the Invention (including drawings, if filed)
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 USC 113) [Total Sheets 11]
4. ☒ Oath or Declaration (unexecuted) [Total Sheets 02]
 - a. ☐ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
 - i. ☐ DELETION OF INVENTORS(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).
 - c. ☐ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. ☒ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. ☒ Computer Readable Copy
 - b. ☒ Paper Copy (identical to computer copy)
 - c. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement of Power of Attorney (when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☒ Information Disclosure Statement (IDS)/PTO-1449 ☒ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
14. ☐ Small Entity Statement filed in prior application, Statement(s) Status still proper and desired
15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☐ Other:

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: PCT/US98/20737 filed October 1, 1998.

18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label 20583 (Insert Customer No. or Attach bar code label here) or ☐ Correspondence address below

NAME			
ADDRESS			
CITY	STATE	ZIP CODE	
COUNTRY	TELEPHONE	FAX	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

04-04-00
PENNIE & EDMONDS LLP DOCKET NO. 7969-076-999

Express Mail No.: EL 394 218 095 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Prior application: Examiner To Be AssignedArt Unit To Be AssignedAssistant Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

This is a request for filing a ☒ continuation ☐ divisional application under 37 CFR § 1.53(b), of pending prior application no. PCT/US98/20737 filed on October 1, 1998.

of James W. Jackson and John L. Pace
(inventor(s) currently of record in prior application)for CHLAMYDIA PROTEIN, GENE SEQUENCE AND USES THEREOF
(title of invention)

1. ☒ The filing fee is calculated below:

PATENT APPLICATION FEE VALUE


TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	76	-20	56	\$18.00 each	\$ 1,008.00
Independent	7	-3	4	\$78.00 each	\$ 312.00
Basic Fee					\$ 690.00
Multiple Dependency Fee If Applicable (\$260.00)					\$ 260.00
Total					\$ 2,270.00
50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern					- \$ 0.00
Total Filing Fee					\$ 2,270.00

2. ☒ Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.
3. ☒ Amend the specification by inserting before the first line the following sentence: This is a Continuation of Application No. PCT/US98/20737, filed October 1, 1998.
- 4a. ☐ Transfer the drawings from the prior application to this application and abandon the prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.

- 4b. ☐ New formal drawings are enclosed.
- 4c. ☒ Informal drawings are enclosed.
- 5a. ☐ Priority of application no. filed on in is claimed under 35 U.S.C. §119.
- 5b. ☐ The certified copy has been filed in prior application no. , filed .
6. ☐ The prior application is assigned of record to
- 7a. ☐ The Power of Attorney appears in the original papers in the prior application no. , filed .
- 7b. ☐ Since the Power of Attorney does not appear in the original papers, a copy of the Power in prior application no. , filed is enclosed.
8. ☐ This application contains nucleic acid and/or amino acid sequences required to be disclosed in a Sequence Listing under 37 CFR §§1.821-1.825. It is requested that the Sequence Listing in computer readable form from prior application no., filed on be made a part of the present application as provided for by 37 C.F.R. §1.821(e). The sequences disclosed therein are the same as the sequences disclosed in this application. A copy of the paper Sequence Listing from application no. is enclosed.
9. ☐ The undersigned states, under 37 C.F.R. §1.821(f), that the content of the enclosed paper Sequence Listing from application no. is the same as the content of the computer readable form submitted in application no. .
10. ☒ Additional enclosures or instructions: Information Disclosure Statement with List of References Cited (PTO Form 1449) and a copy of References AA-AD; copy of published International Application No. WO99/17741; copy of International Search Report dated March 24, 1999; copy of Written Opinion dated February 29, 2000

Date Monday, April 3, 2000

Respectfully submitted,


 31,232
 Geraldine F. Baldwin (Reg. No.)
PENNIE & EDMONDS LLP
 1155 Avenue of the Americas
 New York, N.Y. 10036-2711
 (212) 790-9090

Express Mail No.: EL 394 218 095 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jackson and Pace

Application No.: To Be Assigned

Group Art Unit: To Be Assigned

Continuation of PCT/US98/20737

Filed: October 1, 1998

Filed: Concurrently herewith

Examiner: To Be Assigned

For: *CHLAMYDIA* PROTEIN, GENE
SEQUENCE AND USES THEREOF

Attorney Docket No.: 7969-076-999

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-identified application, please enter the
amendments below.

IN THE SPECIFICATION:

Please amend the specification on page 1 after the title to recite --This
application is a continuation of PCT/US98/20737 filed October 1, 1998.--

IN THE CLAIMS:

Please amend claims 25, 38 and 39 as follows:

25. (Once Amended) A diagnostic reagent selected from the group consisting
of: the protein of claim 1, the nucleic acid molecule of claim 10, the immunogenic

composition of claim 20, and the antigenic composition of claim 19[, the antisera of claim 23, the vector of claim 12, the transformed cell of claim 14, and the antibodies of claim 24].

38. (Once Amended) The protein of any one of claims 1, 4, or 6[, 16 and 17], wherein the protein binds to heparin or heparan-sulfate.


39. (Once Amended) The protein of any one of claims 1, 4, or 6[, 16 or 17], wherein the protein is an outer membrane protein.

REMARKS

The claims are amended merely to put them into proper format for U.S. practice and avoid improperly multiply dependent claims. No new matter is added.

Respectfully submitted,

Date Monday, April 3, 2000


Geraldine F. Baldwin 31,232
(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

CHLAMYDIA PROTEIN, GENE SEQUENCE AND USES THEREOF

1. FIELD OF THE INVENTION

The present invention generally relates to a high molecular weight ("HMW") protein of *Chlamydia*, the amino acid sequence thereof, and antibodies, including cytotoxic antibodies, that specifically bind the HMW protein. The invention further encompasses prophylactic and therapeutic compositions comprising the HMW protein, a fragment thereof, or an antibody that specifically binds the HMW protein or a portion thereof or the nucleotide sequence encoding the HMW protein or a fragment thereof, including vaccines. The invention additionally provides methods of preventing, treating or ameliorating disorders in mammals and birds related to *Chlamydia* infections and for inducing immune responses to *Chlamydia*. The invention further provides isolated nucleotide sequences and degenerate sequences encoding the HMW protein, vectors having said sequences, and host cells containing said vectors. Diagnostic methods and kits are also included.

2. BACKGROUND OF THE INVENTION

Chlamydia are prevalent human pathogens causing disorders such as sexually transmitted diseases, respiratory diseases including pneumonia, neonatal conjunctivitis, and blindness. *Chlamydia* are obligate intracellular bacteria that infect the epithelial lining of the lung, conjunctivae or genital tract. The most common species of *Chlamydia* include *Chlamydia trachomatis*, *Chlamydia psittaci*, *Chlamydia pecorum* and *Chlamydia pneumoniae*. Recently, the newly designated species of *Chlamydia*, *C. pneumoniae* (formerly *C. trachomatis* TWAR), has been implicated as a major cause of epidemic human pneumonitis and perhaps may play a role in atherosclerosis.

There are currently 18 recognized *C. trachomatis* serovars, causing trachoma and a broad spectrum of sexually transmitted diseases: with the A, B and C serovars being most

frequently associated with trachoma, while the D-K serovars are the most common cause of genital infections.

C. trachomatis is the major cause of sexually transmitted disease in many industrialized countries, including the United States. While the exact incidence of *C. trachomatis* infection in the U.S. is not known, current epidemiological studies indicate that more than 4 million chlamydial infections occur each year, compared to an estimated 2 million gonococcal infections. While all racial, ethnic and socioeconomic groups are affected, the greatest prevalence of chlamydial infections occur among young, 12 to 20 year-old, sexually active individuals. Most genitourinary chlamydial infections are clinically asymptomatic. Prolonged carriage in both men and women is common. As many as 25% of men and 75% of women diagnosed as having chlamydial infections have no overt signs of infection. As a consequence, these asymptomatic individuals constitute a large reservoir that can sustain transmission of the agent within the community.

Far from being benign, serious disease can develop from these infections including: urethritis, lymphogranuloma venereum (LGV), cervicitis, and epididymitis in males. Ascending infections from the endocervix commonly gives rise to endometritis, pelvic inflammatory disease (PID) and salpingitis which can cause tubal occlusion and lead ultimately to infertility.

C. trachomatis infection of neonates results from perinatal exposure to the mother's infected cervix. Nearly 70% of neonates born vaginally to mothers with chlamydial cervicitis become infected during delivery. The mucus membranes of the eye, oropharynx, urogenital tract and rectum are the primary sites of infection. Chlamydial conjunctivitis has become the most common form of ophthalmia neonatorum. Approximately 20-30% of exposed infants develop inclusion conjunctivitis within 14 days of delivery even after receiving prophylaxis with either silver nitrate or antibiotic ointment. *C. trachomatis* is also the leading cause

of infant pneumonia in the United States. Nearly 10-20% of neonates delivered through an infected cervix will develop chlamydial pneumonia and require some type of medical intervention.

5 In developing countries, ocular infections of *C. trachomatis* cause trachoma, a chronic follicular conjunctivitis where repeated scar formation leads to distortion of the eyelids and eventual loss of sight. Trachoma is the world's leading cause of preventable
10 blindness. The World Health Organization estimates that over 500 million people worldwide, including about 150 million children, currently suffer from active trachoma and over 6 million people have been blinded by this disease.

In industrialized countries, the costs associated
15 with treating chlamydial infections are enormous. In the U.S., the annual cost of treating these diseases was estimated at \$2.5-3 billion in 1992 and has been projected to exceed \$8 billion by the year 2000.

One potential solution to this health crisis would
20 be an effective chlamydial vaccine. Several lines of evidence suggest that developing an effective vaccine is feasible.

Studies in both humans and primates have shown that short-term protective immunity to *C. trachomatis* can be
25 produced by vaccinating with whole *Chlamydia*. However, protection was characterized as short lived, serovar specific, and due to mucosal antibody. Additionally, in some vaccinees disease was exacerbated when these individuals became naturally infected with a serovar different from that
30 used for immunization. This adverse reaction was ultimately demonstrated to be due to a delayed-type hypersensitivity response. Thus, the need exists to develop a subunit-based chlamydial vaccine capable of producing an efficacious but nonsensitizing immune response. Such a subunit vaccine may
35 need to elicit both mucosal neutralizing secretory IgA antibody and/or cellular immune response to be efficacious.

002040-0224500

Subunit vaccine development efforts to date have focused almost exclusively on the major outer membrane protein (MOMP). MOMP is an integral membrane protein of approximately 40 kDa in size and comprises up to about 60% of the infectious elementary body (EB) membrane protein (Caldwell, H.D., J.Kromhout, and L.Schachter. 1981. Infect. Immun., 31:1161-1176). MOMP imparts structural integrity to the extracellular EB and is thought to function as a porin-like molecule when the organism is growing intracellularly and is metabolically active. With the exception of four surface exposed variable domains (VDI-VDIV), MOMP is highly conserved among all 18 serovars. MOMP is highly immunogenic and can elicit a local neutralizing anti-Chlamydia antibody. However, problems exists with this approach.

To date, most MOMP-specific neutralizing epitopes that have been mapped are located within the VD regions and thus give rise only to serovar-specific antibody. Attempts to combine serovar-specific epitopes in various vaccine vectors (e.g. poliovirus) to generate broadly cross-reactive neutralizing antibodies have been only marginally successful (Murdin, A.D., H. Su, D.S. Manning, M.H. Klein, M.J. Parnell, and H.D. Caldwell. 1993. Infect. Immun., 61:4406-4414; Murdin, A.D., H. Su, M.H. Klein, and H.D. Caldwell. 1995. Infect. Immun., 63:1116-1121).

Two other major outer membrane proteins in *C. trachomatis*, the 60 kDa and 12 kDa cysteine-rich proteins, as well as the surface-exposed lipopolysaccharide, are highly immunogenic but, unlike MOMP, have not been shown to induce a neutralizing antibody (Cerrone et al., 1991, Infect. Immun., 59:79-90). Therefore, there remains a need for a novel subunit-based chlamydial vaccine.

3. SUMMARY OF THE INVENTION

An object of the present invention is to provide an isolated and substantially purified high molecular weight protein of a *Chlamydia* sp. ("HMW protein"), wherein the HMW protein has an apparent molecular weight of about 105-115

5 kDa, as determined by SDS-PAGE, or a fragment or analogue thereof. Preferably the HMW protein has substantially the amino acid sequence of any of SEQ ID Nos.: 2, 15 and 16.

Preferred fragments of the HMW protein include SEQ ID Nos: 3,
5 17, and 25-37. As used herein, "substantially the sequence" is intended to mean that the sequence is at least 80%, more preferably at least 90% and most preferably at least 95% identical to the referenced sequence. Preferably, the HMW protein is an outer membrane protein. More preferably, the
10 outer membrane HMW protein is surface localized. Preferably, the HMW protein has a heparin binding domain. Preferably, the HMW Protein has a porin-like domain. It is intended that all species of *Chlamydia* are included in this invention, however preferred species include *Chlamydia trachomatis*,
15 *Chlamydia psittaci*, *Chlamydia percorum* and *Chlamydia pneumoniae*. The substantially purified HMW protein is at least 70 wt% pure, preferably at least about 90 wt% pure, and may be in the form of an aqueous solution thereof.

Also included in this invention are recombinant
20 forms of the HMW protein, wherein in transformed *E. coli* cells, the expressed recombinant form of the HMW protein has an apparent molecular weight of about 105-115 kDa, as determined by SDS-PAGE, or a fragment or analogue thereof. The term HMW-derived polypeptide is intended to include
25 fragments of the HMW protein; variants of wild-type HMW protein or fragment thereof, containing one or more amino acid deletions, insertions or substitutions; and chimeric proteins comprising a heterologous polypeptide fused to the C-terminal or N-terminal or internal segment of a whole or a
30 portion of the HMW protein.

As used herein and in the claims, the term "HMW protein" refers to a native purified or recombinant purified high molecular weight protein of a species of *Chlamydia* wherein the apparent molecular weight (as determined by SDS-
35 PAGE) is about 105-115 kDa. As used herein and in the claims, the term "rHMW protein" refers to recombinant HMW protein.

Another object of the present invention is to provide an isolated substantially pure nucleic acid molecule encoding a HMW protein or a fragment or an analogue thereof. Preferred is the nucleic acid sequence wherein the encoded

5 HMW protein comprises the amino acid sequence of any of SEQ ID Nos.: 2, 15 and 16, or a fragment thereof, particularly SEQ ID Nos.: 3, 17, 25-37. Also included is an isolated nucleic acid molecule comprising a DNA sequence of any of SEQ ID Nos.: 1, 23-24 or a complementary sequence thereof; a

10 fragment of the HMW DNA sequence having the nucleic acid sequence of any of SEQ ID Nos.: 4-14, 18-22 or the complimentary sequence thereto; and a nucleic acid sequence which hybridizes under stringent conditions to any one of the sequences described above. The nucleic acid that hybridizes

15 under stringent condition preferably has a sequence identity of about 70 % with any of the sequences identified above, more preferably about 90 %.

The production and use of derivatives and analogues of the HMW protein are within the scope of the present

20 invention. In a specific embodiment, the derivative or analogue is functionally active, i.e., capable of exhibiting one or more functional activities associated with a full-length, wild-type HMW protein. As one example, such derivatives or analogues which have the desired

25 immunogenicity or antigenicity can be used, for example, in immunoassays, for immunization, etc. A specific embodiment relates to a HMW fragment that can be bound by an anti-HMW antibody. Derivatives or analogues of HMW can be tested for the desired activity by procedures known in the art.

30 In particular, HMW derivatives can be made by altering HMW sequences by substitutions, additions or deletions that provide for functionally equivalent molecules. Due to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid

35 sequence as a HMW gene may be used in the practice of the present invention. These include but are not limited to nucleotide sequences comprising all or portions of genes

which are altered by the substitution of different codons that encode a functionally equivalent amino acid residue within the sequence, thus producing a silent change.

Likewise, the HMW derivatives of the invention include, but are not limited to, those containing, as a primary amino acid sequence, all or part of the amino acid sequence of a HMW protein including altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a silent change. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

In a specific embodiment of the invention, proteins consisting of or comprising a fragment of a HMW protein consisting of at least 6 (continuous) amino acids of the HMW protein is provided. In other embodiments, the fragment consists of at least 7 to 50 amino acids of the HMW protein. In specific embodiments, such fragments are not larger than 35, 100 or 200 amino acids. Derivatives or analogues of HMW include but are not limited to those molecules comprising regions that are substantially homologous to HMW or fragments thereof (e.g., in various embodiments, at least 60% or 70% or 80% or 90% or 95% identity over an amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art) or whose encoding nucleic acid is capable

of hybridizing to a coding HMW sequence, under stringent, moderately stringent, or nonstringent conditions.

By way of example and not limitation, useful computer homology programs include the following: Basic

5 Local Alignment Search Tool (BLAST) (www.ncbi.nlm.nih.gov) (Altschul et al., 1990, J. of Molec. Biol., 215:403-410, "The BLAST Algorithm; Altschul et al., 1997, Nuc. Acids Res. 25:3389-3402) a heuristic search algorithm tailored to searching for sequence similarity which ascribes significance
10 using the statistical methods of Karlin and Altschul 1990, Proc. Nat'l Acad. Sci. USA, 87:2264-68; 1993, Proc. Nat'l Acad. Sci. USA 90:5873-77. Five specific BLAST programs perform the following tasks:

1) The BLASTP program compares an amino acid query
15 sequence against a protein sequence database.

2) The BLASTN program compares a nucleotide query sequence against a nucleotide sequence database.

3) The BLASTX program compares the six-frame conceptual translation products of a nucleotide query
20 sequence (both strands) against a protein sequence database.

4) The TBLASTN program compares a protein query sequence against a nucleotide sequence database translated in all six reading frames (both strands).

5) The TBLASTX program compares the six-frame
25 translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

Smith-Waterman (database: European Bioinformatics Institute wwwz.ebi.ac.uk/bic_sw/) (Smith-Waterman, 1981, J. of Molec. Biol., 147:195-197) is a mathematically rigorous
30 algorithm for sequence alignments.

FASTA (see Pearson et al., 1988, Proc. Nat'l Acad. Sci. USA, 85:2444-2448) is a heuristic approximation to the Smith-Waterman algorithm. For a general discussion of the procedure and benefits of the BLAST, Smith-Waterman and FASTA
35 algorithms see Nicholas et al., 1998, "A Tutorial on Searching Sequence Databases and Sequence Scoring Methods" (www.psc.edu) and references cited therein.

cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH₄; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

- 5 In addition, analogues and derivatives of HMW can be chemically synthesized. For example, a peptide corresponding to a portion of a HMW protein which comprises the desired domain, or which mediates the desired activity in vitro, can be synthesized by use of a peptide synthesizer.
- 10 Furthermore, if desired, nonclassical amino acids or chemical amino acid analogues can be introduced as a substitution or addition into the HMW sequence. Non-classical amino acids include but are not limited to the D-isomers of the common amino acids, α -amino isobutyric acid, 4-aminobutyric acid,
- 15 Abu, 2-amino butyric acid, γ -Abu, ϵ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, β -alanine, fluoro-amino
- 20 acids, designer amino acids such as β -methyl amino acids, C α -methyl amino acids, N α -methyl amino acids, and amino acid analogues in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

- Another object of the invention is to provide a
- 25 recombinant expression vector adapted for transformation of a host or for delivery of a HMW protein to a host comprising the nucleic acid molecule of SEQ ID No.: 1, 23 or 24 or any fragment thereof. Preferably, the recombinant expression vector is adapted for transformation of a host and comprises
- 30 an expression means operatively coupled to the nucleic acid molecule for expression by the host of said HMW protein or the fragment or analogue thereof. More preferred is the expression vector wherein the expression means includes a nucleic acid portion encoding a leader sequence for secretion
- 35 from the host or an affinity domain coupled to either the N- or C-terminus of the protein or the fragment or analogue thereof.

A further aspect of the invention includes a transformed host cell containing an expression vector described above and the recombinant HMW protein or fragment or analogue thereof producible by the transformed host cell.

5 Still a further aspect of the invention is directed to a HMW protein recognizable by an antibody preparation that specifically binds to a peptide having the amino acid sequence of SEQ ID No. 2, 15-16 or a fragment or conservatively substituted analogue thereof.

10 Antigenic and/or immunogenic compositions are another aspect of the invention wherein the compositions comprise at least one component selected from the following group:

- 15 a) a HMW protein, wherein the molecular weight is about 105-115 kDa, as determined by SDS-PAGE, or a fragment or analogue thereof;
- b) an isolated nucleic acid molecule encoding a HMW protein, or a fragment or analogue thereof;
- 20 c) an isolated nucleic acid molecule having the sequence of SEQ ID Nos. 1, 22, 23 or 24, the complimentary sequence thereto or a nucleic acid sequence which hybridizes under stringent conditions thereto or fragment thereof;
- 25 d) an isolated recombinant HMW protein, or fragment or analogue thereof, producible in a transformed host comprising an expression vector comprising a nucleic acid molecule as defined in b) or c) and expression means
- 30 operatively coupled to the nucleic acid molecule for expression by the host of said HMW protein or the fragment or analogue thereof;
- 35 e) a recombinant vector comprising a nucleic acid encoding a HMW protein or fragment or analogue thereof;

- f) a transformed cell comprising the vector of e) and optionally an adjuvant, and a pharmaceutically acceptable carrier or diluent therefor, said composition producing an immune response when administered to a host.

Preferred adjuvants include cholera holotoxin or subunits, *E. coli* heat labile holotoxin, subunits and mutant forms thereof, alum, QS21, and MPL. Particularly, preferred are alum, LTR192G, mLT and QS21.

- Also included are methods for producing an immune response in a mammal or a bird comprising administering to said mammal, an effective amount of the antigenic or the immunogenic composition described above.

- Another aspect of the invention is directed to antisera raised against the antigenic or immunogenic composition of the invention, and antibodies present in the antisera that specifically bind a HMW protein or a fragment or analogue thereof. Preferably the antibodies bind a HMW protein having the amino acid sequence of SEQ ID Nos.: 2, 15-16 or fragment or a conservatively substituted analogue thereof. Also included are monoclonal antibodies that specifically bind a HMW protein or a fragment or analogue thereof.

- A further aspect of the invention includes pharmaceutical and vaccine compositions comprising an effective amount of at least one component selected from the following group:

- a) a HMW protein, wherein the isolated protein molecular weight is about 105-115 kDa, as determined by SDS-PAGE, or a fragment or analogue thereof;
- b) an isolated nucleic acid molecule encoding a HMW protein, or a fragment or analogue thereof;
- c) an isolated nucleic acid molecule having the sequence of SEQ ID Nos.: 1, 22, 23 or 24 the complimentary sequence thereto or a nucleic

- b) detecting the presence of or measuring the amount of said immunocomplexes formed during step a) as an indication of the presence of said *Chlamydia* or anti-*Chlamydia* antibodies in the test sample.

5 The diagnostic kits for detecting *Chlamydia* or antibodies thereto comprise antibodies, or an antigenic or immunogenic composition comprising *Chlamydia* HMW protein or a fragment or analogue thereof, a container means for contacting said
10 antibodies or composition with a test sample suspected of having anti-*Chlamydia* antibodies or *Chlamydia* and reagent means for detecting or measuring *Chlamydia* antigen: anti-*Chlamydia* antibody immunocomplexes formed between said
15 antigenic or immunogenic composition or said antibodies and said test sample.

A further aspect of the present invention provides methods for determining the presence of nucleic acids encoding a HMW protein or a fragment or analogue thereof in a test sample, comprising the steps of:

- 20 a) contacting the test sample with the nucleic acid molecule provided herein to produce duplexes comprising the nucleic acid molecule and any said nucleic acid molecule encoding the HMW protein in the test sample and specifically hybridizable therewith; and
25 b) determining the production of duplexes.

The present invention also provides a diagnostic kit and reagents therefor, for determining the presence of nucleic acid encoding a HMW protein or fragment or analogue
30 thereof in a sample, comprising:

- a) the nucleic acid molecule as provided herein;
b) means for contacting the nucleic acid with the test sample to produce duplexes comprising the nucleic acid molecule and any said nucleic acid molecule encoding the HMW protein in the
35 test sample and specifically hybridizable therewith; and

c) means for determining the production of duplexes.

Also included in this invention are methods of preventing, treating or ameliorating disorders related to *Chlamydia* in an animal including mammals and birds in need of such treatment comprising administering an effective amount of the pharmaceutical or vaccine composition of the invention. Preferred disorders include a *Chlamydia* bacterial infection, trachoma, conjunctivitis, urethritis, lymphogranuloma venereum (LGV), cervicitis, epididymitis, or endometritis, pelvic inflammatory disease (PID), salpingitis, tubal occlusion, infertility, cervical cancer, and atherosclerosis. Preferred vaccine or pharmaceutical compositions include those formulated for *in vivo* administration to a host to confer protection against disease or treatment therefor caused by a species of *Chlamydia*. Also preferred are compositions formulated as a microparticle, capsule, liposome preparation or emulsion.

4. ABBREVIATIONS

anti-HMW	=	HMW polypeptide antibody or antiserum
ATCC	=	American Type Culture Collection
immuno-reactive	=	capable of provoking a cellular or humoral immune response
kDa	=	kilodaltons
OG	=	n-octyl β -D-glucopyranoside or octyl glucoside
OMP	=	outer membrane protein
OMPs	=	outer membrane proteins
PBS	=	phosphate buffered saline
PAGE	=	polyacrylamide gel electrophoresis
polypeptide	=	a peptide of any length, preferably one having ten or more amino acid residues
SDS	=	sodium dodecylsulfate

SDS-PAGE = sodium dodecylsulfate polyacrylamide
gel electrophoresis

Nucleotide or nucleic acid sequences defined herein
are represented by one-letter symbols for the bases as
5 follows:

- A (adenine)
- C (cytosine)
- G (guanine)
- T (thymine)
- 10 U (uracil)
- M (A or C)
- R (A or G)
- W (A or T/U)
- S (C or G)
- 15 Y (C or T/U)
- K (G or T/U)
- V (A or C or G; not T/U)
- H (A or C or T/U; not G)
- D (A or G or T/U; not C)
- 20 B (C or G or T/U; not A)
- N (A or C or G or T/U) or (unknown)

Peptide and polypeptide sequences defined herein
are represented by one-letter symbols for amino acid residues
25 as follows:

- A (alanine)
- R (arginine)
- N (asparagine)
- D (aspartic acid)
- 30 C (cysteine)
- Q (glutamine)
- E (glutamic acid)
- G (glycine)
- H (histidine)
- 35 I (isoleucine)
- L (leucine)

- K (lysine)
M (methionine)
F (phenylalanine)
P (proline)
5 S (serine)
T (threonine)
W (tryptophan)
Y (tyrosine)
V (valine)
10 X (unknown)

The present invention may be more fully understood by reference to the following detailed description of the invention, non-limiting examples of specific embodiments of
15 the invention and the appended figures.

5. BRIEF DESCRIPTION OF THE FIGURES

20 **Figure 1:** Western blot analysis of *C. trachomatis* L₂ elementary bodies (EBs).
Gradient purified EBs were solubilized in standard Laemmli SDS-PAGE sample buffer containing 2-mercaptoethanol, boiled for ~3
25 minutes and loaded onto a 4-12% Tris-glycine gradient gel containing SDS and electrophoresed at 100V. Immediately following electrophoresis, proteins were electroblotted onto PVDF membranes at 4°C for ~2.5 hours at ~50V. The blocked membrane was
30 probed using a 1/5,000 dilution of anti-rHMWP' antibody (K196) for 1.5 hours at room temperature. Following washing, the membrane was treated with a 1/5,000 dilution of a goat anti-rabbit IgG antibody conjugated to HRP for
35 1 hour at room temperature. The blot was developed using a standard TMB substrate system.

Three immunoreactive bands detected in EBs and RBs. Dot indicates HMW Protein of about 105-115 kDa.

Figure 2.

Consensus Nucleic Acid Sequence encoding the open reading frame of the HMW protein from *C. trachomatis* LGV L₂.

Figure 3.

Deduced Amino Acid Sequence of the HMW protein from the PCR open reading frame from *C. trachomatis* LGV L₂.

Figure 4.

SDS-PAGE of partially purified recombinant HMW protein from *C. trachomatis* LGV L₂ expressed in *E. coli*. Counterstained and prestained SDS-PAGE standards were used as molecular weight markers. The positions of the molecular weight markers in the gel are noted on the left and right side of the figure by lines to the molecular weights (kDa) of some of the markers. See Text Example 10 for details.

Lane A: Mark 12 Wide Range Molecular Weight Markers (Novex); myosin, 200 Kdal; B-galactosidase, 116.3 Kdal; phosphorylase B, 97.4 Kdal; bovine serum albumin, 66.3 Kdal.

Lane B: *C. trachomatis* L2 recombinant HMWP.

Lane C: SeeBlue Prestained Molecular Weight markers (Novex); myosin, 250 Kdal; bovine serum albumin, 98 Kdal; glutamic dehydrogenase, 64 Kdal.

Figure 5.

Map of plasmids pAH306, pAH310, pAH312, pAH316 and the PCR open reading frame.

Figure 6.

Predicted amino acid sequences, of HMW Protein for *C. trachomatis* L₂, B, and F.

The *C. trachomatis* L2 sequence is given in the top line and begins with the first residue of the mature protein, E. Potential eucaryotic N-glycosylation sequences are underlined. A hydrophobic helical region flanked by proline-rich segments and of suitable length to span

5 Figure 7

the lipid bilayer is underlined and enclosed in brackets. Amino acid differences identified in the B and F serovars are designated below the L₂ HMWP protein sequence. Indirect florescence antibody staining of *C. trachomatis* N11 (serovar F) inclusion bodies using anti-rHMWP' antibody.

10

Panel A: Post-immunization sera from rabbit K196. *Chlamydia* inclusion bodies are stained yellow.

Panel B: Pre-immunization sera from rabbit K196.

6. DETAILED DESCRIPTION OF THE INVENTION

15

The term "antigens" and its related term "antigenic" as used herein and in the claims refers to a substance that binds specifically to an antibody or T-cell receptor. Preferably said antigens are immunogenic.

20

The term "immunogenic" as used herein and in the claims refers to the ability to induce an immune response, e.g., an antibody and/or a cellular immune response in a animal, preferably a mammal or a bird.

25

The term "host" as used herein and in the claims refers to either *in vivo* in an animal or *in vitro* in mammalian cell cultures.

30

An effective amount of the antigenic, immunogenic, pharmaceutical, including, but not limited to vaccine, composition of the invention should be administered, in which "effective amount" is defined as an amount that is sufficient to produce a desired prophylactic, therapeutic or ameliorative response in a subject, including but not limited to an immune response. The amount needed will vary depending upon the immunogenicity of the HMW protein, fragment, nucleic acid or derivative used, and the species and weight of the subject to be administered, but may be ascertained using standard techniques. The composition elicits an immune response in a subject which produces antibodies, including

anti-HMW protein antibodies and antibodies that are opsonizing or bactericidal. In preferred, non-limiting, embodiments of the invention, an effective amount of a composition of the invention produces an elevation of antibody titer to at least three times the antibody titer prior to administration. In a preferred, specific, non-limiting embodiment of the invention, approximately 0.01 to 2000 μ g and preferably 0.1 to 500 μ g are administered to a host. Preferred are compositions additionally comprising an adjuvant.

Immunogenic, antigenic, pharmaceutical and vaccine compositions may be prepared as injectables, as liquid solutions or emulsions. The HMW protein may be mixed with one or more pharmaceutically acceptable excipient which is compatible with the HMW protein. Such excipients may include, water, saline, dextrose, glycerol, ethanol, and combinations thereof.

Immunogenic, antigenic, pharmaceutical and vaccine compositions may further contain one or more auxiliary substance, such as wetting or emulsifying agents, pH buffering agents, or adjuvants to enhance the effectiveness thereof. Immunogenic, antigenic, pharmaceutical and vaccine compositions may be administered parenterally, by injection, subcutaneously or intramuscularly.

Alternatively, the immunogenic, antigenic, pharmaceutical and vaccine compositions formed according to the present invention, may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces. Thus, the immunogenic, antigenic, pharmaceutical and vaccine compositions may be administered to mucosal surfaces by, for example, the nasal, oral (intragastric), ocular, branchiolar, intravaginal or intrarectal routes. Alternatively, other modes of administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example, polyalkalene glycols or triglycerides. Oral formulations may include normally employed incipients such as, for example, pharmaceutical

grades of saccharine, cellulose and magnesium carbonate. These compositions can take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain about 0.001 to 95% of the
5 HMW protein. The immunogenic, antigenic, pharmaceutical and vaccine compositions are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective, protective or immunogenic.

Further, the immunogenic, antigenic, pharmaceutical
10 and vaccine compositions may be used in combination with or conjugated to one or more targeting molecules for delivery to specific cells of the immune system, such as the mucosal surface. Some examples include but are not limited to vitamin B12, bacterial toxins or fragments thereof,
15 monoclonal antibodies and other specific targeting lipids, proteins, nucleic acids or carbohydrates.

The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize antibodies,
20 and if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of 0.1 to 1000
25 micrograms of the HMW protein, fragment or analogue thereof. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations. The dose may also depend on the route(s) of administration and will vary
30 according to the size of the host.

The concentration of the HMW protein in an antigenic, immunogenic or pharmaceutical composition according to the invention is in general about 0.001 to 95%. A vaccine which contains antigenic material of only one
35 pathogen is a monovalent vaccine. Vaccines which contain antigenic material of several pathogens are combined vaccines and also belong to the present invention. Such combined

vaccines contain, for example, material from various pathogens or from various strains of the same pathogen, or from combinations of various pathogens.

5 The antigenic, immunogenic or pharmaceutical preparations, including vaccines, may comprise as the immunostimulating material a nucleotide vector comprising at least a portion of the gene encoding the HMW protein, or the at least a portion of the gene may be used directly for immunization.

10 To efficiently induce humoral immune responses (HIR) and cell-mediated immunity (CMI), immunogens are typically emulsified in adjuvants. Immunogenicity can be significantly improved if the immunogen is co-administered with an adjuvant. Adjuvants may act by retaining the
15 immunogen locally near the site of administration to produce a depot effect facilitating a slow, sustained release of antigen to cells of the immune system. Adjuvants can also attract cells of the immune system to an immunogen depot and stimulate such cells to elicit immune responses.

20 Many adjuvants are toxic, inducing granulomas, acute and chronic inflammations (Freund's complete adjuvant, FCA), cytotoxicity (saponins and Pluronic polymers) and pyrogenicity, arthritis and anterior uveitis (LPS and MDP). Although FCA is an excellent adjuvant and widely used in
25 research, it is not licensed for use in human or veterinary vaccines because of its toxicity.

Desirable characteristics of ideal adjuvants include:

- 30 (1) lack of toxicity;
(2) ability to stimulate a long-lasting immune response;
(3) simplicity of manufacture and stability in long-term storage;
(4) ability to elicit either CMI or HIR or both to
35 antigens administered by various routes, if required;
(5) synergy with other adjuvants;

(6) capability of selectively interacting with populations of antigen presenting cells (APC);

(7) ability to specifically elicit appropriate T_H1 or T_H2 cell-specific immune responses; and

5 (8) ability to selectively increase appropriate antibody isotype levels (for example, IgA) against antigens.

Immunostimulatory agents or adjuvants have been used for many years to improve the host immune responses to, for example, vaccines. Intrinsic adjuvants, such as
10 lipopolysaccharides, normally are the components of the killed or attenuated bacteria used as vaccines. Extrinsic adjuvants are immunomodulators which are typically non-covalently linked to antigens and are formulated to enhance the host immune responses. Thus, adjuvants have been
15 identified that enhance the immune response to antigens delivered parenterally. Aluminum hydroxide and aluminum phosphate (collectively commonly referred to as alum) are routinely used as adjuvants in human and veterinary vaccines. The efficacy of alum in increasing antibody responses to
20 diphtheria and tetanus toxoids is well established and a HBsAg vaccine has been adjuvanted with alum.

Other extrinsic adjuvants may include saponins complexed to membrane protein antigens (immune stimulating complexes), pluronic polymers with mineral oil, killed
25 mycobacteria in mineral oil, Freund's complete adjuvant, bacterial products, such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS), as well as lipid A, and liposomes.

International Patent Application, PCT/US95/09005 incorporated herein by reference describes mutated forms of
30 heat labile toxin of enterotoxigenic *E. coli* ("mLT"). U.S. Patent 5,057,540, incorporated herein by reference, describes the adjuvant, Qs21, an HPLC purified non-toxic fraction of a saponin from the bark of the South American tree *Quillaja saponaria* molina 3D-MPL is described in great Britain Patent
35 2,220,211, and is incorporated herein by reference.

U.S. Patent No. 4,855,283 granted to Lockhoff et al on August 8, 1989 which is incorporated herein by reference,

teaches glycolipid analogues including N-glycosylamides, N-glycosylureas and N-glycosylcarbamates, each of which is substituted in the sugar residue by an amino acid, as immunomodulators or adjuvants. Lockhoff reported that N-glycosphospholipids and glyco glycerolipids, are capable of eliciting strong immune responses in both herpes simplex virus vaccine and pseudorabies virus vaccine. Some glycolipids have been synthesized from long chain-alkylamines and fatty acids that are linked directly with the sugars through the anomeric carbon atom, to mimic the functions of the naturally occurring lipid residues.

U.S. Patent No. 4,258,029 granted to Moloney, incorporated herein by reference thereto, teaches that octadecyl tyrosine hydrochloride (OTH) functioned as an adjuvant when complexed with tetanus toxoid and formalin inactivated type I, II and III poliomyelitis virus vaccine. Lipidation of synthetic peptides has also been used to increase their immunogenicity.

Therefore, according to the invention, the immunogenic, antigenic, pharmaceutical, including vaccine, compositions comprising a HMW protein, or a fragment or derivative thereof or a HMW encoding nucleic acid or fragment thereof or vector expressing the same, may further comprise an adjuvant, such as, but not limited to alum, mLT, QS21 and all those listed above. Preferably, the adjuvant is selected from alum, LT, 3D-mPL, or Bacille Calmette-Guerine (BCG) and mutated or modified forms of the above, particularly mLT and LTR192G. The compositions of the present invention may also further comprise a suitable pharmaceutical carrier, including but not limited to saline, bicarbonate, dextrose or other aqueous solution. Other suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field, which is incorporated herein by reference in its entirety.

Immunogenic, antigenic and pharmaceutical, including vaccine, compositions may be administered in a suitable, nontoxic pharmaceutical carrier, may be comprised

in microcapsules, and/or may be comprised in a sustained release implant.

Immunogenic, antigenic and pharmaceutical, including vaccine, compositions may desirably be administered at several intervals in order to sustain antibody levels, and/or may be used in conjunction with other bacteriocidal or bacteriostatic methods.

As used herein and in the claims, "antibodies" of the invention may be obtained by any conventional methods known to those skilled in the art, such as but not limited to the methods described in Antibodies A Laboratory Manual (E. Harlow, D. Lane, Cold Spring Harbor Laboratory Press, 1989) which is incorporated herein by reference in its entirety. The term "antibodies" is intended to include all forms, such as but not limited to polyclonal, monoclonal, purified IgG, IgM, IgA and fragments thereof, including but not limited to fragments such as Fv, single chain Fv (scFv), F(ab')₂, Fab fragments (Harlow and Leon, 1988, Antibody, Cold Spring Harbor); single chain antibodies (U.S. Patent No. 4,946,778) chimeric or humanized antibodies (Morrison et al., 1984, Proc. Nat'l Acad. Sci. USA 81:6851); Neuberger et al., 1984, Nature 81:6851) and complementary determining regions (CDR), (see Verhoeven and Windust, in Molecular Immunology 2ed., by B.D. Hames and D.M. Glover, IRL Press, Oxford University Press, 1996, at pp. 283-325), etc.

In general, an animal (a wide range of vertebrate species can be used, the most common being mice, rats, guinea pig, bovine, pig, hamsters, sheep, birds and rabbits) is immunized with the HMW protein or nucleic acid sequence or immunogenic fragment or derivative thereof of the present invention in the absence or presence of an adjuvant or any agent that enhances the immunogen's effectiveness and boosted at regular intervals. The animal serum is assayed for the presence of desired antibody by any convenient method. The serum or blood of said animal can be used as the source of polyclonal antibodies.

For monoclonal antibodies, animals are treated as described above. When an acceptable antibody titre is detected, the animal is euthanized and the spleen is aseptically removed for fusion. The spleen cells are mixed with a specifically selected immortal myeloma cell line, and the mixture is then exposed to an agent, typically polyethylene glycol or the like, which promotes the fusion of cells. Under these circumstances fusion takes place in a random selection and a fused cell mixture together with unfused cells of each type is the resulting product. The myeloma cell lines that are used for fusion are specifically chosen such that, by the use of selection media, such as HAT: hypoxanthine, aminopterin, and thymidine, the only cells to persist in culture from the fusion mixture are those that are hybrids between cells derived from the immunized donor and the myeloma cells. After fusion, the cells are diluted and cultured in the selective media. The culture media is screened for the presence of antibody having desired specificity towards the chosen antigen. Those cultures containing the antibody of choice are cloned by limiting dilution until it can be adduced that the cell culture is single cell in origin.

Antigens, Immunogens and Immunoassays

The HMW protein or nucleic acid encoding same, and fragments thereof are useful as an antigen or immunogen for the generation of anti-HMW protein antibodies or as an antigen in immunoassays including enzyme-linked immunosorbent assays (ELISA), radioimmunoassays (RIA) and other non-enzyme linked antibody binding assays or procedures known in the art for the detection of anti-bacterial, anti-*Chlamydia*, and anti-HMW protein antibodies. In ELISA assays, the HMW protein is immobilized onto a selected surface, for example, a surface capable of binding proteins such as the wells of a polystyrene microtiter plate. After washing to remove incompletely absorbed HMW protein, a nonspecific protein solution that is known to be antigenically neutral with

regard to the test sample may be bound to the selected surface. This allows for blocking of nonspecific absorption sites on the immobilizing surface and thus reduces the background caused by nonspecific bindings of antisera onto the surface.

- The immobilizing surface is then contacted with a sample, such as clinical or biological materials, to be tested in a manner conducive to immune complex (antigen/antibody) formation. This may include diluting the sample with diluents, such as solutions of bovine gamma globulin (BGG) and/or phosphate buffered saline (PBS)/Tween. The sample is then allowed to incubate for from 2 to 4 hours, at temperatures such as of the order of about 20° to 37°C. Following incubation, the sample-contacted surface is washed to remove non-immunocomplexed material. The washing procedure may include washing with a solution, such as PBS/Tween or a borate buffer. Following formation of specific immunocomplexes between the test sample and the bound HMW protein, and subsequent washing, the occurrence, and even amount, of immunocomplex formation may be determined by subjecting the immunocomplex to a second antibody having specificity for the first antibody. If the test sample is of human origin, the second antibody is an antibody having specificity for human immunoglobulins and in general IgG.
- To provide detecting means, the second antibody may have an associated activity such as an enzymatic activity that will generate, for example, a color development upon incubating with an appropriate chromogenic substrate. Detection may then be achieved by detecting color generation.
- Quantification may then be achieved by measuring the degree of color generation using, for example, a visible spectrophotometer and comparing to an appropriate standard. Any other detecting means known to those skilled in the art are included.
- Another embodiment includes diagnostic kits comprising all of the essential reagents required to perform a desired immunoassay according to the present invention.

The diagnostic kit may be presented in a commercially packaged form as a combination of one or more containers holding the necessary reagents. Such a kit may comprise HMW protein or nucleic acid encoding same or fragment thereof, a monoclonal or polyclonal antibody of the present invention in combination with several conventional kit components. Conventional kit components will be readily apparent to those skilled in the art and are disclosed in numerous publications, including Antibodies A Laboratory Manual (E. Harlow, D. Lane, Cold Spring Harbor Laboratory Press, 1989) which is incorporated herein by reference in its entirety. Conventional kit components may include such items as, for example, microtitre plates, buffers to maintain the pH of the assay mixture (such as, but not limited to Tris, HEPES, etc.), conjugated second antibodies, such as peroxidase conjugated anti-mouse IgG (or any anti-IgG to the animal from which the first antibody was derived) and the like, and other standard reagents.

20 Nucleic Acids and Uses Thereof

The nucleotide sequences of the present invention, including DNA and RNA and comprising a sequence encoding the HMW protein or a fragment or analogue thereof, may be synthesized using methods known in the art, such as using conventional chemical approaches or polymerase chain reaction (PCR) amplification using convenient pairs of oligonucleotide primers and ligase chain reaction using a battery of contiguous oligonucleotides. The sequences also allow for the identification and cloning of the HMW protein gene from any species of *Chlamydia*, for instance for screening chlamydial genomic libraries or expression libraries.

The nucleotide sequences encoding the HMW protein of the present invention are useful for their ability to selectively form duplex molecules with complementary stretches of other protein genes. Depending on the application, a variety of hybridization conditions may be employed to achieve varying sequence identities. In specific

aspects, nucleic acids are provided which comprise a sequence complementary to at least 10, 15, 25, 50, 100, 200 or 250 nucleotides of the HMW protein gene (Figure 2). In specific embodiments, nucleic acids which hybridize to an HMW protein 5 nucleic acid (e.g. having sequence SEQ ID NO: 1, 23 or 24) under annealing conditions of low, moderate or high stringency conditions.

For a high degree of selectivity, relatively stringent conditions are used to form the duplexes, such as, 10 by way of example and not limitation, low salt and/or high temperature conditions, such as provided by 0.02 M to 0.15 M NaCl at temperatures of between about 50°C to 70°C. For some applications, less stringent hybridization conditions are required, by way of example and not limitation such a 0.15 M 15 to 0.9 M salt, at temperatures ranging from between about 20°C to 55°C. Hybridization conditions can also be rendered more stringent by the addition of increasing amounts of formamide, to destabilize the hybrid duplex. Thus, particular hybridization conditions can be readily 20 manipulated, and will generally be a method of choice depending on the desired results. By way of example and not limitation, in general, convenient hybridization temperatures in the presence of 50% formamide are: 42°C for a probe which is 95 to 100% homologous to the target fragment, 37°C for 90 25 to 95% homology and 32°C for 70 to 90% homology.

Low, moderate and high stringency conditions are well known to those of skill in the art, and will vary predictably depending on the base composition and length of the particular nucleic acid sequence and on the specific 30 organism from which the nucleic acid sequence is derived. For guidance regarding such conditions see, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Press, N.Y., pp. 9.47-9.57; and Ausubel et al., 1989, Current Protocols in 35 Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y. which is incorporate herein, by reference.

Clones in libraries with insert DNA encoding the HMW protein or fragments thereof will hybridize to one or more of the degenerate oligonucleotide probes. Hybridization of such oligonucleotide probes to genomic libraries are
5 carried out using methods known in the art. For example, hybridization with the two above-mentioned oligonucleotide probes may be carried out in 2X SSC, 1.0% SDS at 50°C and washed using the same conditions.

In yet another aspect, clones of nucleotide
10 sequences encoding a part or the entire HMW protein or HMW-derived polypeptides may also be obtained by screening *Chlamydia* expression libraries. For example, *Chlamydia* DNA or *Chlamydia* cDNA generated from RNA is isolated and random fragments are prepared and ligated into an expression vector
15 (e.g., a bacteriophage, plasmid, phagemid or cosmid) such that the inserted sequence in the vector is capable of being expressed by the host cell into which the vector is then introduced. Various screening assays can then be used to select for the expressed HMW protein or HMW-derived
20 polypeptides. In one embodiment, the various anti-HMW antibodies of the invention can be used to identify the desired clones using methods known in the art. See, for example, Harlow and Lane, 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring
25 Harbor, NY, Appendix IV. Clones or plaques from the library are brought into contact with the antibodies to identify those clones that bind.

In an embodiment, colonies or plaques containing DNA that encodes HMW protein or HMW-derived polypeptide could
30 be detected using DYNA Beads according to Olsvick et al., 29th ICAAC, Houston, Tex. 1989, incorporated herein by reference. Anti-HMW antibodies are crosslinked to tosylated DYNA Beads M280, and these antibody-containing beads would then be used to adsorb to colonies or plaques expressing HMW
35 protein or HMW-derived polypeptide. Colonies or plaques expressing HMW protein or HMW-derived polypeptide is identified as any of those that bind the beads.

Alternatively, the anti-HMW antibodies can be nonspecifically immobilized to a suitable support, such as silica or Celite™ resin. This material would then be used to adsorb to bacterial colonies expressing HMW protein or HMW-5 derived polypeptide as described in the preceding paragraph.

In another aspect, PCR amplification may be used to produce substantially pure DNA encoding a part of or the whole of HMW protein from *Chlamydia* genomic DNA.

Oligonucleotide primers, degenerate or otherwise, corresponding to known HMW protein sequences can be used as primers. In particular embodiments, an oligonucleotide, degenerate or otherwise, encoding the peptide having an amino acid sequence of SEQ ID NO: 2, 3 or 15-17 or any portion thereof may be used as the 5' primer. For fragment examples, a 5' primer may be made from any one of the nucleotide sequences of SEQ ID NO: 4-7, 10, 12, 22-24 or any portion thereof. Nucleotide sequences, degenerate or otherwise, that are reverse complements of SEQ ID NO: 11, 13 or 14 may be used as the 3' primer.

PCR can be carried out, e.g., by use of a Perkin-Elmer Cetus thermal cycler and Taq polymerase (Gene Amp™). One can choose to synthesize several different degenerate primers, for use in the PCR reactions. It is also possible to vary the stringency of hybridization conditions used in priming the PCR reactions, to allow for greater or lesser degrees of nucleotide sequence similarity between the degenerate primers and the corresponding sequences in *Chlamydia* DNA. After successful amplification of a segment of the sequence encoding HMW protein, that segment may be molecularly cloned and sequenced, and utilized as a probe to isolate a complete genomic clone. This, in turn, will permit the determination of the gene's complete nucleotide sequence, the analysis of its expression, and the production of its protein product for functional analysis, as described *infra*.

In a clinical diagnostic embodiment, the nucleic acid sequences of the HMW protein genes of the present invention may be used in combination with an appropriate

indicator means, such as a label, for determining hybridization. A wide variety of appropriate indicator means are known in the art, including radioactive, enzymatic or other ligands, such as avidin/biotin and digoxigenin-
5 labelling, which are capable of providing a detectable signal. In some diagnostic embodiments, an enzyme tag such as urease, alkaline phosphatase or peroxidase, instead of a radioactive tag may be used. In the case of enzyme tags, colorimetric indicator substrates are known which can be
10 employed to provide a means visible to the human eye or spectrophotometrically, to identify specific hybridization with samples containing HMW protein gene sequences.

The nucleic acid sequences of the HMW protein genes of the present invention are useful as hybridization probes
15 in solution hybridizations and in embodiments employing solid-phase procedures. In embodiments involving solid-phase procedures, the test DNA (or RNA) from samples, such as clinical samples, including exudates, body fluids (e.g., serum, amniotic fluid, middle ear effusion, sputum, semen,
20 urine, tears, mucus, bronchoalveolar lavage fluid) or even tissues, is absorbed or otherwise affixed to a selected matrix or surface. The fixed, single-stranded nucleic acid is then subjected to specific hybridization with selected probes comprising the nucleic acid sequences of the HMW
25 protein encoding genes or fragments or analogues thereof of the present invention under desired conditions. The selected conditions will depend on the particular circumstances based on the particular criteria required depending on, for example, the G+C contents, type of target nucleic acid,
30 source of nucleic acid, size of hybridization probe etc. Following washing of the hybridization surface so as to remove non-specifically bound probe molecules, specific hybridization is detected, or even quantified, by means of the label. It is preferred to select nucleic acid sequence
35 portions which are conserved among species of *Chlamydia*. The selected probe may be at least 15 bp and may be in the range of about 30 to 90 bp.

Expression of the HMW protein Gene

- Plasmid vectors containing replicon and control sequences which are derived from species compatible with the host cell may be used for the expression of the genes
- 5 encoding the HMW protein or fragments thereof in expression systems. Expression vectors contain all the necessary elements for the transcription and translation of the inserted protein coding sequence. The vector ordinarily carries a replication site, as well as marking sequences
- 10 which are capable of providing phenotype selection in transformed cells. For example, *E. coli* may be transformed using pBR322 which contains genes for ampicillin and tetracycline resistance cells. Other commercially available vectors are useful, including but not limited to pZERO,
- 15 pTrc99A, pUC19, pUC18, pKK223-3, pEX1, pCAL, pET, pSPUTK, pTrxFus, pFastBac, pThioHis, pTrcHis, pTrcHis2, and pLEx. The plasmids or phage, must also contain, or be modified to contain, promoters which can be used by the host cell for expression of its own proteins.
- 20 In addition, phage vectors containing replicon and control sequences that are compatible with the host can be used as a transforming vector in connection with these hosts. For example, the phage in lambda GEM™-11 may be utilized in making recombinant phage vectors which can be used to
- 25 transform host cells, such as *E. coli* LE392.
- Promoters commonly used in recombinant DNA construction include the β -lactamase (penicillinase) and lactose promoter systems and other microbial promoters, such as the T7 promoter system as described in U.S. Patent No.
- 30 4,952,496. Details concerning the nucleotide sequences of promoters are known, enabling a skilled worker to ligate them functionally with genes. The particular promoter used will generally be matter of choice depending upon the desired results.
- 35 In accordance with this invention, it is preferred to make the HMW protein by recombinant methods, particularly when the naturally occurring HMW protein as isolated from a

culture of a species of *Chlamydia* may include trace amounts of toxic materials or other contaminants. This problem can be avoided by using recombinantly produced HMW protein in heterologous systems which can be isolated from the host in a
5 manner to minimize contaminants in the isolated material. Particularly desirable hosts for expression in this regard include Gram positive bacteria which do not have LPS and are, therefore endotoxin free. Such hosts include species of *Bacillus* and may be particularly useful for the production of
10 non-pyrogenic rHMW protein, fragments or analogues thereof.

A variety of host-vector systems may be utilized to express the protein-coding sequence. These include but are not limited to mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems
15 infected with virus (e.g., baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA. Hosts that are appropriate for expression of the HMW protein genes, fragments, analogues or variants thereof, may include *E. coli*, *Bacillus* species, *Haemophilus*, fungi, yeast, such as *Saccharomyces pichia*, *Bordetella*, or the baculovirus expression system may be used. Preferably, the host cell is a bacterium, and most preferably the bacterium is *E. coli*, *B. subtilis* or *Salmonella*.

25 The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used. In a preferred embodiment, a chimeric protein comprising HMW
30 protein or HMW-derived polypeptide sequence and a pre and/or pro sequence of the host cell is expressed. In other preferred embodiments, a chimeric protein comprising HMW protein or HMW-derived polypeptide sequence fused with, for example, an affinity purification peptide, is expressed. In
35 further preferred embodiments, a chimeric protein comprising HMW protein or HMW-derived polypeptide sequence and a useful immunogenic peptide or protein is expressed. In preferred

embodiments, HMW-derived protein expressed contains a sequence forming either an outer-surface epitope or the receptor-binding domain of native HMW protein.

Any method known in the art for inserting DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/ translational control signals and the protein coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombinants (genetic recombination). Expression of a nucleic acid sequence encoding HMW protein or HMW-derived polypeptide may be regulated by a second nucleic acid sequence so that the inserted sequence is expressed in a host transformed with the recombinant DNA molecule. For example, expression of the inserted sequence may be controlled by any promoter/enhancer element known in the art. Promoters which may be used to control expression of inserted sequences include, but are not limited to the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42) for expression in animal cells; the promoters of β -lactamase (Villa-Komaroff et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731), *tac* (DeBoer et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25), P_L , or *trc* for expression in bacterial cells (see also "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94); the nopaline synthetase promoter region or the cauliflower mosaic virus 35S RNA promoter (Gardner et al., 1981, Nucl. Acids Res. 9:2871), and the promoter of the photosynthetic enzyme ribulose biphosphate carboxylase (Herrera-Estrella et al., 1984, Nature 310:115-120) for expression in plant cells; promoter elements from yeast or other fungi such as the Gal4 promoter, the ADC (alcohol

dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter.

Expression vectors containing HMW protein or HMW-derived polypeptide coding sequences can be identified by
5 three general approaches: (a) nucleic acid hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences such as reactivity with anti-HMW antibody. In the first approach, the presence of a foreign gene inserted in an expression vector can be detected
10 by nucleic acid hybridization using probes comprising sequences that are homologous to the inserted HMW protein or HMW-derived polypeptide coding sequence. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of
15 certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector. For example, if the HMW protein or HMW-derived polypeptide coding
20 sequence is inserted within the marker gene sequence of the vector, recombinants containing the insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the foreign gene product expressed by the
25 recombinant. Such assays can be based, for example, on the physical or functional properties of HMW protein or HMW-derived polypeptide in in vitro assay systems, e.g., binding to an HMW ligand or receptor, or binding with anti-HMW antibodies of the invention, or the ability of the host cell
30 to hemagglutinate or the ability of the cell extract to interfere with hemagglutination by *Chlamydia*.

Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host system and
35 growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As explained above, the expression vectors which can be used

include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda), and
5 plasmid and cosmid DNA vectors, to name but a few.

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be
10 elevated in the presence of certain inducers; thus, expression of the genetically engineered HMW protein or HMW-derived HMW may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and
15 modification of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed.

The proteins, polypeptides, peptides, antibodies and nucleic acids of the invention are useful as reagents for
20 clinical or medical diagnosis of *Chlamydia* infections and for scientific research on the properties of pathogenicity, virulence, and infectivity of *Chlamydia*, as well as host defense mechanisms. For example, DNA and RNA of the invention can be used as probes to identify the presence of
25 *Chlamydia* in biological specimens by hybridization or PCR amplification. The DNA and RNA can also be used to identify other bacteria that might encode a polypeptide related to the *Chlamydia* HMW protein. The proteins of the invention may be used to prepare polyclonal and monoclonal antibodies that can
30 be used to further purify compositions containing the proteins of the invention by affinity chromatography. The proteins can also be used in standard immunoassays to screen for the presence of antibodies to *Chlamydia* in a sample.

35 7. BIOLOGICAL DEPOSITS

Certain plasmids that contain portions of the gene having the open reading frame of the gene encoding the HMW

protein of *Chlamydia* that are described and referred to herein have been deposited with the American Type Culture Collection (ATCC) located at 10801 University Boulevard, Manassas, Virginia 20110-2209, U.S.A., pursuant to the
5 Budapest Treaty and pursuant to 37 CFR 1.808 and prior to the filing of this application. The identifications of the respective portions of the genes present in these plasmids are shown below.

Samples of the deposited materials will become
10 available to the public upon grant of a patent based upon this United States patent application. The invention described and claimed herein is not to be limited by the scope of the plasmids deposited, since the deposited embodiment is intended only as an illustration of the
15 invention. Any equivalent or similar plasmids that encode similar or equivalent proteins or fragments or analogues thereof as described in this application are within the scope of the invention.

20 Plasmid	ATCC Accession No.	Date Deposited
pAH342	ATCC 985538	September 8, 1997

8. EXAMPLES

The above disclosure generally describes the
25 present invention. A more specific description is provided below in the following examples. The examples are described solely for the purpose of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances
30 suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitation.

Methods of molecular genetics, protein biochemistry and immunology used but not explicitly described in the
35 disclosure and examples are amply reported in the scientific literature and are well within the ability of those skilled in the art.

8.1. EXAMPLE 1: ISOLATION AND PURIFICATION OF MATURE CHLAMYDIA PROTEINS

McCoy cells were cultured either in standard 225 cm² tissue culture flasks or in Bellco spinner flasks (Cytodex 5 microcarrier, Pharmacia) at 37°C in 5% CO₂ using DMEM media supplemented with 10% *Chlamydia*-antibody free fetal bovine serum, glucose and nonessential amino acids. *C. trachomatis* L₂ elementary bodies (ATCC VR-902B) were prepared from lysates of infected McCoy cells. Basically, McCoy cells infected with *C. trachomatis* L₂ (LGV) were sonicated and cellular debris was removed by centrifugation. The supernatant containing chlamydial elementary bodies (EBs) was then centrifuged and the pellet containing EBs was resuspended in Hanks' balanced salts solution (HBSS). RNase/DNase solution was added and incubated at 37°C for 1 hour with occasional mixing. The EB containing solution was layered onto a discontinuous density gradient (40%, 44% and 54%) of Angiovist 370 (mixture of diatrizoate meglumine and diatrizoate sodium, Berlex Laboratories, Wayne, NJ) and ultracentrifuged for separation of the EBs on the gradient. After centrifugation the EBs were harvested from the gradient between the interface of the 44% and 54% Angiovist 370 layers. The EBs were washed in phosphate buffered saline and resuspended in HBSS.

Purified EBs were sequentially extracted with 0.1% OGP [high ionic strength] in HBSS to remove peripheral surface proteins and held on ice. The same EB preparation was then extracted with 1.0% OGP, 10 mM DTT, 1 mM PMSF, 10 mM EDTA, in a 50 mM Tris pH 7.4 buffer. Extracts were dialyzed (3500 MWCO) to remove detergent and other reagents and concentrated by lyophilization. Protein containing extracts were diluted in HBSS and passed over commercially available heparin-sepharose columns (HiTrap Col., Pharmacia). After samples were applied to the heparin column nonadhered proteins were removed by washing with excess HBSS. Bound proteins were batch eluted with PBS containing 2 M sodium chloride. Eluents were dialyzed extensively to remove salt

and then lyophilized. The heparin-binding proteins were size fractionated by SDS-PAGE and visualized by silver staining or analyzed by Western blotting. Protein(s) of about 105-115 KDa present in moderate amounts were detected as shown in Figure 1. The isoelectric point of the native HMW protein was determined to be about 5.95.

To obtain one N-terminal amino acid sequence, sufficient quantities of the HMW protein ($\geq 5 \mu\text{g}$) were electroblotted onto a PVDF membrane (Applied Biosystems), and stained with Coomassie blue. Immobilized HMW protein was released from the membrane and treated in situ with low levels of endopeptidase Lys-C, endopeptidase Arg-C and/or endopeptidase Glu-C to fragment the native protein. The resulting peptide fragments were purified by HPLC and their N-terminal amino acid sequences determined using an ABI 430 Protein Sequenator and standard protein sequencing methodologies. The N-terminal amino acid sequence is:

E-I-M-V-P-Q-G-I-Y-D-G-E-T-L-T-V-S-F-X-Y

and is denoted SEQ ID No.: 3.

When a composite PDB+SwissProt+PIR+GenPept database (>145 K unique sequences) was searched with the HMW protein N-terminal sequence (20 residues) using rigorous match parameters, no precise homologies were found. Thus the HMW protein is a novel chlamydial protein. Since this protein was isolated under conditions that should release only peripheral membrane proteins (e.g. Omp2), these data indicate that the HMW protein is a surface-associated protein.

8.2. EXAMPLE 2: PREPARATION OF ANTIBODIES TO WHOLE CHLAMYDIA EBS

To aid in the characterization of the HMW protein, hyperimmune rabbit antisera was raised against whole EBS from *C. trachomatis* L₂. Each animal was given a total of three immunizations of about 250 μg of *Chlamydia* EBS per injection (beginning with complete Freund's adjuvant and followed with

incomplete Freund's adjuvant) at approximately 21 day intervals. At each immunization, approximately half of the material was administered intramuscularly (i.m.) and half was injected intranodally. Fourteen days after the third
5 vaccination a fourth booster of about 100 µg of EBs was given i.m. and the animals exsanguinated 7-10 days later. A titre of 1:100,000 was obtained as determined by ELISA.

8.3. EXAMPLE 3: DETERMINATION OF POST-TRANSLATIONAL

10 MODIFICATIONS

Recently, several *C. trachomatis* membrane-associated proteins have been shown to be post-translationally modified. The 18 kDa and 32 kDa cysteine-rich EB proteins, which are lectin-binding proteins, have
15 been shown to carry specific carbohydrate moieties (Swanson, A.F. and C.C. Kuo. 1990. Infect. Immun. 58:502-507). Incorporation of radiolabelled palmitic acid has been used to demonstrate that the about 27 kDa *C. trachomatis* Mip-like protein is lipidated (Lundemose, A.G., D.A. Rouch, C.W. Penn,
20 and J.H. Pearce. 1993. J. Bacteriol. 175:3669-3671). Swanson et al. have discovered that the MOMP from the L₂ serovar contains N-acetylglucosamine and/or N-acetylgalactosamine and these carbohydrate moieties mediate binding of MOMP to Hela cell membranes.

25 To ascertain whether the HMW protein is glycosylated, EBs are grown on McCoy cells in the presence of tritiated galactose or glucosamine, subjected to heparin affinity chromatography and the heparin binding proteins analyzed by SDS-PAGE and autoradiography. Briefly, McCoy
30 cells are grown in T225 flasks under standard conditions (DMEM + 10% FCS, 35 ml per flask, 10% CO₂) to about 90% confluency and inoculated with sufficient EBs to achieve 90%-100% infectivity. Following a 3 hour infection period at 37°C cycloheximide is added (1 µg/ml) to inhibit host cell
35 protein synthesis and the cultures reincubated for an additional 4-6 hours. Approximately 0.5 mCi of tritiated galactose (D-[4,5-³H(N)]galactose, NEN) or glucosamine (D-

[1,6-³H(N)glucosamine, NEN) is then be added to each flask and the cultures allowed to incubate for an additional 30-40 hours. Cells are harvested by scraping and EBs purified by gradient centrifugation. HMW protein is isolated from 1.0% OGP surface extracts by affinity chromatography, eluted with NaCl and analyzed by SDS-PAGE using ¹⁴C-labelled molecular weight markers (BRL) then subjected to autoradiography. Dried gels are exposed for 1-4 weeks to Kodak X-AR film at -70°C.

- 10 To determine post synthesis lipid modification, *C. trachomatis* serovar L₂ is cultivated on monolayers of McCoy cells according to standard procedures. Approximately 24 hours postinfection, conventional culture media (DMEM + 10% FCS) is removed and replaced with a serum-free medium
- 15 containing cycloheximide (1 µg/ml) and [U-¹⁴C]palmitic acid (0.5 mCi/T225 flask, NEN) and incubated for a further 16-24 hours to allow protein lipidation to occur. Surface EB extracts are prepared, heparin-binding proteins are isolated and analyzed by autoradiography as described above.
- 20 The functionality of glycosylated or lipidated moieties is assessed by treating whole EBs or OGP surface extracts with appropriate glycosidases. Following carbohydrate removal, extracts are subjected to affinity chromatography and SDS-PAGE to determine whether the HMW
- 25 protein retains the ability to bind to heparin sulfate.

8.4. EXAMPLE 4: Cloning of the N-terminal Segment of the HMW Protein Gene

Degenerate oligonucleotides were designed based on the N-terminal amino acid sequence of the HMW protein and were synthesized. These oligonucleotides were then used to generate gene-specific PCR products that were employed as hybridization probes to screen a *C. trachomatis* L₂ λZAPII DNA library to isolate the gene for the HMW protein.

- 35 Briefly, appropriate low degeneracy peptide segments were identified from the N-terminal and internal amino acid sequence data by computer analysis (MacVector,

IBI) and used to guide the design of low degeneracy sequence-specific oligonucleotide PCR primer sets.

Using the N-terminal primary sequence as a guide, four degenerate oligonucleotide probes complementary to the first six residues of the HMW peptide E-I-M-V-P-Q (residues 1-6 of SEQ ID No.: 3), and comprising all possible nucleotide combinations (total degeneracy = 192 individual sequences), have been designed and employed as forward amplification primers.

10

SEQ ID No.4	5'-GAA-ATH-ATG-GTN-CCN-CAA-3'.
SEQ ID No.5	5'-GAA-ATH-ATG-GTN-CCN-CAG-3'
SEQ ID No.6	5'-GAG-ATH-ATG-GTN-CCN-CAA-3'
SEQ ID No.7	5'-GAG-ATH-ATG-GTN-CCN-CAG-3'

15

Two additional oligonucleotide probes representing the reverse complement DNA sequence of the internal five residue peptide Y-D-G-E-T (residues 9-13 of SEQ ID No.: 3), and comprising all possible nucleotide combinations (total degeneracy = 128 individual sequences), have been designed and employed as reverse amplification primers.

SEQ ID No.8	5'-NGT-YTC-NCC-RTC-ATA-3'
SEQ ID No.9	5'-NGT-YTC-NCC-RTC-GTA-3'

25

Oligonucleotides were synthesized on an ABI Model 380B DNA synthesizer using a 0.2 μ mol scale column (trityl-on, auto-cleavage) and standard phosphoramidite chemistry. Crude oligonucleotides were manually purified over C-18 syringe columns (OP Columns, ABI). Purity and yield were ascertained spectrophotometrically (230/260/280 ratios).

Standard PCR amplification reactions (2 mM Mg^{2+} , 200 μ mol dNTPs, 0.75 units AmpliTaq, 50 μ l final volume) were programmed using about 0.2 μ g *C. trachomatis* L₂ DNA (about 3×10^7 copies of the HMW protein gene if single copy) and about 100 pmol of each forward (N-terminal oligo) and reverse (internal oligo) primer. Higher than normal concentrations

of primers (~20 pmol/50 μ l) were used for amplification, at least initially, in order to compensate for primer degeneracy. Amplification of target sequences was achieved using a standard 30-cycle, three-step thermal profile, i.e. 5 95°C, 30 sec; 60°C, 45 sec, 72°C, 1 min. Amplification was carried out in sealed 50 μ l glass capillary tubes using a Idaho Technologies thermal cycler. To verify that the PCR products generated during these amplification reactions were specific for the HMW protein coding sequence and were not 10 "primer-dimer" or other DNA amplification artifacts, amplimers were purified using silica-gel spin columns (QIAGEN), cloned into the PCR cloning vector pZERO (StrataGene), and subjected to direct DNA sequence analysis.

The DNA sequence for the cloned PCR products were 15 determined using conventional dideoxy-terminator sequencing chemistry and a modified T7 DNA polymerase (Sequenase, USB). Briefly, each double stranded plasmid template was denatured by a brief treatment with NaOH. Following neutralization, each denatured template was used to program 4 separate 20 sequencing reactions. Each reaction contained the M13 universal forward sequencing primer (21-mer) but a different ddNTP/dNTP termination mix (i.e. A,G,C, or T). Termination products were labelled by including [α -³⁵S]dATP in the reaction (~50uCi/reaction, >3000Ci/mmol, Amersham). 25 Individual extension products were denatured (formamide, ~95°C) and subjected to high resolution denaturing polyacrylamide gel electrophoresis (6% acrylamide, 8M urea, TAE buffer, ~500V, ~90min). Sequencing gels were then transferred to filter paper (Whatmann 3MM), dried under 30 vacuum, and then autoradiographed at -70°C for 24-72 hours. Base ladders were read manually from each gel and a consensus sequence determined.

HMW protein-specific amplimers suitable for library screening and/or Southern blotting were produced by PCR and 35 uniformly radiolabelled during the amplification process by adding [α -³²P]dNTPs (about 50 μ Ci each dNTP, Amersham, >5000 Ci/mmol) to the reaction mixture. Labelling reactions were

performed as above except reactions were performed in 0.5 ml microcentrifuge tubes using a Bellco Thermal Cycler.

Unincorporated label and amplification primers were removed from the reaction mixture using centrifugal size-exclusion chromatography columns (BioSpin 6 columns, BioRad).

A highly redundant *C. trachomatis* serovar L₂ DNA library (>50,000 primary clones) has been constructed by cloning size-fractionated fragments ≥ 10 Kbp produced from a partial EcoRI digest of genomic DNA into the lambda cloning vector λ ZAPII (Stratagene). Radiolabelled HMW protein-specific PCR products were used to screen this library for recombinant clones that carry all or part of the HMW protein coding sequence. Standard recombinant DNA procedures and methodologies were employed for these experiments. All phage that hybridized with these probes were purified to homogeneity by sequential rounds of plating and hybridization screening. Once reactive phage were purified, insert-containing phagmids (pBluescript SK- derivatives) were excision-rescued from the parental phage by coinfecting host cells with an appropriate helper phage, e.g. R408 or VCSM13 (Stratagene). Individual phagmids were further purified by streak-plating on LB agar containing ampicillin (100 μ g/ml) and selecting for individual colonies.

To confirm purified phagemid derivatives carried the HMW protein sequences, plasmid DNA was prepared and used to program amplification reactions containing the HMW protein-specific PCR primer sets. The presence of HMW protein-specific inserts was confirmed by the production of the appropriate sized PCR product.

Plasmid pAH306 is one HMW protein-containing derivative that was isolated by these methodologies.

Physical Mapping of pAH306

The inserts from pAH306 were physically mapped and the location of HMW protein gene determined using appropriate six-base restriction endonucleases (e.g. EcoRI, HindIII, BamHI, PstI, SmaI, KpnI, etc.) and HMW protein coding

sequences localized by Southern hybridization employing radiolabelled N-terminal-specific PCR products as probes. The orientation and extent of HMW protein-specific sequences were determined by PCR analysis using primer sets consisting of HMW protein-specific forward primers and reverse primers complementary to either the T3 or T7 promoter sequences located in the cloning vector.

Plasmid pAH306 was determined to contain a single ~6.6 Kbp EcoRI fragment of chlamydial origin. Directional PCR analysis of pAH306 demonstrated this derivative encodes roughly 1.5Kbp of the N-terminal region of the HMW protein gene.

The DNA sequence for the HMW protein gene encoded on pAH306 was obtained for both strands via conventional "sequence-walking" coupled with asymmetric PCR cycle sequencing methodologies (ABI Prism Dye-Terminator Cycle Sequencing, Perkin-Elmer). Sequencing reactions were programmed with undigested plasmid DNA (~0.5 µg/rxn) as a template and appropriate HMW protein-specific sequencing primers (~3.5 pmol/rxn).

In addition to the template and sequencing primer, each sequencing reaction (~20 µl) contained the four different dNTPs (i.e. A,G,C, and T) and the four corresponding ddNTPs (i.e. ddA, ddG, ddC, and ddT) terminator nucleotides; with each terminator being conjugated to one of four different fluorescent dyes. Single strand sequencing elongation products were terminated at random positions along the template by the incorporation of the dye-labelled ddNTP terminators. Fluorescent dye-labelled termination products were purified using microcentrifuge size-exclusion chromatography columns (Princeton Genetics), dried under vacuum, suspended in a Template Resuspension Buffer (Perkin-Elmer), denatured at 95°C for ~5min, and resolved by high resolution capillary electrophoresis on an ABI 310 Automated DNA Sequenator (Perkin-Elmer).

DNA sequence data produced from individual reactions were collected and the relative fluorescent peak

intensities analyzed automatically on a PowerMAC computer using ABI Sequence Analysis Software (Perkin-Elmer). Individually autoanalyzed DNA sequences were edited manually for accuracy before being merged into a consensus sequence "string" using AutoAssembler software (Perkin-Elmer). Both strands of the HMW protein gene segment encoded by pAH306 were sequenced and these data compiled to create a composite sequence for the HMW protein gene segment. The sequence encoding the segment of HMW protein is listed as SEQ ID No.: 10 and is represented by nucleotides 382 to 1979 in Figure 2. A map of pAH306 is shown in Figure 5.

Database analysis (e.g. primary amino acid homologies, hydropathy profiles, N-/O-glycosylation sites, functional/conformational domain analyses) of the DNA and predicted amino acid sequences for the HMW protein was performed using GeneRunner and Intelligentics software, indicating the HMW protein is novel.

8.5. Example 5: CLONING OF THE C-TERMINAL SEGMENT OF THE HMW PROTEIN GENE

Chromosome walking was employed to isolate the C-terminal portion of the HMW protein gene. A ~0.6 Kbp BamHI-EcoRI fragment distal to the N-terminal sequence of the mature HMW protein and proximal to the T3 promoter sequence of the vector was chosen as the probe for the initial chromosome walk. Briefly, pAH306 was digested to completion with BamHI and EcoRI and the digestion products size fractionated by agarose gel electrophoresis (0.8% agarose in TAE buffer). The desired ~0.6 Kbp BamHI/EcoRI (B/E) band was excised from the gel and purified using commercially available silica gel microcentrifuge chromatography columns and reagents (QIAGEN).

The purified 0.6 Kbp B/E fragment was radiolabelled with [α -dATP] (>3000Ci/mmol, Amersham) via random-priming labelling methodologies employing commercially available reagents (Boehringer Mannheim) and used to probe Southern

blots of *C. trachomatis* L₂ genomic DNA that had been digested to completion with HindIII.

The 0.6 Kbp B/E probe from pAH306 hybridized to a ~1.4Kbp HindIII genomic fragment. Based on the experimentally derived restriction map of the HMW protein gene segment encoded on pAH306, this fragment encodes ~0.2Kbp of the C-terminal HMW protein sequence.

The radiolabelled 0.6 Kbp B/E fragment was used subsequently to probe a moderately redundant (~5,000 primary clones) *C. trachomatis* L2 library to identify clones that contain the ~1.4Kbp HindIII fragment. Briefly, *C. trachomatis* L₂ genomic DNA was digested to completion using a ~10-fold excess of the restriction endonuclease HindIII (~10 units per 1 µg of genomic DNA, 37°C, 18-24 hours). Digestion products were size fractionated by agarose gel electrophoresis (0.8% agarose, TAE) and DNA fragments ranging in size from ~1.0 Kbp to 2.0 Kbp were excised from the gel. Excised agarose strips contain the desired DNA fragment sizes were dissolved in a solubilization/binding solution (QX1, QIAGEN) and purified using commercially available silica-gel spin columns (QIAGEN). Purified 1.0-2.0 Kbp genomic HindIII fragments were then cloned into the pBlueScript SK- plasmid which had been previously digested to completion with HindIII and treated with calf intestinal phosphatase to prevent vector religation.

Vector/insert ligations were performed in a ~50 µl final reaction volume (50 mM Tris-HCl, pH 7.00; 10 mM NaCl; 1 mM ATP; 0.5 mM DTT) at 25°C for ~16-24 hours using T4 DNA ligase (~10 units/reaction) and a vector:insert molar ratio of approximately 1:10. Following ligation, aliquots (~50 ng ligated DNA) were used to electroporate a competent *E. coli* host, e.g. *E. coli* TOP10. Electroporated cells were then plated onto LB agar containing ~100µg/ml ampicillin to select for plasmid-harboring clones. Approximately 1,000 plasmid-harboring Ap^R transformants were transferred directly from LB Ap¹⁰⁰ agar plates onto nylon membranes (HyBond N+, Amersham) by capillary action.

Following transfer, plates were re-incubated at 37°C to regenerate viable colonies for further manipulation. Colonies transferred to membranes were lysed and DNA liberated by treating the colony blots with a denaturing SDS/NaOH solution. A Tris buffered NaCl solution was used to neutralize and stabilize lysis material. Released DNA was immobilized onto the membranes by UV irradiation. Standard recombinant DNA procedures and methodologies were employed to probe the colony blots with the radiolabelled 0.6 Kbp B/E fragment and identify recombinant derivatives which carry the desired ~1.4Kbp HindIII fragment.

Plasmid pAH310 was one derivative isolated by these procedures and the coding segment of the HMW protein is represented by nucleotides 994-2401 in Figure 2.

Restriction analysis using HindIII and EcoRI, individually and in combination, together with DNA sequence analysis of purified plasmid DNA confirmed pAH310 encodes the expected ~1.4 Kbp HindIII fragment. These analyses also demonstrated that the ~1.4 Kbp insert consists of the same ~1.2 Kbp HindIII-EcoRI fragment that is present in pAH306 and a unique ~0.2 Kbp EcoRI-HindIII fragment that encodes C-terminal HMW protein-specific DNA.

The ~0.2 Kbp EcoRI-HindIII (E/H) fragment was chosen as the probe for the second chromosome walk. Briefly, pAH310 was digested to completion with EcoRI and HindIII and the digestion products size fractionated by agarose gel electrophoresis (0.8% agarose in TAE buffer). The desired ~0.2 Kbp (E/H) band was excised from the gel, purified, radiolabelled with [α -P³²]dATP, and used as a probe to identify clones in the original *C. trachomatis* L₂ λ ZAPII genomic library that encode the C-terminal segment of the HMW protein gene.

Plasmid pAH316 is one derivative isolated by these procedures. Restriction analysis of pAH316 demonstrated that this derivative contains a *C. trachomatis* L₂ insert of ~4.5 Kbp which consists of two EcoRI fragments of ~2.5 Kbp and ~2.0 Kbp in size. Southern hybridization analysis using the

~0.2 Kbp E/H fragment as a probe localized this sequence to the ~2.5 Kbp EcoRI fragment of pAH316. Directional PCR analyses employing purified pAH316 plasmid DNA as a template and amplification primer sets specific for ~0.2 Kbp E/H
5 fragment and T3 and T7 vector sequences demonstrated pAH316 encodes the C-terminal segment of the HMW protein gene. The coding segment of the HMW protein is represented by nucleotides 1974 to 3420 in Figure 2, and is listed as SEQ ID No.:11.

10

8.6. Example 6: PRODUCTION OF TRUNCATED HMW RECOMBINANT PROTEIN

The N-terminal half of the HMW protein was PCR cloned as a ~1.5Kbp fragment into the commercially available
15 *E.coli* expression plasmid pTrcHisB (Invitrogen). The forward primer used in these reactions was designated 140FXHO (57-mer), listed as SEQ ID No. 18, and contains sequences complementary to the first 10 N-terminal residues of the mature HMW protein. In addition to the HMW protein coding
20 sequences, this forward primer also carries a unique XhoI restriction site located optimally located upstream of the first residue of the mature HMW protein (Glu/E) for proper fusion to the (His)₆ affinity purification domain encoded on the vector plasmid, and 5' terminal 6 base G/C clamp for
25 effective amplification and a 12 base internal spacer for effective endonuclease recognition and digestion.

SEQ ID No.18 5' - AAG-GGC-CCA-ATT-ACG-CAG-AGC-TCG-AGA-GAA-ATT-ATG-GTT-CCT-CAA-GGA-ATT-TAC-GAT - 3'

30

SEQ ID No.19 5' - CGC-TCT-AGA-ACT-AGT-GGA-TC - 3'

The commercially available reverse sequencing primer SK (20mer, StrataGene), SEQ ID No. 19, which is complementary to
35 phagemid sequences downstream of the EcoRI site in pAH306, was used as the reverse amplification primer in these reactions. To obtain acceptable yields of the HMW protein ORF

product (~1.5 Kbp), PCR amplification was performed using a mixture of thermostable DNA polymerases consisting of *T. thermophilus* DNA polymerase (Advantage Polymerase), as the primary amplification polymerase and a minor amount of a second high fidelity thermostable DNA polymerase to provide additional 5' - 3' proofreading activity (CloneTech). An anti-Tth DNA polymerase antibody was added to the reaction mixture to provide automatic "hot-start" conditions which foster the production of large >2Kbp amplimers. pAH306
10 plasmid DNA purified using a commercially available alkaline/SDS system (QIAGEN) and silica gel spin columns (QIAGEN) was used to program these amplification reactions (~0.2 ng/reaction).

The ~1.5 Kbp amplimer was purified from
15 unincorporated primers using silica gel spin columns and digested to completion using an excess of XhoI and EcoRI (~10 units per 1 µg DNA). The purified and digested N-terminal truncated HMW protein ORF was then be cloned into the commercially available expression plasmid pTrcHisB that had
20 been previously digested with both XhoI and EcoRI (5:1, insert:vector ratio). Aliquots from the ligation reaction were then be used to electrotransform a suitable *E.coli* host (e.g. TOP10).

Mini-prep DNA from ampicillin-resistant
25 transformants picked at random were prepared, digested to completion with XhoI, EcoRI, or a combination of both and examined for the presence and orientation of the ~1.5 Kbp truncated HMW protein ORF insert by agarose gel electrophoresis. Mini-prep DNA from clones determined to
30 carry the ~1.5 Kbp XhoI/EcoRI insert was prepared and used to program asymmetric PCR DNA sequencing reactions to confirm the fidelity of the junction formed between the HMW protein fragment and the (His)₆ affinity purification domain of the expression vector. Plasmid pJJ36-J was one recombinant
35 derivative isolated by these procedures and is represented by nucleotides 446 to 1977 in figure 2. The deduced amino acid sequence of the truncated fragment of HMW protein is

represented by amino acids 29 to 532 in Figure 3 and is listed as SEQ ID No. 17.

8.7. EXAMPLE 7: DETERMINATION OF PRESENCE IN OTHER SPECIES

5 Polymerase chain reaction analyses were undertaken to establish the presence of the HMW gene in several clinically recognized *C. trachomatis* strains and as well as other chlamydial species, e.g., *C. pneumoniae*. *Chlamydia trachomatis* strains as frozen stocks from the ATCC 10 (Rockville, MD) were used to infect subconfluent monolayers (about 80%) of McCoy cells according to standard procedures. Infected monolayers were either centrifuged in a Sorvall RT6000B centrifuge (~1,300 rpm, 25°C, 30 min) and/or treated with dextran sulfate (~50 µg/ml) at the time of infection to 15 enhance initial attachment of the low infectivity biovars (non-LGV) to host cells and thus increase the final EB yield. Roughly 48 hours later, infected monolayers were collected by scraping and host cells disrupted by sonication to release elementary bodies (EBs). Total DNA was extracted from 20 purified EBs (~10⁷-10⁸) of each strain using the proteinase K/Nonidet P40 method described by Denamur, et al., J. Gen. Microbiol. 137:2525-2530 (1991), incorporated herein by reference, and further purified by phenol/chloroform extraction and salt precipitation. Purified *Chlamydia* 25 *pneumoniae* (AR-139) genomic DNA was purchased from Advanced Biotechnologies Inc.

To determine the presence of the HMW protein gene in these strains, amplification reactions were programmed using total *Chlamydia* DNA as template and the HMW protein 30 segment-specific oligonucleotide primer (21mers) sets listed below.

SEQ ID No.20 5' - ATG-GTT-CCT-CAA-GGA-ATT-TAC-G - 3'

SEQ ID No.21 5' - GGT-CCC-CCA-TCA-GCG-GGA-G - 3'

Briefly, standard PCR amplification reactions (2 mM 35 Mg²⁺, 100 µmol dNTPs, 0.75 units AmpliTaq polymerase, 50 µl final volume) were programmed using approximately 15 µl of the crude *C. trachomatis* DNA extracts (~10 µl of the

commercially available *C. pneumoniae* DNA) and ~20 pmol of each forward and reverse HMW protein-specific amplification primers of SEQ ID No. 20 and 21. Amplification of small target sequences (≤ 2 Kbp) was achieved using a 32-cycle, 5 three-step thermal profile, i.e. 95°C, 30 sec; 60°C, 30 sec, 72°C, 1 min. Amplification of longer target sequences for ORF-cloning and sequencing was carried out using the crude DNA extracts in an identical fashion except that a MAb-inactivated Tth/Vent DNA polymerase enzyme combination was 10 employed (Advantage PCR, Clontech) and a 72°C extension time was used that matched the size of the desired PCR product plus 2 min (i.e. desired PCR product = 6Kbp, extension time = 8 min).

Both conventional and long-distance PCRs were 15 carried out using 0.2 ml thin-walled polypropylene microcentrifuge tubes in an ABI 2400 Thermal Cycler (Perkin-Elmer). Following thermal cycling, aliquots (~20 μ l) of the reactions were analyzed and PCR products identified by standard agarose gel electrophoresis (0.8% agarose in TAE 20 buffer) and ethidium bromide staining. The results showed that the HMW protein is highly conserved in clinically relevant serovars; the HMW gene was present in all *C. chlamydia* samples strains tested, including serovars B, Ba, D, E, F, G, H, I, J, K, L₁, L₂ and MoPn and in *C. pneumoniae*.

25

8.8. EXAMPLE 8: DETERMINATION OF SEQUENCE VARIATION

To establish the degree of DNA and amino acid sequence variation among different *Chlamydia* strains, the gene for the HMW protein was PCR-cloned from both a *C. trachomatis* B serovar (representing the trachoma group of 30 organisms) and from a *C. trachomatis* F serovar (representing the low infectivity STD biovars) and compared to the HMW protein consensus *C. trachomatis* L₂ sequence.

Briefly, LD-PCR was used to generate ~6Kbp HMW 35 protein-specific DNA fragments from *C. trachomatis* B and F genomic DNA that contain the complete coding sequence for the mature HMW protein. Amplification conditions for these LD-

PCR exercises were as described in Example 6. The reverse amplification primer employed in these reactions (p316Kpn-RC, 56mer), listed as SEQ ID No. 13, is complementary to a sequence located ~3 Kbp downstream of the predicted HMW protein termination codon. As an aide to cloning the desired ~6 Kbp amplimer, a single KpnI restriction endonuclease site 5' to the chlamydial sequence was engineered into the p316Kpn-RC primer. The forward amplification primer used for these reactions (p306Kpn-F, 56mer), listed as SEQ ID No. 12, contains the sequence complementary to the first 10 amino acid residues (30 nucleotides) specifying the mature HMW protein as well as a 5' sequence specifying a KpnI site. p306Kpn-F was designed such that the sequence encoding the N-terminus of the mature HMW protein could be linked in-frame to a hexa-His affinity domain encoded downstream of the highly efficient trc promoter on the *E.coli* expression vector pTrcHisB (ClonTech) when the ~6 Kbp amplimer was inserted into the KpnI site of this vector.

20 SEQ ID No.12 5' -AAG-GGC-CCA-ATT-ACG-CAG-AGG-GTA-CCG-AAA-
TTA-TGG-TTC-CTC-AAG-GAA-TTT-ACG-AT-3'

SEQ ID No.13 5' -AAG-GGC-CCA-ATT-ACG-CAG-AGG-GTA-CCC-TAA-
GAA-GAA-GGC-ATG-CCG-TGC-TAG-CGG-AG- 3'

25

The ~6 Kbp HMW protein products were purified using silica-gel spin columns (QIAGEN) and the fragments subjected to two 8-10 hour cycles of KpnI digestion using a 10-fold excess of KpnI (~10 units per 1 μ g of purified fragment, 37°C).

30 Following the second digestion, residual restriction enzyme activity was removed using QIAGEN spin columns and the ~6 Kbp KpnI HMW protein fragments cloned into the pTrcHisB plasmid which had been previously digested to completion with KpnI and treated with calf intestinal phosphatase to prevent
35 vector religation.

Vector/insert ligations were performed in a ~50 μ l final reaction volume (50 mM Tris-HCl, pH 7.00; 10 mM NaCl; 1

mmM ATP; 0.5 mM DTT) at 25°C for ~2 hours using T4 DNA ligase (~10 units/reaction) and a vector:insert molar ratio of approximately 1:5. Following ligation, aliquots (~50 ng ligated DNA) was used to electroporate a competent *E.coli* host, e.g. *E.coli* TOP10. Plasmid-harboring transformants were selected by plating electrotransformed cells onto LB agar containing 100 µg/ml ampicillin. Ampicillin-resistant (Ap^R) transformants appearing after a ~18-24 hour incubation period at 37°C were picked at random and restreaked onto the same selective media for purification.

A single, purified Ap^R colony from each initial transformant was used to inoculate ~5ml of LB broth and grown overnight at 37°C in a incubator shaker with mild aeration (~200 rpm). Cells from broth cultures were harvested by centrifugation and used to prepare small quantities of plasmid DNA. Commercially available reagents (QIAGEN Plasmid Mini Kits) were employed for these plasmid extractions. Plasmid derivatives carrying inserts were presumptively identified by electrophoresing the non-digested plasmid DNA in agarose gels (0.8% agarose in TAE buffer) and identifying derivatives greater in size than vector plasmid. Insert-containing derivatives were confirmed and the orientation of the HMW protein inserts relative to vector sequences were determined using appropriate restriction endonucleases (KpnI, EcoRI, HindIII, BamHI, etc.), either separately or together in various combinations.

The DNA sequence of the *C. trachomatis* B and F HMW protein genes were obtained for both strands using "sequence walking" the asymmetric dye-terminator PCR cycle sequencing methodology (ABI Prism Dye-Terminator Cycle Sequencing, Perkin-Elmer) described in Example 4. Reactions were programmed with plasmid mini-prep DNA and individual HMW protein sequence-specific primers that were employed in the sequencing of the HMW protein gene from the L₂ type strain.

DNA sequence data were collected using the ABI 310 Sequenator and analyzed automatically on a PowerMAC computer and appropriate computer software as described in Example 4.

Individually autoanalyzed DNA sequences were edited manually for accuracy before being merged into a consensus sequence "string" using AutoAssembler software (Perkin-Elmer). Both strands of the HMW protein gene from the *C. trachomatis* B and F serovars were sequenced and these data compiled to create composite consensus sequences for both the *C. trachomatis* B and F HMW protein genes. These sequences are listed as SEQ ID Nos.: 14 and 15. Sequence comparisons of the L₂, F and B strains are presented in Figure 6.

10

8.9. EXAMPLE 9: PRODUCTION OF RECOMBINANT PROTEIN

To produce sufficient quantities of recombinant HMW protein for both immunogenicity and animal protection studies, the HMW gene has been PCR cloned into suitable *E.coli* and baculovirus expression systems. Large quantities of rHMW protein are produced in an *E.coli* - based system as a chimeric fusion protein containing an N-terminal (His)₆ affinity purification domain. The complete HMW protein open reading frame (ORF) was PCR-cloned from the *C. trachomatis* L₂ genome as a single KpnI fragment and fused in the proper orientation and in the correct reading frame to the (His)₆ affinity purification domain encoded on the high expression plasmid vector pTrcHisB (CloneTech) as described in Example 5.

The (His)₆ affinity purification domain is part of a high expression locus consisting of the highly efficient *tac* promoter (IPTG-inducible) and consensus Shine and Delgarno ribosome binding site (RBS) located immediately upstream of the (His)₆ affinity purification domain. The HMW protein genes from *C. trachomatis* LGV L₂, *C. trachomatis* B, and *C. trachomatis* F were PCR cloned as ~3.0 Kbp fragments. The forward primer (56-mer) used in these reactions was designated p306Kpn-F and contains sequences complementary to the first 10 N-terminal amino acid residues of the mature HMW protein, listed as SEQ ID No 12. In addition to the HMW protein coding sequences, this forward primer also carries a unique KpnI restriction site located optimally located

upstream of the first residue of the mature HMW protein(Glu) for proper fusion to the (His)₆ affinity purification domain encoded on the vector plasmid, and 5' terminal 6 base G/C clamp for effective amplification and a 12 base internal
5 spacer for effective endonuclease recognition/digestion. The reverse PCR primer, designated p316Kpn-3RC, contains a reverse complement sequence to a *C. trachomatis* sequence located ~0.2Kbp downstream of the HMW protein termination codon, listed as SEQ ID No. 14. As with p306Kpn-F, the
10 reverse primer also contains a KpnI restriction site 5' to the *C. trachomatis* sequences, a 6 base G/C clamp, and a 12 base internal spacer.

To obtain acceptable yields of the HMW protein ORF product (about 3,500bp), PCR amplification was performed
15 using a mixture of thermostable DNA polymerases consisting of *T. thermophilus* DNA polymerase as the primary amplification polymerase and a minor amount of a second high fidelity thermostable DNA polymerase to provide additional 5'-3' proofreading activity (Advantage Polymerase, CloneTech). An
20 anti-Tth DNA polymerase antibody was added to the reaction mixture to provide automatic 'hot-start' conditions which foster the production of large (>2 Kbp) amplimers.

Genomic DNA from the various *C. trachomatis* strains was isolated from EBs as described in the example above and
25 used to program these reactions. Following amplification, the desired reaction products were purified from excess primers using commercially available silica-gel spin columns and reagents (QIAGEN) and digested to completion with an excess of KpnI (~10 units per 1μg DNA). The purified and
30 digested KpnI HMW protein ORF was then be cloned into the KpnI predigested pTrcHisB expression plasmid (5:1, insert:vector ratio). Aliquots from the ligation reaction were then used to electrotransform a suitable *E. coli* host (e.g. TOP10).

35 Mini-prep DNA from ampicillin-resistant transformants picked at random were prepared, digested to completion with KpnI, HindIII, or a combination of both and

examined for the presence and orientation of the ~3.2 Kbp HMW protein ORF insert by agarose gel electrophoresis and ethidium bromide staining. Mini-prep DNA was used to program asymmetric PCR DNA sequencing reactions as described in example(s) above to confirm the fidelity of the junction formed between the HMW protein fragment and the (His)₆ affinity purification domain of the vector. Plasmid pAH342 was one derivative isolated by these procedures, which contains the HMW protein gene ORF from *C. trachomatis* L₂ and is represented by nucleotides 446 to 3421 in Figure 2.

Recombinants were grown in 2X-YT broth containing 100 µg/ml Ap to mid-log phase (~0.5 O.D.₆₀₀) and induced with IPTG (1mM final) for an additional 4-5 hours to activate transcription from the vectors *trc* promoter. Cells were harvested by centrifugation and crude cell lysates prepared by lysis using a French pressure cell.

Alternatively, expression of rHMW protein may be obtained by using a baculovirus expression system. Here, the HMW protein ORF from *C. trachomatis* L₂ and *C. trachomatis* F were PCR-cloned as ~3 Kbp PCR products into a baculovirus transfer vector (e.g. pFastBacHTb) that had been previously digested to completion with KpnI and treated with CIP to minimize vector religation in essentially the same manner as described for pTrcHisB. The HMW protein expression cartridge generated in this cloning exercise (i.e. the baculovirus polyhedron promoter, N-terminal (His)₆ affinity purification domain, HMW protein gene ORF) was then transferred to the baculovirus genome by site-specific transposition using a commercially available bacmid system (Bac-to-Bac, Gibco)

Briefly, the HMW protein baculovirus expression plasmid was used to transform competent *E. coli* DH10bac (Gibco) cells containing a bacmid (a hybrid baculovirus-plasmid replicon) to gentamicin resistance using standard transformation and selection methodologies. Transformants where the HMW protein expression cartridge had successfully transposed from the expression plasmid to the appropriate receptor site within the *lacZ* gene located on the bacmid

replicon were identified using a standard IPTG/X-gal blue-white selection.

White, Gm^R transformants were picked at random and restreaked for purification. Bacmid DNA was prepared from 5 broth cultures by the method of Ish-Horowitz, N. A. R. 9:2989-2993 (1981) incorporated herein by reference, and is used to transfect *Spodoptera frugiperda* 9 cells. Following plaque purification, recombinant HMW protein baculovirus is used to infect large scale *Spodoptera* suspension cultures. A 10 yeast expression system is used to generate a glycosylated form of HMW protein.

8.10. EXAMPLE 10: PURIFICATION OF RECOMBINANT PROTEIN

Recombinant HMW protein was purified to homogeneity 15 using standard preparative immobilized metal affinity chromatography (IMAC) procedures. Briefly, an *E. coli* strain harboring an expression plasmid containing HMW protein gene was grown in Luria broth in a 5l fermenter (New Brunswick) at 37°C with moderate aeration until mid-log phase (~0.5 O.D.₆₀₀) 20 and induced with IPTG (1mM final) for 4-5 hours. Cell paste was collected, washed in PBS and stored at -20°C. Aliquots of frozen cell paste (~9-10 grams wet weight) were suspended in ~120 ml of D-PBS by mechanical agitation and lysed by passage through a French pressure cell (2X, 14,000psi, 4°C). 25 Soluble protein was then removed from rHMW protein inclusion bodies by high speed centrifugation (~10,000Xg, 4°C, 30min).

The insoluble pellet containing rHMW protein was suspended in ~20ml of ice cold D-PBS by homogenization and centrifuged as above. Washed rHMW protein inclusion bodies 30 were then denatured by suspension in a sodium phosphate buffer (0.1 M, pH 7.0) containing 6M guanidine hydrochloride and loaded onto a Ni²⁺-affinity column (1.5 cm X 25 cm, bed volume ~15 ml) prepared from Fast-Flow Chelating Sepharose (Pharmacia) and charged with Ni²⁺ or Zn²⁺ ions by standard 35 procedures. Unbound material was removed by washing the column with ~5-10 column volumes of a sodium phosphate buffer (0.1 M, pH 7.0) containing 8M urea.

Recombinant HMW protein bound to the affinity resin by virtue of the N-terminal (His)₆ affinity purification domain was eluted using a pH 4.0 sodium phosphate/8M urea buffer (~20 ml). Eluted material was neutralized by the addition of 1.0 M Tris-HCl (~2.5 ml, pH 7.5) and dialyzed against TE buffer containing SDS (0.5%) to remove the urea. Dialyzed material was concentrated using a Centricon-30 centrifugal concentrator (Amicon, 30,000 MWCO) and mixed with a 1/5 volume of 5X SDS gel sample buffer containing 1 mM 2-mercaptoethanol (Lammeli) and boiled at 100°C for 5 minutes.

Samples were loaded onto Tris/glycine preparative acrylamide gels (4% stacking gel, 12% resolving gel, 30:0.8 acrylamide:bis solution, 3mm thickness). A prestained molecular weight standard (SeeBlue, Novex) was run in parallel with the rHMW protein samples to identify size fractions on the gel. The area of the gel containing proteins having molecular masses of ~50-70 Kdal was excised and the proteins electroeluted using an Elu-Trap device and membranes (S&S) as specified by the manufacturer. Electroeluted protein was dialyzed to remove SDS. The protein concentration of the sample was determined using a Micro-BCA system (Pierce) and BSA as a concentration standard. The purity of rHMW protein was determined using conventional SDS-PAGE and commercially available silver staining reagents (Silver Stain Plus, Novex) as shown in Figure 4.

The apparent molecular weight of the isolated mature rHMW is about 105-115 kDa as determined by SDS-PAGE.

8.11. EXAMPLE 11: PREPARATION OF ANTIBODIES TO HMW PROTEIN

Polyvalent antisera directed against the HMW protein were generated by vaccinating rabbits with the purified HMW protein or fragments thereof. Each animal was given a total of three immunizations of about 250 µg HMW protein or fragment thereof per injection (beginning with complete Freund's adjuvant and followed with incomplete Freund's adjuvant) at approximately 21 day intervals. At

each immunization, approximately half of the material was administered intramuscularly (i.m.) and half was injected intranodally. Fourteen days after the third vaccination a fourth booster of about 100 µg HMW protein was given i.m. and the animals exsanguinated 7-10 days later. Anti-HMW protein titers were measured by ELISA using purified HMW protein (1.0 µg/well) or *C. trachomatis* L₂ EBs (whole and crude protein extracts) as capture ligands. Immunogen specific IgG ELISA titres of 1/320,000 were observed using purified rHMW truncated protein and 1/2500 using either EBs or RBs.

Serial dilutions of antisera were made in PBS and tested by ELISA in duplicate. Goat HRP-conjugated anti-rabbit antibody diluted 1/1000 was used as the second reporter antibody in these assays. Titers are expressed as the greatest dilution showing a positive ELISA reaction, i.e. an O.D.₄₅₀ value >2SD above the mean negative control value (prebleed rabbit sera). Hyperimmune antisera was then used to probe Western blots of crude EB or RB extracts as well as 1.0% OGP EB extract preparations to determine whether other *C. trachomatis* serovars and *Chlamydia* species express the HMW protein. *C. trachomatis* serovars B, Ba, D, F, G, I, J, K, L₁, L₂, L₃, MoPn and *Chlamydia pneumoniae* were tested and found to have a protein of an apparent molecular weight of 105-115 KDa reactive with antisera generated against HMW protein.

8.12. EXAMPLE 12: SURFACE LOCALIZATION

Surface localization of the HMW protein on different *Chlamydia* strains and derivatives were examined by indirect fluorescence antibody (IFA). IFA was performed using the procedures generally known in the art using hyperimmune anti-HMW protein as the primary antibody. Hak cells infected with whole EBs from one of *C. trachomatis* serovars L₂, B, and F, *C. pneumoniae* or *C. psittaci* are achieved by the following method.

McCoy or Hak cells were grown to confluence in D-MEM media on 12 mm plain coverslips inside 24 well tissue culture plates then centrifugally inoculated with ~5X10⁴ inclusion forming units (IFU) of the *C. trachomatis* strain

N11 (serover F). After ~24 hours incubation, the culture media was removed and infected cells fixed in methanol for 10 min. The fixed monolayer was then washed with PBS (1X) to remove fixative and overlaid with $>300 \mu\text{l}$ of anti-60Kdal truncated HMWP rabbit antibody that had been diluted $\sim 1/100$ in PBS. After 1 hour incubation with the primary antibody, the cells were washed gently with PBS then incubated for ~30 min. with a $1/200$ dilution of a mouse anti-rabbit IgG antibody conjugated with FITC. The second antibody was diluted using a PBS solution containing 0.0091% Evans Blue as a counter stain to visualize the monolayer. Cells were washed 2X in PBS to remove the secondary antibody, the coverslips removed from the culture plates, and mounted onto microscope slides using a fluorescent mounting medium.

Identical cell samples stained with prebleed rabbit antibody or FITC-conjugated second antibody alone were processed in parallel and served as antibody specificity (negative) controls. Counterstained samples were examined at a 1000-X magnification with a Zeiss Axioskop photomicroscope equipped with plan-neoflur objectives. Results using *C. trachomatis* NI1 (F serovar) are shown in Figure 7. The results show that enhanced fluorescence of samples stained with HMW protein antibody compared to the controls confirmed the surface location of the HMW protein. Furthermore, fluorescence of samples stained with HMW protein antibodies show binding to surface localized HMW protein from L₂, B and MoPn serovars and *C. pneumoniae*.

9. EXAMPLE: IN VITRO NEUTRALIZATION MODEL

30 The *in vitro* neutralization model has been used to
show that protective antiserum inhibited chlamydial infection
(neutralization) of various tissue culture cell lines.
Animal models are also essential for testing vaccine efficacy
with both small animal (non-primate) and primate models
35 necessary for preclinical evaluation. The guinea-pig has
been used for studying experimental ocular and genital

infection by the Guinea-pig inclusion conjunctivitis agent (GPIC), *C. psittaci*.

The mouse offers a consistent and reproducible model of genital tract infection using human genital tract isolates. This mouse model is a generally accepted pre-clinical assay, and was used to evaluate MOMP as a subunit vaccine. Another model is known as the primate model of trachoma infection wherein the induction of secretory IgA was shown to be a prime component of protection. Vaccinogenic ability of new subunit antigen candidates is determined using the above-mentioned generally accepted in vitro neutralization and animal model systems.

As a preliminary exercise to the animal protection studies, hyperimmune anti-HMW antibody was evaluated for its ability to block the infectivity of various *C. trachomatis* serovars (e.g. L₂, B, F) in vitro. Although McCoy cells were used to propagate *Chlamydia*, these cells also allow antibody-mediated uptake via Fc receptors. Therefore, to evaluate anti-HMW antibody inhibition of infectivity, Hak cells, which do not display Fc receptors, were used in these analyses.

Cells were grown on coverslips in 24-well plates to a subconfluent monolayer (about 90% confluency = 1×10^5 cells/ml) at 37°C in 5% CO₂. Anti-HMW-antibody was diluted to about 100 µg/ml (total protein) in sucrose-phosphate-glutamate (SPG) buffer and then serially diluted in SPG buffer. Frozen aliquots of pretitered *Chlamydia* was diluted in SPG buffer to about 2×10^4 IFU/ml. EBs were premixed with the diluted anti-HMW-antibody to about 10-20 IFU/µl and incubated 30 minutes at 37°C on a rocking platform.

Prepared Hak cells were washed in HBSS and then incubated with the anti-HMW-antibody/*Chlamydia* EB mixture in triplicate for each antibody using 500 IFU/ml. Plates were incubated for 2 hours at 37°C, then the inoculum removed and plates washed 3 times with HBSS. Tissue culture media containing 1 µg/ml of cyclohexamide was added and plates incubated for about 24-36 hours at 37°C in 5% CO₂ to allow inclusion bodies to develop. After incubation, the media was

removed and cell monolayers washed 3X in PBS. Plates were fixed in methanol for 20 minutes and re-washed in PBS.

Cells were stained to visualize inclusions by incubating with anti-*Chlamydia* LPS antibody (diluted about 1:500, ViroStat), cells washed 3 times in PBS, followed by incubation with FITC-conjugated goat secondary antibody for 30 minutes at 37°C. Coverslips were washed, air dried, and mounted in glycerol on glass coverslips. Inclusions were counted in five fields through the midline of the coverslip on a Zeiss fluorescence photomicroscope. Results are reported as the percent reduction of inclusion-containing cells with respect to a heterogenous antibody control (rabbit prebleed sera).

10. EXAMPLE: VACCINE EFFICACY (Mouse Model of Salpingitis and Fertility)

10.1. METHODS

10.1.1. IMMUNIZATION AND CHALLENGE

The Tuffrey murine infertility model was employed to evaluate the efficacy of rHMWP to protect animals against *Chlamydia trachomatis*-induced salpingitis and infertility. Three groups of 17 female C3H HeOuJ mice (~6 weeks of age, Jackson Labs) were employed for this evaluation. The test group of 17 animals was immunized at weeks 0, 2, and 3 by intranasal administration of ~20 µl of a vaccine formulation containing approximately 10-12 µg of gel-purified rHMWP and ~5 µg mL (SmithKline Beecham) as adjuvant. Prior to immunization mice were sedated using an anesthesia cocktail consisting of 16% Ketaject and 16% Xylaject in 68% pyrogen-free PBS (100 µl i.p./animal). Sedated animals were placed on their backs and using a standard laboratory pipette administered the vaccine formulation; ~10 µl of the vaccine solution per nostril with a 5-10 minute wait period between applications.

Two groups of 17 female mice (per test group) were immunized similarly but with a preparation containing only 5 µg mL (i.e. adjuvant only, no antigen). One of these groups

was subsequently challenged with *C. trachomatis* (sham-immunized, infected) and served as the negative fertility control while the other group was not challenged (sham immunized, sham infected) and served as the positive fertility control.

At week 4, all animals were administered a single i.p. dose of progesterone (2.5 mg in pyrogen-free PBS, Depo-Provera, Upjohn) to stabilize the uterine epithelium. At week 5, animals immunized with rHMWP and animals in the negative control group were infected by bilateral intrauterine inoculation with $\sim 5 \times 10^5$ inclusion forming units (IFU) of *C. trachomatis* NI1 (serovar F) in 100 μ l of sucrose phosphate glutamate buffer (SPG). To mimic the manipulations to the reproductive tract experienced by the other two groups, animals in the positive control were bilaterally inoculated with 100 μ l of a McCoy cell extract that contained no *C. trachomatis*. At week 7, 5-7 animals from each group were sacrificed by CO₂ asphyxiation and the complete genital tract (both upper and lower reproductive tracts) removed for histopathological analysis. At week 9, the remaining females from each group were caged with 8 - 10 week old male C3H mice for a 2 month breeding period to assess fertility (1 male for every 2 females per cage with weekly rotation of the males within each group, animals from different experimental groups were not mixed). Palpation and periodic weighing were used to determine when animals in each pair became pregnant. The parameters used to estimate group fertility were: F, the number of mice which littered at least once during the mating period divided by the total number of mice in that study group; M, the number of newborn mice (born dead or alive) divided by the number of litters produced in that group during the mating period; and N, the number of newborn mice (born dead or alive) divided by the total number of mice in that group.

10.1.2. HISTOPATHOLOGY

Genital tracts were treated for ≥ 24 hrs in Bouin's fixative, progressively dehydrated in 50%, 70%, and 100%

methanol, soaked in toluol, and either paraffin embedded or directly embedded in OCT compound (Tissue-TEK, Miles) and subsequently snap frozen in liquid nitrogen. Tissue sections (~6 μ m) were stained with hematoxylin and eosin (after
5 deparaffinization of the Bouin fixed samples). Inflammatory changes in the oviducts and ovaries were graded as follows: 0, no apparent inflammatory reaction; 1, a few mononuclear cells infiltrating the periovarial space or the submucosa of the oviduct; 2, same as 1 but to a greater extent; 3, same as
10 2 but with a thickened oviductal submucosa and the presence of inflammatory cells in the oviductal lumen; 4, same as 3 but to a greater extent. Inflammation in the cervix/vagina was scored based on the level of the intraepithelial infiltrate observed.

15 10.1.3. DETERMINATION OF rHMWP-SPECIFIC HUMORAL RESPONSES

Blood samples were collected periodically during the immunization and challenge phases by retroorbital bleeding and serum prepared by centrifugation. Vaginal
20 secretions were collected by repeated injection of 50 μ l of sterile PBS into the vagina with a standard laboratory pipettor and immediately withdrawing the solution. Two-to-three injection/withdrawal cycles were performed.

Quantitation of antibody (Ab) responses by ELISA
25 were performed as described in Section 8.11. Microwell ELISA plates (Maxisorb, NUNC) for determining Ab levels were coated overnight at 4°C with ~0.5-1.0 μ g of gel-purified rHMWP per well in 10mM carbonate/bicarbonate buffer (pH 9.6), washed with PBS containing 0.1% Tween-20 (washing buffer) and
30 blocked for ~1hr at 37°C with a PBS solution containing 3% BSA. For the determination of antigen-specific serum IgG levels, test sera were serially diluted in washing buffer containing 0.5% BSA and aliquots (100 μ l) incubated in the antigen-coated wells for ~2hr at 37°C. The plates were then
35 washed and incubated for ~1hr at 37°C with a horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG second antibody (Sigma). A HRP-conjugated goat anti-mouse IgA

secondary antibody was used to detect the presence of rHMWP-specific IgA in vaginal secretions. After incubation with the appropriate secondary Ab, the plates were washed and incubated for ~20-30 minutes at room temperature with TMB substrate (Sigma). Reactions were stopped by the addition of 2M H₂SO₄ and the absorbance determined at 450 nm on a Molecular Devices SpectroMax microplate reader. Titers were determined as the reciprocal of the sample dilution corresponding to an optical density of 1.0 at 450 nm.

10 10.1.4. DETERMINATION OF rHMWP-SPECIFIC CELLULAR RESPONSES

Groups of 6 female C3H HeOuJ mice (Jackson Labs) were sedated and immunized at weeks 0, 2, and 3 by intranasal administration with the rHMWP + mLT vaccine as described in Section 10.1.3. At weeks 4 and 5 immediately prior to progesterone treatment and intrauterine challenge, respectively, 3 animals from each group were sacrificed by CO₂ asphyxiation and spleens aseptically removed and single cell suspensions prepared using conventional methodologies.

20 Spleen cells from immunized animals were analyzed separately. For both the positive control group (sham immunized and sham infected) and the negative control group (sham immunized, infected) spleen cells were pooled and tested for restimulation.

25 For the measurement of spleen cell proliferation, spleens were ground (5 to 10 rounds) in 5ml of RPMI 1640 Glutamax I supplemented with 10% fetal calf serum, 25 mM HEPES, 50 U/ml penicillin, 50 µg/ml streptomycin, 1 mM sodium pyruvate, nonessential amino acids, and 50 µM 2-mercaptoethanol (Gibco-BRL). Live cells were counted by Trypan Blue staining and diluted in the same media to reach a density of 1.0 - 2.0X10⁶ cells/ml (Falcon 2063 polypropylene tubes). Triplicate cultures were set-up in round bottom 96-well culture plates (Nunc, Nunc) using ~5X10⁵ responder cells per well in 200 µl of media. Cells were stimulated with either 1.0 µg/ml of rHMWP (antigen-specific proliferation) or with 4 µg/ml concanavalin A (Boehringer Mannheim) as a

positive stimulation control; unrestimulated cell cultures were used as a negative control of cellular activation. After 72-96 hours of incubation at 37°C in 5% CO₂ cells were pulsed labelled for ~18hrs with 1.0 µCi ³H-thymidine

5 (Amersham) per well. Pulsed cells were harvested onto glass-fiber sheets using a Tomtec Cell Harvester (Mk III) and counted for beta-emission in a 3-channel Wallac 1450 Trilux Liquid Scintillation Counter. The stimulation index (SI) for a sample (individual or pooled) was defined as the mean of
10 the antigen or ConA-stimulated T-cell uptake of ³H-thymidine for triplicate wells divided by the mean of the unstimulated uptake for triplicate wells. SIs for both antigen-specific (rHMWP-specific) and ConA-specific proliferation were determined.

15

10.2. RESULTS

10.2.1. EFFECT ON MOUSE FERTILITY AFTER A HETEROTYPIC CHALLENGE

Evidence that mucosal immunization with rHMWP
20 combined with mLT can afford protection against infertility caused by a human clinical isolate of C.trachomatis (strain NI1, serovar F) is shown in Table 1. Animals immunized with the rHMWP displayed a significantly higher fertility rate (70%, i.e. number of fertile females in group/total number of
25 animals in the group) than animals in the negative control group (30%, sham immunized and infected). Similarly, the rHMWP immunized group produced more offspring and exhibited a group fecundity greater than those observed in the negative control group (51 vs 24 offspring and 5.1 ± 4.7 vs 2.4 ±
30 4.6 fecundity scores, respectively). As a group, animals immunized with the rHMWP vaccine displayed a comparable fertility rate, total number of offspring, and a fecundity score to those observed in the sham infected positive control group (80% fertility rate, 56 total offspring, 4.9 ± 2.7
35 fecundity).

The protection against C.trachomatis-induced infertility obtained in this experiment also demonstrates the

utility of the rHMWP to afford cross-biovar and cross-serovar protection against C.trachomatis disease. The recombinant HMWP antigen employed in this experiment was cloned from a strain belonging to the C.trachomatis lymphogranuloma venereum (LGV) group (strain L2) which causes systemic as well as more localized mucosal infections of the eye and genital tract. The C.trachomatis challenge organism used in these experiments, strain NI1 is an F serovar organism that belongs to the trachoma biovar which causes numerous urogenital tract infections.

15

20

25

30

35

Table 1. Fertility Assessments Observed After ~2 Breeding Cycles

Group	Number of Animals per Group	Percent Fertile Animals	Number of Off-spring	Group Fecundity ¹ (Mean + SD)
rHMWP-Immunized	10	70 p = 0.089 ²	51	5.10 ± 4.68 p = 0.105 ³
Sham Immunized Sham Infected (Positive Control)	10	80 p = 0.035	56	4.90 ± 2.70 p = 0.078
Sham Immunized Infected (Negative Control)	10	30	24	2.40 ± 4.61

¹ Mean number of pups per group

² Fisher's exact test, one-sided, 95% confidence interval
p-values are given relative to the negative control

³ Student's t-test, unpaired, Gaussian distribution, 95% confidence interval

p-values are given relative to the negative control

10.2.2. EFFECT ON CELLULAR IMMUNE RESPONSE

The rHMWP-specific activation of the cellular immune system was demonstrated using a conventional spleen cell proliferation assay. When spleen cells were tested during week 4 (immediately prior to progesterone treatment) (Table 2) and week 5 (~7 days after hormone treatment but before intrauterine challenge) (Table 3), all samples collected from rHMWP-immunized animals developed a strong

antigen-specific proliferative immune response. The antigen-specific Stimulation Indexes (SIs) obtained prior to progesterone treatment from rHMWP-immunized animals were equal to or greater than the SIs obtained via mitogenic stimulation with ConA (mean values for antigen and ConA stimulation obtained from 3 rHMWP-immunized animals: 26.2 vs 18.4, respectively). Spleen cells obtained from either sham

immunized animals or naive animals (i.e. animals that were not exposed to either the rHMWP antigen or mLT) did not respond to in vitro restimulation with the rHMWP material, thus establishing the specificity of the proliferative response observed in the immunized animals. Progesterone treatment did not affect the antigen-specific proliferative response observed in rHMWP immunized animals. Antigen-specific SIs obtained with spleen cells obtained after hormone treatment were greater than obtained via mitogenic stimulation (mean values for antigen and ConA stimulation obtained from 3 rHMWP-immunized animals: 92.4 vs 37.8, respectively). Again samples collected from sham immunized or naive animals failed to demonstrate any antigen-specific proliferative response.

15

Table 2. rHMWP-Specific Cell Proliferation Before Hormone Treatment

20	Group	Cell Proliferation (cpm) Untreated / ConA / rHMWP	Stimulation Index (Treated cpm/ Untreated cpm) ConA / rHMWP
	rHMWP Immunized Animal #1	1557 / 20739 / 65741	13.3 / 42.2
25	rHMWP Immunized Animal #2	1508 / 26975 / 28361	17.9 / 18.8
	rHMWP Immunized Animal #3	1238 / 29991 / 23453	24.0 / 18.9
30	Sham-Immunized Animals (Pooled)	1687 / 30546 / 1292	18 / <1.0
	Naive Animals (Pooled)	335 / 23886 / 838	71 / 2.5

35

Table 3. rHMWP-Specific Cell Proliferation After Hormone Treatment

5	Group	Cell Proliferation	Stimulation Index
		(cpm) Untreated / ConA / rHMWP	(Treated cpm/ Untreated cpm) ConA / rHMWP
	rHMWP Immunized Animal #1	767 / 15934 / 97458	20.8 / 127.0
10	rHMWP Immunized Animal #2	546 / 17212 / 28172	31.5 / 51.6
	rHMWP Immunized Animal #3	297 / 18139 / 29300	61.1 / 98.6
15	Sham-Immunized Animal (Pooled)	273 / 18094 / 150	66.3 / <1.0
	Naive Animals (Pooled)	345 / 16740 / 1341	48.5 / 3.9

20

10.2.3. EFFECT ON HUMORAL IMMUNE RESPONSE

To demonstrate that immunization with the full length rHMWP produces a humoral immune response, IgG titers were measured by ELISA on sera collected at week 5 immediately prior to challenge (i.e. approximately 2 weeks after the third immunization). As shown in Table 4, immunization of C3H mice with three doses of ~10-12 µg rHMWP produced detectable levels of anti-rHMWP IgG in all animals. Vaginal secretions were also collected from these animals at the same time and tested for the presence of anti-rHMWP mucosal IgA. Antigen-specific vaginal IgA was detected in three animals (Table 4).

35

Table 4. rHMWP-Specific Humoral Response

	rHMWP Immunized Animal	Anti-rHMWP Serum IgG ELISA Titer	Presence of Anti-rHMWP Vaginal IgA
5	4.4	5,000	
	4.5	6,000	
	4.6	12,000	+
	4.7	130	
10	4.8	100	
	4.9	54,000	+
	4.10	670	
	4.11	100	
	4.12	570	
15	4.13	100,000	+
	4.14	4,500	
	4.15	400	
	4.16	1,600	
20	4.17	2,500	
	4.18	700	
	4.19	70,000	
	4.20	500	
	4.21	2,000	
25	4.22	18,000	
	4.23	3,000	
	Mean \pm S.D.	18.5 \pm 29.6	

30

11. EXAMPLE: CONSTRUCTION OF PJJ701

A plasmid containing the entire *C. trachomatis* L₂ HMWP gene was constructed by selectively removing the EcoRI site upstream to the HMWP N-terminus in pAH306 (Described in
 35 Section 8.4). This was accomplished by digesting pAH306 to completion with XhoI and then religating the plasmid to

create pAH306-XhoA-1. The ~2.5 Kbp EcoRI fragment from pAH316 (described in Section 8.5) which contains the remaining HMWP C-terminus was isolated from preparative agarose gels that had been loaded with a complete EcoRI digestion of pAH316. An agarose gel slice containing the appropriate ~2.5 Kbp fragment was then excised, dissolved with NaI buffer and purified from residual agarose by hydroxyapatite spin column chromatography (QiaGen). The purified C-terminal HMWP EcoRI fragment was then ligated into the single EcoRI site of pAH306-XhoA-1, located at the 3'-end of the HMWP N-terminal coding sequence, using T4 DNA ligase and standard molecular biology protocols. E.coli Top10 cells were transformed with an aliquot of the pAH306-XhoA-1 (EcoRI digested and phosphatase treated vector) and the 2.5 Kbp EcoRI C-terminal fragment ligation reaction and recombinants selected on 2X-YT agar containing 100 µg/ml ampicillin. Ampicillin-resistant transformants were picked at random. Plasmid DNA was isolated from individual Ap^R transformants using a QiaGen Mini-Prep Plasmid DNA Isolation System and screened for the presence of plasmids greater in size than pAH306-XhoA-1 by conventional agarose gel electrophoresis and ethidium bromide staining. Derivatives of pAH306-XhoA-1 carrying the 2.5 Kbp HMWP fragment in the proper orientation that would allow expression of the full length HMWP were identified by restriction analyses using EcoRI and/or XhoI. Plasmid pAH374 was one derivative isolated from this experiment.

A PCR-based site-directed mutagenesis procedure (Quik-Change Site-Directed Mutagenesis System, Stratagene) was employed to effect a desired DNA change, namely to remove the NdeI site within the HMWP coding sequence of pAH374. Mutagenic PCR primers, 41 bases in length and complementary to the sequencing containing the NdeI site and designated 140-Nde-FX and 140-NdeRCX, were designed so as to eliminate the NdeI recognition site but not change the corresponding protein coding sequence. The sequences of the two PCR

mutagenic primers employed to remove the NdeI site in pAH374 are given below.

140-Nde-FX (SEQ ID NO: 38)

5 5'- GGG TTT GGG AAT CAG CAC ATG AAA ACC TCA TAT ACA TTT GC -
3'

140-Nde-RCX (SEQ ID NO: 39)

5'- GCA AAT GTA TAT GAG GTT TTC ATG TGC TGA TTC CCA AAC CC -
10 3'

Following Pfu DNA polymerase (Stratagene) mutagenesis and DpnI digestion, to cleave any unaltered pAH374 parental plasmid, mutated plasmid DNA was then
15 transformed into E.coli XL1-Blue. Plasmid harboring transformants were selected on 2X-YT agar containing 100 µg/ml ampicillin. Antibiotic resistant transformants were picked at random and screened for plasmids of the size as pAH374. The identity of plasmids isolated from transformants
20 was determined by restriction enzyme digestion using EcoRI. The absence of the NdeI site in these plasmids was determined by digestion using NdeI. To verify the loss of the HMWP NdeI site and to ensure no unwanted DNA sequence changes had occurred in this region during the mutagenesis procedure,
25 mutagenized plasmids were further subjected to DNA sequence analysis using a sequence-specific sequencing primer located upstream of the NdeI site. Plasmid pAH374-NdeΔ-1 was one plasmid isolated from this experiment.

A DNA fragment encoding the *C. trachomatis* L₂ HMWP
30 without the internal NdeI site, plasmid pAH374-NdeΔ-1, was PCR amplified from reactions programmed with plasmid pAH374-NdeΔ-1 (~50 ng) and primers 306-Nde-Met1 and 312H6Xba1. Primer 306NdeMet1 was designed to contain a central NdeI site for directed cloning onto pMG81. The NdeI site in 306NdeMet1
35 overlapped the ATG start codon for HMWP signal sequence and was flanked by a 20 base G/C clamp on the 5' side and

sequences complementary to the first 15 residues of the HMWP signal sequence on the 3' side. Primer 312H6XbaI was designed to contain sequences complementary to the C-terminus of the HMWP followed by a (CAT)₆ motif specifying a hexahistidine affinity purification domain. This primer also contained two UAA termination codons, an XbaI recognition sequence, and a 20 base G/C clamp at the 3' end of the primer. The sequences of the 306NdeMet1 and 312H6XbaI PCR primers are given below.

10

306NdeMet1 (SEQ ID NO: 40)

5'- AAG GGC CCA ATT ACG CAG ACA TAT GGA AAC GTC TTT CCA TAA
GTT CTT TCT TTC A - 3'

15 312H6XbaI (SEQ ID NO: 41)

5'- AAG GGC CCA ATT ACG CAG AGT CTA GAT TAT TAA TGA TGA TGA
TGA TGA TGG AAC CGG ACT CTA TTT CCT GCA CTC AAA CC - 3'

PCR amplification conditions described in Section 8.4 were used to generate the NdeI - XbaI HMWP gene cassette. Following amplification, the PCR product was purified using hydroxyapatite spin columns (QiaGen) and digested overnight at 37°C with a ~10-fold excess of NdeI and XbaI to generate the required 'overhangs' at the ends of the fragment. The digested fragment was again purified using spin columns and ~250 ng ligated to ~50 ng pMG81 plasmid DNA that had been previously digested to completion with NdeI and XbaI and subsequently treated with CIP to prevent vector religation. An aliquot of the ligation reaction was used to transform E.coli strain AR58 which had been made competent by the method of Lederberg and Cohen. Transformants were selected on 2X-YT agar containing 40 µg/ml kanamycin sulfate. Due to the temperature inducible promoter on pMG81, the transformed cells were grown at 30°C. Kanamycin-resistant transformants were picked at random and screened for the presence of plasmids ~3.0 Kbp larger in size than pMG81. Insert containing derivatives of pMG81 were confirmed by restriction

enzyme analysis using NdeI, XbaI, EcoRI and NcoI. Plasmid pJJ701 was one plasmid isolated from this exercise.

12. Example 16: PRODUCTION OF FULL LENGTH rHMWP FROM AR58 (PJJ701)

One milliliter of a frozen stock of E. coli strain AR58 containing plasmid pJJ701 was used to inoculate ~100 ml of 2X-YT broth containing 40 µg/ml kanamycin and grown overnight at 30°C to prepare a fermentor seed culture.

Approximately 20 ml of the overnight seed culture was then used to inoculate a New Brunswick Bioflow 3000 fermentor loaded with ~2.0l of 2X-YT broth containing 40 µg/ml kanamycin. The AR58 (pJJ701) culture was grown at 30°C with vigorous aeration until an O.D.₆₂₅ value of 0.5 - 0.6 was attained. Expression of rHMWP was induced by increasing the temperature of the fermentor culture to ~39°C to 42°C. Incubation at the elevated temperature was continued for approximately 4 - 5 hours.

At the end of the induction period, the E. coli culture, with some cells displaying classic recombinant protein inclusion bodies, was harvested by continuous flow centrifugation using an Heraeus Contifuge 28RS centrifuge. Following centrifugation, cell mass was scraped from the centrifuge bowl and stored at -70°C until processed.

Approximately 15 gm of the AR58 (pJJ701) frozen cell paste was resuspended by vortexing and trituration in ~40 ml of ice cold 10mM sodium phosphate buffer, pH7.3. Once suspended, lysozyme (Chicken egg white, Sigma) and DNase I (Bovine pancreas, Sigma) were added to final concentrations of 1.0 mg/ml and 0.01 mg/ml, respectively, and the mixture incubated on ice for 30 - 45 minutes. Cells were disrupted by 2 sequential passes through a pre-cooled (~4°C) SLM Aminco French Pressure Cell (~14 Kpsi, 1" diameter bore). The cell lysate was then centrifuged for 5min at ~500Xg (4°C) in a Sorvall SS34 rotor to remove unbroken cells. Insoluble material containing the rHMWP was isolated (pelleted) by centrifugation for 45min at ~20,000Xg (4°C) in a Sorvall SS34

rotor. The supernatant from this centrifugation was discarded and the insoluble fraction stored at -20°C in pellet form.

To selectively extract contaminating proteins and remove endotoxin, the rHMWP-containing insoluble pellet was thawed on ice and washed twice with 10ml of PBS buffer containing 2.0% Triton X-100. Washing was performed at room temperature and suspension of the gelatinous rHMWP-containing pellet was accomplished by vortexing and homogenization in a conventional glass tissue grinder. Insoluble material containing the rHMWP was recovered after washing by centrifugation at ~10,000Xg for 20 minutes (room temperature) in a Sorvall SS34 rotor. Insoluble material was then washed (again by vortexing and homogenization) 2-times with 10 ml of a 4.0 M urea solution containing 2.0 M NaCl. Washed rHMWP material was recovered by centrifugation as above. The insoluble rHMWP fraction was further washed 2-times with 10 ml of a PBS solution containing 1.0% Zwittergent 3-14 (Sigma).

The rHMWP pellet recovered after centrifugation of the final wash solution was then solubilized for 2 hours at room temperature in standard Laemmli SDS-PAGE sample buffer containing 4 M urea. Solubilized rHMWP was size fractionated into a single protein band of ~110 Kdal by electrophoresis through a standard ~14 cm X ~20 cm X ~3 mm 10% polyacrylamide (36:1, acrylamide:bis-acrylamide) Tris/glycine/SDS preparative gel. A 4% polyacrylamide stacking gel formed using a 5-well, ~500 µl/well preparative comb was polymerized on top of the resolving gel. Electrophoresis was carried out on a BioRad Protean unit for ~12 hours at ~22°C (~80 - 85 volts, constant voltage) using a conventional Tris/glycine/SDS running buffer (BioRad). Prestained molecular weight standards (SeeBlue, Novex) were loaded into a parallel lane and were used to gauge the degree and efficiency of separation of the protein species. Following electrophoresis, the gel sandwich was disassembled and a vertical slice was removed from the rHMWP sample lane

adjacent to the molecular weight markers and stained with
coomassie blue R250 to visualize the rHMWP band. The stained
section was then repositioned onto the remaining unstained
preparative gel and the strip of acrylamide containing the
5 rHMWP identified and excised.

rHMWP was eluted from the gel slice using a
Schleicher and Schuell EluTrap electroelution device.
Electroelution was carried out according to the manufacturers
recommendations except 1/4-strength SDS running buffer
10 (Novex) was used as the elution buffer. Elution was carried
out at ~40 mA for ~12-14 hours, at room temperature. At the
end of the elution period the polarity of the cell was
reversed for ~2-3 minutes to remove any protein absorbed to
the BT1 membrane. The rHMWP-containing solution was removed
15 from the collection chamber and stored in a polypropylene
conical tube at 4°C.

Excess SDS detergent was removed using an SDS
precipitation system (SDS-OUT Precipitation kit, Pierce
Chemical). Removal of excess detergent from the gel-eluted
20 protein solution was accomplished following the
manufacturer's protocol. Detergent extracted rHMWP was
diluted approximately 15 fold with sterile, endotoxin-free
10m Molar sodium phosphate buffer (pH 7.4) and concentrated
to approximately 1.0 mg/ml by ultrafiltration in an Amicon
25 stirred concentration cell using a YM30 ultrafiltration
membrane.

Residual endotoxin was removed from the
concentrated rHMWP solution by polymyxin B Affi-Prep
Polymyxin Matrix (BioRad) treatment. Affi-Prep treatment was
30 performed overnight at 4°C in a batch mode according to the
manufacturers recommendations.

The protein concentration of the concentrated,
polymyxin B-treated rHMWP was determined using the Micro BCA
method (Pierce Chem.) and BSA as a standard.

35 Purified rHMWP (~0.9-1.2 mg/ml protein
concentration) was evaluated for purity, identity, and
residual endotoxin burden by SDS-PAGE, Western blot, and a

colorimetric endotoxin assay (BioWhittaker), respectively. The gel-purified rHMWP material displayed a purity of >95% as a single band of the expected molecular size (~110 Kdal) by gel analysis and reacted vigorously with rHMWP-specific K196 5 antibody in Western blots. Residual endotoxin was calculated to be ≤ 0.05 EU/ μ g.

10

15

20

25

30

35

MICROORGANISMS

Optional Sheet in connection with the microorganism referred to on page 39, lines 20-21 of the description *

A. IDENTIFICATION OF DEPOSIT *

Further deposits are identified on an additional sheet *

Name of depositary institution *

American Type Culture Collection

Address of depositary institution (including postal code and country) *

10801 University Blvd.
Manassas, VA 20110-2209
US

Date of deposit * September 8, 1997 Accession Number * 985538

B. ADDITIONAL INDICATIONS * (leave blank if not applicable). This information is continued on a separate attached sheet

C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE * (if the indications are not all designated States)

D. SEPARATE FURNISHING OF INDICATIONS * (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later * (Specify the general nature of the indications e.g., "Accession Number of Deposit")

E. ☐ This sheet was received with the International application when filed (to be checked by the receiving Office)

(Authorized Officer)

☐ The date of receipt (from the applicant) by the International Bureau *

was

(Authorized Officer)

WHAT IS CLAIMED IS:

1. An isolated *Chlamydia* species HMW protein wherein the apparent molecular weight is about 105-115 kDa, as determined by SDS-PAGE, or a fragment or analogue thereof.

2. The protein of claim 1 which is substantially purified.

3. The protein of claim 1 wherein the *Chlamydia* species is *Chlamydia trachomatis*, *Chlamydia pecorum*, *Chlamydia psittaci* or *Chlamydia pneumoniae*.

4. The protein of claim 1 having an amino acid sequence shown in SEQ ID No.: 2, 15 or 16 or a fragment or conservatively substituted analogue thereof.

5. The fragment of claim 4, having an amino acid sequence shown in SEQ ID No.: 3, 17 or 25-37.

6. The protein of claim 1 recognizable by an antibody preparation that specifically binds to a peptide having an amino acid sequence of SEQ ID No.: 2, 15 or 16 or a fragment or conservatively substituted analogue thereof.

7. An isolated nucleic acid molecule encoding the HMW protein of claim 1 or a fragment or an analogue thereof.

8. The nucleic acid molecule of claim 7 wherein the *Chlamydia* species is *Chlamydia trachomatis*, *Chlamydia pecorum*, *Chlamydia psittaci* or *Chlamydia pneumoniae*.

9. The nucleic acid molecule of claim 7 wherein the encoded protein has the amino acid sequence of SEQ ID No.: 2, 15 or 16 or a fragment or conservatively substituted analogue thereof.

10. An isolated nucleic acid molecule having a sequence selected from the group consisting of:

- a) a DNA sequence of SEQ ID No.: 1, 23 or 24, or a complementary sequence or fragment thereof;
- 5 b) a DNA sequence encoding a HMW protein having the amino acid sequence of SEQ ID No.: 2, 15 or 16 or fragment thereof;
- c) a DNA sequence encoding a deduced amino acid sequence of SEQ ID No.: 2, 15 or 16 or the
10 complimentary or degenerate sequence thereto or fragment thereof; and
- d) a nucleic acid sequence which hybridizes under stringent conditions to any one of the sequences defined in a), b) or c).

15 11. A recombinant expression vector adapted for transformation of a host comprising the nucleic acid molecule of claim 7 or 10.

20 12. A recombinant expression vector adapted for transformation of a host comprising the nucleic acid molecule of claim 7 or 10 and expression means operatively coupled to the nucleic acid molecule for expression by the host of HMW protein or a fragment or analogue thereof.

25 13. The expression vector of claim 12, wherein the expression means includes a nucleic acid portion encoding a leader sequence for secretion from the host of the HMW protein or a fragment or analogue thereof.

30 14. A transformed host cell containing an expression vector of claim 12.

35 15. A transformed host cell containing an expression vector of claim 13.

16. An isolated recombinant protein or fragment or analogue thereof producible by the transformed host of claim 14.

5 17. An isolated recombinant protein or fragment or analogue thereof producible by the transformed host of claim 15.

18. A recombinant vector for delivery of a HMW
10 protein or fragment or analogue thereof to a host comprising the nucleic acid molecule of claim 7 or 10.

19. An immunogenic composition, comprising at least one component selected from the group consisting of:

- 15 a) an isolated HMW protein, wherein the apparent molecular weight is about 105-115 kDa, as determined by SDS-PAGE, or a fragment or conservatively substituted analogue thereof;
- 20 b) an isolated nucleic acid molecule encoding a HMW protein of a) or a fragment or analogue thereof;
- 25 c) an isolated nucleic acid molecule having the sequence of SEQ ID No.: 1, 23 or 24, the complimentary sequence thereto or a nucleic acid sequence which hybridizes under stringent conditions thereto or fragment thereof;
- 30 d) an isolated recombinant protein or fragment or analogue thereof producible in a transformed host comprising an expression vector comprising a nucleic acid molecule as defined in b) or c) and expression means operatively coupled to the nucleic acid molecule for expression by the host of said HMW protein or the fragment or analogue thereof;
- 35 e) a recombinant vector comprising a nucleic acid sequence of b) or c) encoding a HMW protein or fragment or analogue thereof; and

f) a transformed cell comprising the vector of e),
and optionally an adjuvant, and a pharmaceutically acceptable carrier or diluent therefor, said composition producing an
5 immune response when administered to a host.

20. An antigenic composition, comprising at least one component selected from the group consisting of:

- 10 a) an isolated HMW protein, wherein the apparent molecular weight is about 105-115 kDa as determined by SDS-PAGE, or a fragment or analogue thereof;
- 15 b) an isolated nucleic acid molecule encoding a HMW protein of a), or a fragment or analogue thereof;
- 20 c) an isolated nucleic acid molecule having the sequence of SEQ ID No.: 1, 22, 23 or 24, the complimentary or degenerate sequence thereto or a nucleic acid sequence which hybridizes under stringent conditions thereto;
- 25 d) an isolated recombinant protein or fragment or analogue thereof producible in a transformed host comprising an expression vector comprising a nucleic acid molecule as defined in b) or c) and expression means operatively coupled to the nucleic acid molecule for expression by the host of said HMW protein or the fragment or analogue thereof;
- 30 e) a recombinant vector, comprising a nucleic acid sequence of b) or c) encoding a HMW protein or fragment or analogue thereof; and
- f) a transformed cell comprising the vector of e),

and optionally an adjuvant, said composition producing an
35 immune response when administered to a host.

21. A method of producing an immune response in an animal comprising administering to said animal an effective amount of the antigenic composition of claim 20 or the immunogenic composition of claim 19.

5

22. The method of claim 21 wherein the animal is a mammal or a bird.

23. Antisera raised against the antigenic
10 composition of claim 20 or the immunogenic composition of claim 19.

24. Antibodies present in the antisera of claim 23 that specifically bind a HMW protein or a fragment or
15 analogue thereof.

25. A diagnostic reagent selected from the group consisting of: the protein of claim 1, the nucleic acid molecule of claim 10, the immunogenic composition of claim
20 20, the antigenic composition of claim 19, the antisera of claim 23, the vector of claim 12, the transformed cell of claim 14, and the antibodies of claim 24.

26. A method for detecting anti-*Chlamydia*
25 antibodies in a test sample comprising the steps of:

- a) contacting a sample with the HMW protein of claim 1, the antigenic composition of claim 20 or the immunogenic composition of claim 19 to form, in the presence of said antibodies, *Chlamydia* antigen: anti-*Chlamydia* antibody immunocomplexes, and further,
30
- b) either detecting the presence of or measuring the amount of said immunocomplexes formed during step a) as an indication of the
35 presence of said anti-*Chlamydia* antibodies in the test sample.

27. A diagnostic kit for detecting antibodies to *Chlamydia*, said kit comprising the HMW protein of claim 1, the antigenic composition of claim 20 or the immunogenic composition of claim 19, a container means for contacting said protein or composition with a test sample suspected of having said antibodies and reagent means for detecting or measuring *Chlamydia* antigen: anti-*Chlamydia* antibody immunocomplexes formed between said protein or composition and said antibodies.

10

28. A method for detecting the presence of *Chlamydia* in a test sample comprising the steps of:

- 15
- a) contacting a test sample with the antibodies of claim 24 for a time sufficient to allow said antibodies to bind *Chlamydia*, if present, and to form a *Chlamydia*: anti-*Chlamydia* antibody immunocomplexes, and further,
- 20
- b) either detecting the presence of or measuring the amount of said immunocomplexes formed during step a) as an indication of the presence of said *Chlamydia* in the test sample.

29. A diagnostic kit for detecting the presence of *Chlamydia*, said kit comprising the antibodies of claim 24, container means for contacting said antibodies with a test sample suspected of having said *Chlamydia* and reagent means for detecting or measuring *Chlamydia*: anti-*Chlamydia* antibody immunocomplexes formed between said antibodies and said *Chlamydia*.

30

30. A pharmaceutical composition comprising an effective amount of at least one component selected from the group consisting of:

- 35
- a) a HMW protein, wherein the apparent molecular weight is about 105-115 kDa, as determined by SDS-PAGE, or a fragment or analogue thereof;

- 002040-0252450
- b) an isolated nucleic acid molecule encoding a HMW protein of a), or a fragment or analogue thereof;
 - 5 c) an isolated nucleic acid molecule having the sequence of SEQ ID No.: 1, 23 or 24, the complimentary or degenerate sequence thereto or a nucleic acid sequence which hybridizes under stringent conditions thereto;
 - 10 d) an isolated recombinant HMW protein or fragment or analogue thereof producible in a transformed host comprising an expression vector comprising a nucleic acid molecule as defined in b) or c) and expression means operatively coupled to the nucleic acid
 - 15 molecule for expression by the host of said HMW protein or the fragment or analogue thereof;
 - e) a recombinant vector, comprising a nucleic acid sequence of b) or c) encoding a HMW
 - 20 protein or fragment or analogue thereof;
 - f) a transformed cell comprising the vector of e), and
 - g) antibodies that specifically bind the component of a), b), c), d), e) or f),
 - 25 and optionally a pharmaceutically acceptable carrier or diluent therefor.

31. A vaccine composition comprising an effective amount of at least one component selected from the group

30 consisting of:

- a) a HMW protein, wherein the apparent molecular weight is about 105-115 kDa, as determined by SDS-PAGE, or a fragment or analogue thereof;
- 35 b) an isolated nucleic acid molecule encoding a HMW protein of a) or a fragment or analogue thereof;

tubal occlusion, infertility, cervical cancer, arteriosclerosis and atherosclerosis.

34. The method of claim 33 wherein the host is a
5 bird or a mammal.

35. The composition of any one of claims 19, 20,
30 or 31 formulated for *in vivo* administration to a host to
confer protection against disease caused by a species of
10 *Chlamydia*.

36. The composition of any one of claims 19, 20,
30, or 31 wherein the species is selected from the group
consisting of *Chlamydia trachomatis*, *Chlamydia pecorum*,
15 *Chlamydia psittaci* and *Chlamydia pneumoniae*.

37. The composition of any one of claims 19, 20,
30 or 31 formulated as a microparticle, capsule, or liposome
preparation.
20

38. The protein of any one of claims 1, 4, 6, 16
and 17, wherein the protein binds to heparin or heparan-
sulfate.

39. The protein of any one of claims 1, 4, 6, 16
or 17, wherein the protein is an outer membrane protein.
25

40. A method for determining the presence of
nucleic acid encoding a HMW protein or a fragment or analogue
30 thereof in a sample, comprising the steps of:

a) contacting a sample with the nucleic acid
molecule of claim 7 or 10 or any fragment
thereof or complementary thereto to produce
duplexes comprising the nucleic acid molecule
and any said nucleic acid molecule encoding
35 the HMW protein in the sample and specifically
hybridizable therewith; and

b) determining the production of duplexes.

41. A diagnostic kit for determining the presence of nucleic acid encoding a HMW protein or fragment or
5 analogue thereof in a sample, comprising:

a) the nucleic acid molecule of claim 7 or 10 or any fragment thereof or complementary thereto;

10 b) means for contacting the nucleic acid with the sample to produce duplexes comprising the nucleic acid molecule and any said nucleic acid encoding the HMW protein in the sample and specifically hybridizable therewith; and

c) means for determining the production of duplexes.

15

20

25

30

35

[illegible]

35

30 —



Figure 2.

GGGCAAAACTCTTCCCCCGGGATTTATATGGGAAAGGGGAAACTTTGGC
CCGTATTCAAGCGCCACGGGTTTTGGGGCGGAATGAATTTTTTCGTTCCG
5 GAAAAAGTAATTCCCCGGGAACGTAGGGTATCGGTTTCATAGGCTCGCCA
AATGGGATATAGGTGGAAAGGTAAAAAACTGAGCCAAGCAAAGGATAG
AGAAGTCTTGTAATCATCGCAGGTTAAAGGGGGGATGTTATTTTAGCCTG
CAAATAGTGTAATTATTGGATCCTGTAAAGAGAAAAGGACGAATGCGCTG
AAGATAAGAACATTTATTGATATTAAATTATTAATTTTTTATGAAGCGGA
10 GTAATTAATTTTATCTCTCAGCTTTTGTGTGATGCAAACGTCTTCCATA
AGTTCTTTCTTCAATGATTCTAGCTTATTCTTGCTGCTCTTTAAATGGG
GGGGGATATGCAGCAGAAATCATGGTTCCTCAAGGAATTTACGATGGGGA
GACGTTAACTGTATCATTTCCCTATACTGTTATAGGAGATCCGAGTGGGA
CTACTGTTTTTTCTGCAGGAGAGTTAACATTAAAAAATCTTGACAATTCT
15 ATTCAGCTTTGCCTTTAAGTTGTTTTGGGAACCTATTAGGGAGTTTTAC
TGTTTTAGGGAGAGGACACTCGTTGACTTTCGAGAACATACGGACTTCTA
CAAATGGGGCAGCTCTAAGTAATAGCGCTGCTGATGGACTGTTTACTATT
GAGGGTTTTTAAAGAATTATCCTTTTCCAATTGCAATTCATTACTTGCCGT
20 ACTGCCTGCTGCAACGACTAATAAGGGTAGCCGACTCCGACGACAACAT
CTACACCGTCTAATGGTACTATTTATTCTAAAACAGATCTTTTGTTACTC
AATAATGAGAAGTCTCATTCTATAGTAATTTAGTCTCTGGAGATGGGGG
AGCTATAGATGCTAAGAGCTTAACGGTTCAAGGAATTAGCAAGCTTTGTG
TCTTCCAAGAAAATACTGCTCAAGCTGATGGGGGAGCTTGTCAAGTAGTC
25 ACCAGTTTCTCTGCTATGGCTAACGAGGCTCCTATTGCCTTTGTAGCGAA
TGTTGCAGGAGTAAGAGGGGGAGGGATTGCTGCTGTTCAGGATGGGCAGC
AGGGAGTGTCATCATCTACTTCAACAGAAGATCCAGTAGTAAGTTTTTCC
AGAAATACTGCGGTAGAGTTTGATGGGAACGTAGCCCGAGTAGGAGGAGG
GATTTACTCCTACGGGAACGTTGCTTTTCTGAATAATGGAAAAACCTTG
30 TTCTCAACAATGTTGCTTCTCCTGTTTACATTGCTGCTAAGCAACCAACA
AGTGGACAGGCTTCTAATACGAGTAATAATTACGGAGATGGAGGAGCTAT
CTTCTGTAAGAATGGTGCGCAAGCAGGATCCAATAACTCTGGATCAGTTT
CCTTTGATGGAGAGGGAGTAGTTTTCTTTAGTAGCAATGTAGCTGCTGGG
AAAGGGGGAGCTATTTATGCCAAAAGCTCTCGGTTGCTAACTGTGGCCC
35 TGTACAATTTTAAAGGAATATCGCTAATGATGGTGGAGCGATTTATTAG
GAGAATCTGGAGAGCTCAGTTTATCTGCTGATTATGGAGATATTATTTTC

GATGGGAATCTTAAAAGAACAGCCAAAGAGAATGCTGCCGATGTTAATGG
 CGTAACTGTGTCCTCACAAGCCATTTTCGATGGGATCGGGAGGGAAAATAA
 CGACATTAAGAGCTAAAGCAGGGCATCAGATTCTCTTTAATGATCCCATC
 GAGATGGCAAACGGAAATAACCAGCCAGCGCAGTCTTCCAAACTTCTAAA
 5 AATTAACGATGGTGAAGGATACACAGGGGATATTGTTTTTGCTAATGGAA
 GCAGTACTTTGTACCAAATGTTACGATAGAGCAAGGAAGGATTGTTCTT
 CGTGAAAAGGCAAATTATCAGTGAATTCTCTAAGTCAGACAGGTGGGAG
 TCTGTATATGGAAGCTGGGAGTACATGGGATTTTGTAACCTCACAACCAC
 CACAACAGCCTCCTGCCGCTAATCAGTTGATCACGCTTCCAATCTGCAT
 10 TTGTCTCTTTCTTCTTTGTTAGCAAACAATGCAGTTACGAATCCTCCTAC
 CAATCCTCCAGCGCAAGATTCTCATCCTGCAGTCATTGGTAGCACAACCTG
 CTGGTTCTGTTACAATTAGTGGGCCTATCTTTTTTGAGGATTGGATGAT
 ACAGCTTATGATAGGTATGATTGGCTAGGTTCTAATCAAAAAATCAATGT
 CCTGAAATTACAGTTAGGGACTAAGCCCCAGCTAATGCCCCATCAGATT
 15 TGA CTCTAGGGAATGAGATGCCTAAGTATGGCTATCAAGGAAGCTGGAAG
 CTTGCGTGGGATCCTAATACAGCAAATAATGGTCCTTATACTCTGAAAGC
 TACATGGACTAAAACTGGGTATAATCCTGGGCCTGAGCGAGTAGCTTCTT
 TGGTTCCAAATAGTTTATGGGGATCCATTTTAGATATACGATCTGCGCAT
 20 TCAGCAATTCAAGCAAGTGTGGATGGGCGCTCTTATTGTGAGGATTATG
 GGTTTCTGGAGTTTCGAATTTCTTCTATCATGACCGCGATGCTTTAGGTC
 AGGGATATCGGTATATTAGTGGGGGTTATTCCTTAGGAGCAAACCTCTAC
 TTTGGATCATCGATGTTTGGTCTAGCATTTACCGAAGTATTTGGTAGATC
 TAAAGATTATGTAGTGTGTCGTTCCAATCATCATGCTTGCATAGGATCCG
 25 TTTATCTATCTACCCAACAAGCTTTATGTGGATCCTATTTGTTTCGGAGAT
 GCGTTTATCCGTGCTAGCTACGGGTTTGGGAATCAGCATATGAAAACCTC
 ATATACATTTGCAGAGGAGAGCGATGTTTCGTTGGGATAATAACTGTCTGG
 CTGGAGAGATTGGAGCGGGATTACCGATTGTGATTACTCCATCTAAGCTC
 TATTTGAATGAGTTGCGTCCTTTTCGTGCAAGCTGAGTTTTCTTATGCCGA
 30 TCATGAATCTTTTACAGAGGAAGGCGATCAAGCTCGGGCATTCAAGAGCG
 GACATCTCCTAAATCTATCAGTTCCCTGTTGGAGTGAAATTTGATCGATGT
 TCTAGTACACATCCTAATAAATATAGCTTTATGGCGGCTTATATCTGTGA
 TGCTTATCGCACCATCTCTGGTACTGAGACAACGCTCCTATCCCATCAAG
 AGACATGGACAACAGATGCCTTTCAATTTAGCAAGACATGGAGTTGTGGTT
 35 AGAGGATCTATGTATGCTTCTCTAACAAGTAATATAGAAGTATATGGCCA
 TGGAAGATATGAGTATCGAGATGCTTCTCGAGGCTATGGTTTGAGTGCAG

GAAGTAGAGTCCGGTTCTAAAAATATTGGTTAGATAGTTAAGTGTTAGCG
ATGCCTTTTTCTTTGAGATCTACATCATTTTTGTTTTTTAGCTTGTTTGTG
TTCCTATTCGTATGGATTCGCGAGCTCTCCTCAAGTGTTAACGCCTAATG
TAACCACTCCTTTTAAGGGAGACGATGTTTACTTGAATGGAGACTGCGCT
5 TTTGTCAATGTCTATGCAGGAGCTGAAGAAGGTTTCGATTATCTCAGCTAA
TGGCGACAATTTAACGATTACCGGACAAAACCATAACATTATCATTACAG
ATTCTCAAGGGCCAGTTCTTCAAATTATGCCTTCATTTACAGCAGGAGAG
ACACTTACTCTGAGAGATTTTTCGAGTCTGATGTTCTCGAAAAATGTTTC
TTGCGGAGAAAAGGGAATGATCTCCGGGAAAACCGTGAGTATTTCCGGAG
10 CAGGCGAAGTGATTTTTCTGGGATAACTCCGTGGGGTATTCTCCTTTATCT
ACTGTGCCAACCTCATCATCAACTCCGCCTGCTCCAACAGTTAGTGATGC
TCGGAAAGGGTCTATTTTTTCTGTAGAGACTAGTTTGGAGATCTCAGGCG
TCAAAAAGGGGTCATGTTTCGATAATAATGCCGGGAATTTCCGGAACAGTT
TTTCGAGGTAAGAATAATAATAATGCTGGTGGTGGAGGCAGTGGGTTCG
15 CTACACCATCAAGTACGACTTTTACAGTTAAAACTGTAAAGGGAAAGTT
TCTTTCACAGATAACGTAGCCTCTTGCGGAGGCGGAGTGGTTTATAAAGG
CATTGTGCTTTTCAAAGACAATGAAGGAGGCATATCTTCCGAGGGAACA
CAGCATACGATGATTTAAGGATTCTTGCTGCTACTAATCAGGATCAGAAT
20 ACGGAGACAGGAGGCGGTGGAGGAGTTATTTGCTCTCCAGATGATTCTGT
AAAGTTTGAAGGCAATAAAGGTTCTATTGTTTTTGATTACAACCTTGCAA
AAGGCAGAGGCGGAAGCATCCTAACGAAAGAATTC

25

30

35

Figure 3.


MQTSFHKFFLSMILAYSCCSLNGGGYAAEIMVPQGIYDGETLTVSFPYTV
IGDPSGTTVFSAGELTLKNLDNSIAALPLSCFGNLLGSFTVLGRGHS�TF
5 ENIRTSTNGAALSNSAADGLFTIEGFKELSFNSCNSLLAVLPAATTNKG
QTPTTTSTPSNGTIYSKTDLLLLNNEKFSFYSNLVSGDGGIDAISLTVQ
GISKLCVFQENTAQADGGACQVVTSSAMANEAPIAFVANVAGVRGGGIA
AVQDGOQGVSSSTSTEDPVVSFSRNTAVEFDGNVARVGGGIYSYGNVAF
NNGKTLFLNNVASPVYIAAKQPTSGQASNTSNNYGDGGAI FCKNGAQAGS
10 NNSGVS F DGEVGVFFSSNVAAGKGGAIYAKKLSVANCGPVQFLRNIAND
GGAIYLGESGELSLSADYGDII FDGNLKR TAKENAADVNGVTVSSQAISM
GSGGKITTLRAKAGHQILFNDPIEMANGNNQPAQSSKLLKINDGEGYTG
IVFANGSSTLYQNVTTIEQGRIVLREKAKLSVNSLSQTGGSLYMEAGSTWD
FVTPQPPQPPAANQLITLSNLHLSLSLLANNAVTPNPPNPPAQDHPA
15 VIGSTTAGSVTISGPIFFEDLDDTAYDRYDWLGSNQKINVLLKLQLGTKPP
ANAPSDLT LGNEMP KYGYQGSWK LAWDPNTANNGPYTLKATWTKTGYNPG
PERVASLVPNSLWGSILDIRSAHSAIQASVDGRSYCRGLWVSGVSNFFYH
DRDALGQGYRYISGGYSLGANSYFGSSMFGLAFTEVFGRSKDYVVCRSNH
20 HACIGSVYLSTQQALCGSYLFGDAFIRASYGFGNQHMKTSYTFAEESDVR
WDNNCLAGEIGAGLPIVITPSKLYLNELRPFVQAEFSYADHESFTEEGDQ
ARAFKSGHLLNLSVPVGVKFDRCSSTHPNKYSFMAAYICDAYRTISGTET
TLLSHQETWTTDAFHRLARHGVVVRGSMYASLTSNIEVYGHGRYEYRDASR
GYGLSAGSRVRF#

25

30

35

Figure 4



1. **Introduction**
 2. **Background**
 3. **Methodology**
 4. **Results**
 5. **Discussion**
 6. **Conclusion**
 7. **References**
 8. **Appendix**
 9. **Figure 1**
 10. **Figure 2**
 11. **Figure 3**
 12. **Figure 4**
 13. **Figure 5**
 14. **Figure 6**
 15. **Figure 7**
 16. **Figure 8**
 17. **Figure 9**
 18. **Figure 10**
 19. **Figure 11**
 20. **Figure 12**
 21. **Figure 13**
 22. **Figure 14**
 23. **Figure 15**
 24. **Figure 16**
 25. **Figure 17**
 26. **Figure 18**
 27. **Figure 19**
 28. **Figure 20**
 29. **Figure 21**
 30. **Figure 22**
 31. **Figure 23**
 32. **Figure 24**
 33. **Figure 25**
 34. **Figure 26**
 35. **Figure 27**
 36. **Figure 28**
 37. **Figure 29**
 38. **Figure 30**
 39. **Figure 31**
 40. **Figure 32**
 41. **Figure 33**
 42. **Figure 34**
 43. **Figure 35**
 44. **Figure 36**
 45. **Figure 37**
 46. **Figure 38**
 47. **Figure 39**
 48. **Figure 40**
 49. **Figure 41**
 50. **Figure 42**
 51. **Figure 43**
 52. **Figure 44**
 53. **Figure 45**
 54. **Figure 46**
 55. **Figure 47**
 56. **Figure 48**
 57. **Figure 49**
 58. **Figure 50**
 59. **Figure 51**
 60. **Figure 52**
 61. **Figure 53**
 62. **Figure 54**
 63. **Figure 55**
 64. **Figure 56**
 65. **Figure 57**
 66. **Figure 58**
 67. **Figure 59**
 68. **Figure 60**
 69. **Figure 61**
 70. **Figure 62**
 71. **Figure 63**
 72. **Figure 64**
 73. **Figure 65**
 74. **Figure 66**
 75. **Figure 67**
 76. **Figure 68**
 77. **Figure 69**
 78. **Figure 70**
 79. **Figure 71**
 80. **Figure 72**
 81. **Figure 73**
 82. **Figure 74**
 83. **Figure 75**
 84. **Figure 76**
 85. **Figure 77**
 86. **Figure 78**
 87. **Figure 79**
 88. **Figure 80**
 89. **Figure 81**
 90. **Figure 82**
 91. **Figure 83**
 92. **Figure 84**
 93. **Figure 85**
 94. **Figure 86**
 95. **Figure 87**
 96. **Figure 88**
 97. **Figure 89**
 98. **Figure 90**
 99. **Figure 91**
 100. **Figure 92**
 101. **Figure 93**
 102. **Figure 94**
 103. **Figure 95**
 104. **Figure 96**
 105. **Figure 97**
 106. **Figure 98**
 107. **Figure 99**
 108. **Figure 100**
 109. **Figure 101**
 110. **Figure 102**
 111. **Figure 103**
 112. **Figure 104**
 113. **Figure 105**
 114. **Figure 106**
 115. **Figure 107**
 116. **Figure 108**
 117. **Figure 109**
 118. **Figure 110**
 119. **Figure 111**
 120. **Figure 112**
 121. **Figure 113**
 122. **Figure 114**
 123. **Figure 115**
 124. **Figure 116**
 125. **Figure 117**
 126. **Figure 118**
 127. **Figure 119**
 128. **Figure 120**
 129. **Figure 121**
 130. **Figure 122**
 131. **Figure 123**
 132. **Figure 124**
 133. **Figure 125**
 134. **Figure 126**
 135. **Figure 127**
 136. **Figure 128**
 137. **Figure 129**
 138. **Figure 130**
 139. **Figure 131**
 140. **Figure 132**
 141. **Figure 133**
 142. **Figure 134**
 143. **Figure 135**
 144. **Figure 136**
 145. **Figure 137**
 146. **Figure 138**
 147. **Figure 139**
 148. **Figure 140**
 149. **Figure 141**
 150. **Figure 142**
 151. **Figure 143**
 152. **Figure 144**
 153. **Figure 145**
 154. **Figure 146**
 155. **Figure 147**
 156. **Figure 148**
 157. **Figure 149**
 158. **Figure 150**
 159. **Figure 151**
 160. **Figure 152**
 161. **Figure 153**
 162. **Figure 154**
 163. **Figure 155**
 164. **Figure 156**
 165. **Figure 157**
 166. **Figure 158**
 167. **Figure 159**
 168. **Figure 160**
 169. **Figure 161**
 170. **Figure 162**
 171. **Figure 163**
 172. **Figure 164**
 173. **Figure 165**
 174. **Figure 166**
 175. **Figure 167**
 176. **Figure 168**
 177. **Figure 169**
 178. **Figure 170**
 179. **Figure 171**
 180. **Figure 172**
 181. **Figure 173**
 182. **Figure 174**
 183. **Figure 175**
 184. **Figure 176**
 185. **Figure 177**
 186. **Figure 178**
 187. **Figure 179**
 188. **Figure 180**
 189. **Figure 181**
 190. **Figure 182**
 191. **Figure 183**
 192. **Figure 184**
 193. **Figure 185**
 194. **Figure 186**
 195. **Figure 187**
 196. **Figure 188**
 197. **Figure 189**
 198. **Figure 190**
 199. **Figure 191**
 200. **Figure 192**
 201. **Figure 193**
 202. **Figure 194**
 203. **Figure 195**
 204. **Figure 196**
 205. **Figure 197**
 206. **Figure 198**
 207. **Figure 199**
 208. **Figure 200**
 209. **Figure 201**
 210. **Figure 202**
 211. **Figure 203**
 212. **Figure 204**
 213. **Figure 205**
 214. **Figure 206**
 215. **Figure 207**
 216. **Figure 208**
 217. **Figure 209**




Figure 6




Figure 6 cont'd

L₂ SQTGGSLYMEAGSTWDFVTPQPPQPPAANQLITLSNLHLSLSSLLANNAVITNPPTNP
 F
 B

600*

L₂ PAQDSHPAVIGSTTAGSVTISGPIFFEDLDDTAYDRYDWLGSNQNVLKLQLGTPKPPA
 F
 B

700*

L₂ NAPSDLTLGNEMPKYGYQGSWKLAWDPNTANNGPYTLKATWTKTGYNPGPERVASLV
 F
 B

L₂ PNSLWGSILDIRSAHSAIQASVDGRSYCRGLWVSGVSNFFYHDRDALGQGYRYISGGYS
 F
 B

800*

L₂ LGANSYFGSSMFGLAFTVFGGRSKDYVCRSNHHACIGSVYLSTQQAALCGSYLFGDAFI
 F
 B

L₂ RASYGFGNQHMKTSYTFEESDVRWDNNCLAGEIGAGLPVITPSKLYLNELRPFVQAEF
 F
 B

900*

L₂ SYADHESFTEEGDQARAFKSGHLLNLSVPVGVKFDRCSSTHPNKYSFMAAYICDAYRTI
 F
 B

1000*

L₂ SGTETTLTLLSHQETWTTDAFHRLRHGVVVRGSMYASLTSNIEVYGHGRYEYRDASRGYGL
 F
 B


1013*

L₂ SAGSRVRF
 F
 B

000040-00004000

[illegible]

Figure 7B



DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below at 201 et seq. underneath my name.

I believe I am the original, first and sole inventor if only one name is listed at 201 below, or an original, first and joint inventor if plural names are listed at 201 et seq. below, of the subject matter which is claimed and for which a patent is sought on the invention entitled

CHLAMYDIA PROTEIN, GENE SEQUENCE AND USES THEREOF

and for which a patent application:

☒ is attached hereto and includes amendment(s) filed on (if applicable)

☐ was filed in the United States on as Application No. (for declaration not accompanying application)

with amendment(s) filed on (if applicable)

☒ was filed as PCT international Application No. PCT/US98/20737 on October 1, 1998 and was amended under PCT Article 19 on (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED PRIOR TO THE FILING DATE OF THE APPLICATION			
APPLICATION NUMBER	COUNTRY	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
			YES <input type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER	FILING DATE

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS		
		PATENTED	PENDING	ABANDONED
08/942,596	10/02/97		X	
PCT/US98/20737	10/01/98		X	

POWER OF ATTORNEY: As a named inventor, I hereby appoint S. Leslie Misrock (Reg. No. 18872), Harry C. Jones, III (Reg. No. 20280), Berj A. Terzian (Reg. No. 20060), David Weild, III (Reg. No. 21094), Jonathan A. Marshall (Reg. No. 24614), Barry D. Rein (Reg. No. 22411), Stanton T. Lawrence, III (Reg. No. 25736), Charles E. McKenney (Reg. No. 22795), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Charles E. Miller (Reg. No. 24576), Gidon D. Stern (Reg. No. 27469), John J. Lauter, Jr. (Reg. No. 27814), Brian M. Poissant (Reg. No. 28462), Brian D. Coggio (Reg. No. 27624), Rory J. Radding (Reg. No. 28749), Stephen J. Harbulak (Reg. No. 29166), Donald J. Goodell (Reg. No. 19766), James N. Palik (Reg. No. 25510), Thomas E. Friebe (Reg. No. 29258), Laura A. Coruzzi (Reg. No. 30742), Jennifer Gordon (Reg. No. 30753), Allan A. Fanucci (Reg. No. 30256), Geraldine F. Baldwin (Reg. No. 31232), Victor N. Balancia (Reg. No. 31231), Samuel B. Abrams (Reg. No. 30605), Steven I. Wallach (Reg. No. 35402), Marcia H. Sundeen (Reg. No. 30893), Paul J. Zegger (Reg. No. 33821), Edmond R. Bannon (Reg. No. 32110), Bruce J. Barker (Reg. No. 33291), Adriane M. Antler (Reg. No. 32605), Thomas G. Rowan (Reg. No. 34419), James G. Markey (Reg. No. 31636), Thomas D. Kohler (Reg. No. 32797), Scott D. Stimpson (Reg. No. 33607), Gary S. Williams (Reg. No. 31066), William S. Galliani (Reg. No. 33885), Ann L. Gisolfi (Reg. No. 31956), Todd A. Wagner (Reg. No. 35399), Scott B. Familant (Reg. No. 35514), Kelly D. Talcott (Reg. No. 39582), Francis D. Cerrito (Reg. No. 38100), Anthony M. Insogna (Reg. No. 35203), Brian M. Rothery (Reg. No. 35340), Brian D. Siff (Reg. No. 35679), and Alan Tenenbaum (Reg. No. 34939), all of Pennie & Edmonds LLP, whose addresses are 1155 Avenue of the Americas, New York, New York 10036, 1667 K Street N.W., Washington, DC 20006 and 3300 Hillview Avenue, Palo Alto, CA 94304, and each of them, my attorneys, to prosecute this application, and to transact all business in the Patent and Trademark Office connected therewith.

SEND CORRESPONDENCE TO:

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, N.Y. 10036-2711

DIRECT TELEPHONE CALLS TO:
PENNIE & EDMONDS LLP DOCKETING
(212) 790-2803

201	FULL NAME OF INVENTOR	LAST NAME JACKSON	FIRST NAME W.	MIDDLE NAME JAMES	
	RESIDENCE & CITIZENSHIP	CITY MARRIOTTSTVILLE	STATE OR FOREIGN COUNTRY MARYLAND	COUNTRY OF CITIZENSHIP U.S.A.	
	POST OFFICE ADDRESS	STREET 1687 ARMISTIC WAY	CITY MARRIOTTSTVILLE	STATE OR COUNTRY MARYLAND	ZIP CODE 21104
202	FULL NAME OF INVENTOR	LAST NAME PACE	FIRST NAME JOHN	MIDDLE NAME L.	
	RESIDENCE & CITIZENSHIP	CITY GERMANTOWN	STATE OR FOREIGN COUNTRY MARYLAND	COUNTRY OF CITIZENSHIP U.S.A.	
	POST OFFICE ADDRESS	STREET 20408 AFTERNOON LANE	CITY GERMANTOWN	STATE OR COUNTRY MARYLAND	ZIP CODE 20874
203	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE
204	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE
205	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE
206	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201 James W. Jackson	SIGNATURE OF INVENTOR 202 John L. Pace	SIGNATURE OF INVENTOR 203
DATE	DATE	DATE
SIGNATURE OF INVENTOR 204	SIGNATURE OF INVENTOR 205	SIGNATURE OF INVENTOR 206
DATE	DATE	DATE

SEQUENCE LISTING

<110> ANTEXBIOLOGICS, INC.

<120> CHLAMYDIA PROTEIN, GENE SEQUENCE AND USES THEREOF

<130> 7969-076

<140>

<141>

<150> 08/942,596

<151> 1997-10-02

<160> 41

<170> PatentIn Ver. 2.0

<210> 1

<211> 4435

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
recombinant expression vector

<400> 1

```

gggcaaaact cttccccccg ggatttatat gggaaagggg aaactttggc ccgtattcaa 60
gcgccacggg ttttggggcg gaatgaattt tttcgttccg gaaaaagtaa ttccccggga 120
acgtagggta tcggtttcat aggctcgcca aatgggatat aggtggaaag gtaaaaaaaaa 180
ctgagccaag caaaggatag agaagtcttg taatcatcgc aggttaaagg ggggatgtta 240
ttttagcctg caaatagtgt aattattgga tcctgtaaag agaaaaggac gaatgcgctg 300
aagataagaa catttattga tattaatta ttaatttttt atgaagcgga gtaattaatt 360
ttatctctca gcttttgtgt gatgcaaacg tctttccata agttctttct ttcaatgatt 420
ctagcttatt cttgctgctc tttaaatggg gggggatatg cagcagaaat catggttcct 480
caaggaattt acgatgggga gacgttaact gtatcatttc cctatactgt tataggagat 540
ccgagtggga ctactgtttt ttctgcagga gagttaacat taaaaaatct tgacaattct 600
attgcagctt tgcctttaag ttgttttggg aacttattag ggagttttac tgttttaggg 660
agaggacact cgttgacttt cgagaacata cggacttcta caaatggggc agctctaagt 720
aatagcgctg ctgatggact gtttactatt gagggtttta aagaattatc cttttccaat 780
tgcaattcat tacttgccgt actgcctgct gcaacgacta ataagggtag ccagactccg 840
acgacaacat ctacaccgtc taatggtact atttattcta aaacagatct tttgttactc 900
aataatgaga agttctcatt ctatagtaat ttagtctctg gagatggggg agctatagat 960
gctaagagct taacggttca aggaattagc aagctttgtg tcttccaaga aaatactgct 1020
caagctgatg ggggagcttg tcaagtagtc accagtttct ctgctatggc taacgaggct 1080
cctattgcct ttgtagcgaa tgttgcagga gtaagagggg gagggattgc tgctgttcag 1140
gatgggcagc agggagtgtc atcatctact tcaacagaag atccagtagt aagtttttcc 1200

```


ggtggaggca gtgggttccg ctacaccatc aagtacgact ttacagtta aaaactgtaa 4140
 agggaaagtt tctttcacag ataacgtagc ctcttgcgga ggcggagtgg ttataaaagg 4200
 cattgtgctt ttcaaagaca atgaaggagg catattcttc cgagggaaca cagcatacga 4260
 tgatttaagg attcttgctg ctactaatca ggatcagaat acggagacag gaggcggtgg 4320
 aggagttatt tgctctccag atgattctgt aaagtttgaa ggcaataaag gttctattgt 4380
 ttttgattac aactttgcaa aaggcagagg cggaagcatc ctaacgaaag aattc 4435

<210> 2

<211> 1012

<212> PRT

<213> Chlamydia

<400> 2

Met Gln Thr Ser Phe His Lys Phe Phe Leu Ser Met Ile Leu Ala Tyr
 1 5 10 15

Ser Cys Cys Ser Leu Asn Gly Gly Gly Tyr Ala Ala Glu Ile Met Val
 20 25 30

Pro Gln Gly Ile Tyr Asp Gly Glu Thr Leu Thr Val Ser Phe Pro Tyr
 35 40 45

Thr Val Ile Gly Asp Pro Ser Gly Thr Thr Val Phe Ser Ala Gly Glu
 50 55 60

Leu Thr Leu Lys Asn Leu Asp Asn Ser Ile Ala Ala Leu Pro Leu Ser
 65 70 75 80

Cys Phe Gly Asn Leu Leu Gly Ser Phe Thr Val Leu Gly Arg Gly His
 85 90 95

Ser Leu Thr Phe Glu Asn Ile Arg Thr Ser Thr Asn Gly Ala Ala Leu
 100 105 110

Ser Asn Ser Ala Ala Asp Gly Leu Phe Thr Ile Glu Gly Phe Lys Glu
 115 120 125

Leu Ser Phe Ser Asn Cys Asn Ser Leu Leu Ala Val Leu Pro Ala Ala
 130 135 140

Thr Thr Asn Lys Gly Ser Gln Thr Pro Thr Thr Ser Thr Pro Ser
 145 150 155 160

Asn Gly Thr Ile Tyr Ser Lys Thr Asp Leu Leu Leu Leu Asn Asn Glu
 165 170 175

Lys Phe Ser Phe Tyr Ser Asn Leu Val Ser Gly Asp Gly Gly Ala Ile
 180 185 190

Ala Ser Leu Val Pro Asn Ser Leu Trp Gly Ser Ile Leu Asp Ile Arg
 705 710 715 720
 Ser Ala His Ser Ala Ile Gln Ala Ser Val Asp Gly Arg Ser Tyr Cys
 725 730 735
 Arg Gly Leu Trp Val Ser Gly Val Ser Asn Phe Phe Tyr His Asp Arg
 740 745 750
 Asp Ala Leu Gly Gln Gly Tyr Arg Tyr Ile Ser Gly Gly Tyr Ser Leu
 755 760 765
 Gly Ala Asn Ser Tyr Phe Gly Ser Ser Met Phe Gly Leu Ala Phe Thr
 770 775 780
 Glu Val Phe Gly Arg Ser Lys Asp Tyr Val Val Cys Arg Ser Asn His
 785 790 795 800
 His Ala Cys Ile Gly Ser Val Tyr Leu Ser Thr Gln Gln Ala Leu Cys
 805 810 815
 Gly Ser Tyr Leu Phe Gly Asp Ala Phe Ile Arg Ala Ser Tyr Gly Phe
 820 825 830
 Gly Asn Gln His Met Lys Thr Ser Tyr Thr Phe Ala Glu Glu Ser Asp
 835 840 845
 Val Arg Trp Asp Asn Asn Cys Leu Ala Gly Glu Ile Gly Ala Gly Leu
 850 855 860
 Pro Ile Val Ile Thr Pro Ser Lys Leu Tyr Leu Asn Glu Leu Arg Pro
 865 870 875 880
 Phe Val Gln Ala Glu Phe Ser Tyr Ala Asp His Glu Ser Phe Thr Glu
 885 890 895
 Glu Gly Asp Gln Ala Arg Ala Phe Lys Ser Gly His Leu Leu Asn Leu
 900 905 910
 Ser Val Pro Val Gly Val Lys Phe Asp Arg Cys Ser Ser Thr His Pro
 915 920 925
 Asn Lys Tyr Ser Phe Met Ala Ala Tyr Ile Cys Asp Ala Tyr Arg Thr
 930 935 940
 Ile Ser Gly Thr Glu Thr Thr Leu Leu Ser His Gln Glu Thr Trp Thr
 945 950 955 960

Thr Asp Ala Phe His Leu Ala Arg His Gly Val Val Val Arg Gly Ser
 965 970 975

Met Tyr Ala Ser Leu Thr Ser Asn Ile Glu Val Tyr Gly His Gly Arg
 980 985 990

Tyr Glu Tyr Arg Asp Ala Ser Arg Gly Tyr Gly Leu Ser Ala Gly Ser
 995 1000 1005

Arg Val Arg Phe
 1010

<210> 3
 <211> 20
 <212> PRT
 <213> Chlamydia

<400> 3
 Glu Ile Met Val Pro Gln Gly Ile Tyr Asp Gly Glu Thr Leu Thr Val
 1 5 10 15

Ser Phe Xaa Tyr
 20

<210> 4
 <211> 18
 <212> DNA
 <213> Chlamydia

<400> 4
 gaaathatgg tnccncaa 18

<210> 5
 <211> 18
 <212> DNA
 <213> Chlamydia

<400> 5
 gaaathatgg tnccncag 18

<210> 6
 <211> 18
 <212> DNA
 <213> Chlamydia

18

18

18

18

15

15

15

15

<400> 10							
gaaatcatgg	ttcctcaagg	aattttacgat	ggggagacgt	taactgtatc	atttccttat	60	
actgttatag	gagatccgag	tgggactact	gttttttctg	caggagagtt	aacattaaaa	120	
aatcttgaca	attctattgc	agctttgcct	ttaagttggt	ttgggaactt	attagggagt	180	
tttactgttt	tagggagagg	acactcgttg	actttcgaga	acatacggac	ttctacaaat	240	
ggggcagctc	taagtaatag	cgctgctgat	ggactgttta	ctattgaggg	ttttaaagaa	300	
ttatcctttt	ccaattgcaa	ttcattactt	gccgtactgc	ctgctgcaac	gactaataag	360	
ggtagccaga	ctccgacgac	aacatctaca	ccgtctaattg	gtactattta	ttctaaaaca	420	
gatcttttgt	tactcaataa	tgagaagttc	tcattctata	gtaatttagt	ctctggagat	480	
gggggagcta	tagatgctaa	gagcttaacg	gttcaaggaa	ttagcaagct	ttgtgtcttc	540	
caagaaaata	ctgctcaagc	tgatggggga	gcttgtcaag	tagtcaccag	tttctctgct	600	
atggctaacg	aggctcctat	tgcctttgta	gcgaatgttg	caggagtaag	agggggaggg	660	
attgctgctg	ttcaggatgg	gcagcagggg	gtgtcatcat	ctacttcaac	agaagatcca	720	
gtagtaagtt	tttcagaaa	tactgcggta	gagtttgatg	ggaacgtagc	ccgagtagga	780	
ggagggattt	actcctacgg	gaacgttgct	ttcctgaata	atggaaaaac	cttgtttctc	840	
aacaatgttg	cttctcctgt	ttacattgct	gctaagcaac	caacaagtgg	acaggcttct	900	

aatacgagta ataattacgg agatggagga gctatcttct gtaagaatgg tgcgcaagca 960
ggatccaata actctggatc agtttctttt gatggagagg gagtagtttt ctttagtagc 1020
aatgtagctg ctgggaaagg gggagctatt tatgcaaaa agctctcggt tgctaactgt 1080
ggccctgtac aatttttaag gaatatcgct aatgatggtg gagcgattta tttaggagaa 1140
tctggagagc tcagttttatc tgctgattat ggagatatta ttttcgatgg gaatcttaaa 1200
agaacagcca aagagaatgc tgccgatgtt aatggcgtaa ctgtgtcctc acaagccatt 1260
tcgatgggat cgggagggaa aataacgaca ttaagagcta aagcagggca tcagattctc 1320
tttaatgatc ccatacgagat ggcaaacgga aataaccagc cagcgcagtc ttccaaactt 1380
ctaaaaatta acgatggtga aggatacaca ggggatattg tttttgctaa tggaagcagt 1440
actttgtacc aaaatgttac gatagagcaa ggaaggattg ttcttcgtga aaaggcaaaa 1500
ttatcagtga a 1511

<210> 11

<211> 1444

<212> DNA

<213> Chlamydia

<400> 11

ttctctaagt cagacaggtg ggagtctgta tatggaagct gggagtacat gggattttgt 60
aactccacaa ccaccacaac agcctcctgc cgctaatacag ttgatcacgc tttccaatct 120
gcatttgtct ctttcttctt tgtagcaaa caatgcagtt acgaatcctc ctaccaatcc 180
tccagcgcaa gattctcatc ctgcagtcac tgtagcaca actgctgggt ctgttacaat 240
tagtgggact atcttttttg aggatttgga tgatacagct tatgataggt atgattggct 300
aggttctaata caaaaaatca atgtcctgaa attacagtta gggactaagc cccagctaa 360
tgcccatca gatttgactc tagggaatga gatgcctaag tatggctatc aaggaagctg 420
gaagcttgcg tgggaccta atacagcaaa taatggctct tatactctga aagctacatg 480
gactaaaact ggggtataatc ctgggcctga gcgagtagct tctttgggtc caaatagttt 540
atggggatcc attttagata tacgatctgc gcattcagca attcaagcaa gtgtggatgg 600
gcgctcttat tgtcgaggat tatgggtttc tggagtttcg aatttcttct atcatgaccg 660
cgatgcttta ggtcagggat atcgggtatat tagtgggggt tattccttag gagcaaacctc 720
ctactttgga tcatcgatgt ttggtctagc atttaccgaa gtatttggtg gatctaaaga 780
ttatgtagtg tgtcgttcca atcatcatgc ttgcatagga tccgtttatc tatctacca 840
acaagcttta tgtggatcct atttggtcgg agatgcgttt atccgtgcta gctacgggtt 900
tggaatcag catatgaaaa cctcatatac atttgagag gagagcgatg ttcgttgga 960
taataactgt ctggctggag agattggagc gggattaccg attgtgatta ctccatctaa 1020
gctctatttg aatgagttgc gtcctttcgt gcaagctgag ttttcttatg ccgatcatga 1080
atcttttaca gaggaaggcg atcaagctcg ggcattcaag agcggacatc tcctaaatct 1140
atcagttcct gttggagtga agtttgatcg atgttctagt acacatccta ataaatatag 1200
ctttatggcg gcttatatct gtgatgctta tcgcaccatc tctggtactg agacaacgct 1260
cctatcccat caagagacat ggacaacaga tgcccttcat ttagcaagac atggagttgt 1320
ggtagagga tctatgtatg cttctctaac aagtaatata gaagtatatg gccatggaag 1380
atatgagtat cgagatgctt ctcgaggcta tggtttgagt gcaggaagta gagtccggtt 1440
ctaa

<210> 12

<211> 56

<212> DNA

<213> Chlamydia

125

Ser Asn Val Ala Ala Gly Lys Gly Gly Ala Ile Tyr Ala Lys Lys Leu

370

375

380

Ser Val Ala Asn Cys Gly Pro Val Gln Leu Leu Gly Asn Ile Ala Asn
385 390 395 400

Asp Gly Gly Ala Ile Tyr Leu Gly Glu Ser Gly Glu Leu Ser Leu Ser
405 410 415

Ala Asp Tyr Gly Asp Met Ile Phe Asp Gly Asn Leu Lys Arg Thr Ala
420 425 430

Lys Glu Asn Ala Ala Asp Val Asn Gly Val Thr Val Ser Ser Gln Ala
435 440 445

Ile Ser Met Gly Ser Gly Gly Lys Ile Thr Thr Leu Arg Ala Lys Ala
450 455 460

Gly His Gln Ile Leu Phe Asn Asp Pro Ile Glu Met Ala Asn Gly Asn
465 470 475 480

Asn Gln Pro Ala Gln Ser Ser Glu Pro Leu Lys Ile Asn Asp Gly Glu
485 490 495

Gly Tyr Thr Gly Asp Ile Val Phe Ala Asn Gly Asn Ser Thr Leu Tyr
500 505 510

Gln Asn Val Thr Ile Glu Gln Gly Arg Ile Val Leu Arg Glu Lys Ala
515 520 525

Lys Leu Ser Val Asn Ser Leu Ser Gln Thr Gly Gly Ser Leu Tyr Met
530 535 540

Glu Ala Gly Ser Thr Leu Asp Phe Val Thr Pro Gln Pro Pro Gln Gln
545 550 555 560

Pro Pro Ala Ala Asn Gln Ser Ile Thr Leu Ser Asn Leu His Leu Ser
565 570 575

Leu Ser Ser Leu Leu Ala Asn Asn Ala Val Thr Asn Pro Pro Thr Asn
580 585 590

Pro Pro Ala Gln Asp Ser His Pro Ala Val Ile Gly Ser Thr Thr Ala
595 600 605

Gly Ser Val Thr Ile Ser Gly Pro Ile Phe Phe Glu Asp Leu Asp Asp
610 615 620

Thr Ala Tyr Asp Arg Tyr Asp Trp Leu Gly Ser Asn Gln Lys Ile Asp

625 630 635 640
 Val Leu Lys Leu Gln Leu Gly Thr Gln Pro Pro Ala Asn Ala Pro Ser
 645 650 655
 Asp Leu Thr Leu Gly Asn Glu Met Pro Lys Tyr Gly Tyr Gln Gly Ser
 660 665 670
 Trp Lys Leu Ala Trp Asp Pro Asn Thr Ala Asn Asn Gly Pro Tyr Thr
 675 680 685
 Leu Lys Ala Thr Trp Thr Lys Thr Gly Tyr Asn Pro Gly Pro Glu Arg
 690 695 700
 Val Ala Ser Leu Val Pro Asn Ser Leu Trp Gly Ser Ile Leu Asp Ile
 705 710 715 720
 Arg Ser Ala His Ser Ala Ile Gln Ala Ser Val Asp Gly Arg Ser Tyr
 725 730 735
 Cys Arg Gly Leu Trp Val Ser Gly Val Ser Asn Phe Phe Tyr His Asp
 740 745 750
 Arg Asp Ala Leu Gly Gln Gly Tyr Arg Tyr Ile Ser Gly Gly Tyr Ser
 755 760 765
 Leu Gly Ala Asn Ser Tyr Phe Gly Ser Ser Met Phe Gly Leu Ala Phe
 770 775 780
 Thr Glu Val Phe Gly Arg Ser Lys Asp Tyr Val Val Cys Arg Ser Asn
 785 790 795 800
 His His Ala Cys Ile Gly Ser Val Tyr Leu Ser Thr Lys Gln Ala Leu
 805 810 815
 Cys Gly Ser Tyr Val Phe Gly Asp Ala Phe Ile Arg Ala Ser Tyr Gly
 820 825 830
 Phe Gly Asn Gln His Met Lys Thr Ser Tyr Thr Phe Ala Glu Glu Ser
 835 840 845
 Asp Val Cys Trp Asp Asn Asn Cys Leu Val Gly Glu Ile Gly Val Gly
 850 855 860
 Leu Pro Ile Val Ile Thr Pro Ser Lys Leu Tyr Leu Asn Glu Leu Arg
 865 870 875 880
 Pro Phe Val Gln Ala Glu Phe Ser Tyr Ala Asp His Glu Ser Phe Thr

885

890

895

Glu Glu Gly Asp Gln Ala Arg Ala Phe Arg Ser Gly His Leu Met Asn
 900 905 910

Leu Ser Val Pro Val Gly Val Lys Phe Asp Arg Cys Ser Ser Thr His
 915 920 925

Pro Asn Lys Tyr Ser Phe Met Gly Ala Tyr Ile Cys Asp Ala Tyr Arg
 930 935 940

Thr Ile Ser Gly Thr Gln Thr Thr Leu Leu Ser His Gln Glu Thr Trp
 945 950 955 960

Thr Thr Asp Ala Phe His Leu Ala Arg His Gly Val Ile Val Arg Gly
 965 970 975

Ser Met Tyr Ala Ser Leu Thr Ser Asn Ile Glu Val Tyr Gly His Gly
 980 985 990

Arg Tyr Glu Tyr Arg Asp Thr Ser Arg Gly Tyr Gly Leu Ser Ala Gly
 995 1000 1005

Ser Lys Val Arg Phe
 1010

<210> 16

<211> 1013

<212> PRT

<213> Chlamydia

<400> 16

Met Gln Thr Ser Phe His Lys Phe Phe Leu Ser Met Ile Leu Ala Tyr
 1 5 10 15

Ser Cys Cys Ser Leu Thr Gly Gly Gly Tyr Ala Ala Glu Ile Met Val
 20 25 30

Pro Gln Gly Ile Tyr Asp Gly Glu Thr Leu Thr Val Ser Phe Pro Tyr
 35 40 45

Thr Val Ile Gly Asp Pro Ser Gly Thr Thr Val Phe Ser Ala Gly Glu
 50 55 60

Leu Thr Leu Lys Asn Leu Asp Asn Ser Ile Ala Ala Leu Pro Leu Ser
 65 70 75 80

Cys Phe Gly Asn Leu Leu Gly Ser Phe Thr Val Leu Gly Arg Gly His
85 90 95

Ser Leu Thr Phe Glu Asn Ile Arg Thr Ser Thr Asn Gly Ala Ala Leu
100 105 110

Ser Asp Ser Ala Asn Ser Gly Leu Phe Thr Ile Glu Gly Phe Lys Glu
115 120 125

Leu Ser Phe Ser Asn Cys Asn Ser Leu Leu Ala Val Leu Pro Ala Ala
130 135 140

Thr Thr Asn Asn Gly Ser Gln Thr Pro Thr Thr Thr Ser Thr Pro Ser
145 150 155 160

Asn Gly Thr Ile Tyr Ser Lys Thr Asp Leu Leu Leu Leu Asn Asn Glu
165 170 175

Lys Phe Ser Phe Tyr Ser Asn Leu Val Ser Gly Asp Gly Gly Thr Ile
180 185 190

Asp Ala Lys Ser Leu Thr Val Gln Gly Ile Ser Lys Leu Cys Val Phe
195 200 205

Gln Glu Asn Thr Ala Gln Ala Asp Gly Gly Ala Cys Gln Val Val Thr
210 215 220

Ser Phe Ser Ala Met Ala Asn Glu Ala Pro Ile Ala Phe Ile Ala Asn
225 230 235 240

Val Ala Gly Val Arg Gly Gly Gly Ile Ala Ala Val Gln Asp Gly Gln
245 250 255

Gln Gly Val Ser Ser Ser Thr Ser Thr Glu Asp Pro Val Val Ser Phe
260 265 270

Ser Arg Asn Thr Ala Val Glu Phe Asp Gly Asn Val Ala Arg Val Gly
275 280 285

Gly Gly Ile Tyr Ser Tyr Gly Asn Val Ala Phe Leu Asn Asn Gly Lys
290 295 300

Thr Leu Phe Leu Asn Asn Val Ala Ser Pro Val Tyr Ile Ala Ala Glu
305 310 315 320

Gln Pro Thr Asn Gly Gln Ala Ser Asn Thr Ser Asp Asn Tyr Gly Asp
325 330 335

Gly Gly Ala Ile Phe Cys Lys Asn Gly Ala Gln Ala Ala Gly Ser Asn
 340 345 350
 Asn Ser Gly Ser Val Ser Phe Asp Gly Glu Gly Val Val Phe Phe Ser
 355 360 365
 Ser Asn Val Ala Ala Gly Lys Gly Gly Ala Ile Tyr Ala Lys Lys Leu
 370 375 380
 Ser Val Ala Asn Cys Gly Pro Val Gln Phe Leu Gly Asn Ile Ala Asn
 385 390 395 400
 Asp Gly Gly Ala Ile Tyr Leu Gly Glu Ser Gly Glu Leu Ser Leu Ser
 405 410 415
 Ala Asp Tyr Gly Asp Ile Ile Phe Asp Gly Asn Leu Lys Arg Thr Ala
 420 425 430
 Lys Glu Asn Ala Ala Asp Val Asn Gly Val Thr Val Ser Ser Gln Ala
 435 440 445
 Ile Ser Met Gly Ser Gly Gly Lys Ile Thr Thr Leu Arg Ala Lys Ala
 450 455 460
 Gly His Gln Ile Leu Phe Asn Asp Pro Ile Glu Met Ala Asn Gly Asn
 465 470 475 480
 Asn Gln Pro Ala Gln Ser Ser Glu Pro Leu Lys Ile Asn Asp Gly Glu
 485 490 495
 Gly Tyr Thr Gly Asp Ile Val Phe Ala Asn Gly Asn Ser Thr Leu Tyr
 500 505 510
 Gln Asn Val Thr Ile Glu Gln Gly Arg Ile Val Leu Arg Glu Lys Ala
 515 520 525
 Lys Leu Ser Val Asn Ser Leu Ser Gln Thr Gly Gly Ser Leu Tyr Met
 530 535 540
 Glu Ala Gly Ser Thr Leu Asp Phe Val Thr Pro Gln Pro Pro Gln Gln
 545 550 555 560
 Pro Pro Ala Ala Asn Gln Leu Ile Thr Leu Ser Asn Leu His Leu Ser
 565 570 575
 Leu Ser Ser Leu Leu Ala Asn Asn Ala Val Thr Asn Pro Pro Thr Asn
 580 585 590

Pro Pro Ala Gln Asp Ser His Pro Ala Val Ile Gly Ser Thr Thr Ala
595 600 605

Gly Pro Val Thr Ile Ser Gly Pro Phe Phe Phe Glu Asp Leu Asp Asp
610 615 620

Thr Ala Tyr Asp Arg Tyr Asp Trp Leu Gly Ser Asn Gln Lys Ile Asp
625 630 635 640

Val Leu Lys Leu Gln Leu Gly Thr Gln Pro Ser Ala Asn Ala Pro Ser
645 650 655

Asp Leu Thr Leu Gly Asn Glu Met Pro Lys Tyr Gly Tyr Gln Gly Ser
660 665 670

Trp Lys Leu Ala Trp Asp Pro Asn Thr Ala Asn Asn Gly Pro Tyr Thr
675 680 685

Leu Lys Ala Thr Trp Thr Lys Thr Gly Tyr Asn Pro Gly Pro Glu Arg
690 695 700

Val Ala Ser Leu Val Pro Asn Ser Leu Trp Gly Ser Ile Leu Asp Ile
705 710 715 720

Arg Ser Ala His Ser Ala Ile Gln Ala Ser Val Asp Gly Arg Ser Tyr
725 730 735

Cys Arg Gly Leu Trp Val Ser Gly Val Ser Asn Phe Ser Tyr His Asp
740 745 750

Arg Asp Ala Leu Gly Gln Gly Tyr Arg Tyr Ile Ser Gly Gly Tyr Ser
755 760 765

Leu Gly Ala Asn Ser Tyr Phe Gly Ser Ser Met Phe Gly Leu Ala Phe
770 775 780

Thr Glu Val Phe Gly Arg Ser Lys Asp Tyr Val Val Cys Arg Ser Asn
785 790 795 800

His His Ala Cys Ile Gly Ser Val Tyr Leu Ser Thr Lys Gln Ala Leu
805 810 815

Cys Gly Ser Tyr Leu Phe Gly Asp Ala Phe Ile Arg Ala Ser Tyr Gly
820 825 830

Phe Gly Asn Gln His Met Lys Thr Ser Tyr Thr Phe Ala Glu Glu Ser
835 840 845

Asp Val Arg Trp Asp Asn Asn Cys Leu Val Gly Glu Ile Gly Val Gly
850 855 860

Leu Pro Ile Val Thr Thr Pro Ser Lys Leu Tyr Leu Asn Glu Leu Arg
865 870 875 880

Pro Phe Val Gln Ala Glu Phe Ser Tyr Ala Asp His Glu Ser Phe Thr
885 890 895

Glu Glu Gly Asp Gln Ala Arg Ala Phe Arg Ser Gly His Leu Met Asn
900 905 910

Leu Ser Val Pro Val Gly Val Lys Phe Asp Arg Cys Ser Ser Thr His
915 920 925

Pro Asn Lys Tyr Ser Phe Met Gly Ala Tyr Ile Cys Asp Ala Tyr Arg
930 935 940

Thr Ile Ser Gly Thr Gln Thr Thr Leu Leu Ser His Gln Glu Thr Trp
945 950 955 960

Thr Thr Asp Ala Phe His Leu Ala Arg His Gly Val Ile Val Arg Gly
965 970 975

Ser Met Tyr Ala Ser Leu Thr Ser Asn Ile Glu Val Tyr Gly His Gly
980 985 990

Arg Tyr Glu Tyr Arg Asp Thr Ser Arg Gly Tyr Gly Leu Ser Ala Gly
995 1000 1005

Ser Lys Val Arg Phe
1010

<210> 17

<211> 505

<212> PRT

<213> Chlamydia

<400> 17

Glu Ile Met Val Pro Gln Gly Ile Tyr Asp Gly Glu Thr Leu Thr Val
1 5 10 15

Ser Phe Pro Tyr Thr Val Ile Gly Asp Pro Ser Gly Thr Thr Val Phe
20 25 30

Ser Ala Gly Glu Leu Thr Leu Lys Asn Leu Asp Asn Ser Ile Ala Ala
35 40 45

Leu Pro Leu Ser Cys Phe Gly Asn Leu Leu Gly Ser Phe Thr Val Leu
50 55 60

Gly Arg Gly His Ser Leu Thr Phe Glu Asn Ile Arg Thr Ser Thr Asn
65 70 75 80

Gly Ala Ala Leu Ser Asn Ser Ala Ala Asp Gly Leu Phe Thr Ile Glu
85 90 95

Gly Phe Lys Glu Leu Ser Phe Ser Asn Cys Asn Ser Leu Leu Ala Val
100 105 110

Leu Pro Ala Ala Thr Thr Asn Lys Gly Ser Gln Thr Pro Thr Thr Thr
115 120 125

Ser Thr Pro Ser Asn Gly Thr Ile Tyr Ser Lys Thr Asp Leu Leu Leu
130 135 140

Leu Asn Asn Glu Lys Phe Ser Phe Tyr Ser Asn Leu Val Ser Gly Asp
145 150 155 160

Gly Gly Ala Ile Asp Ala Lys Ser Leu Thr Val Gln Gly Ile Ser Lys
165 170 175

Leu Cys Val Phe Gln Glu Asn Thr Ala Gln Ala Asp Gly Gly Ala Cys
180 185 190

Gln Val Val Thr Ser Phe Ser Ala Met Ala Asn Glu Ala Pro Ile Ala
195 200 205

Phe Val Ala Asn Val Ala Gly Val Arg Gly Gly Gly Ile Ala Ala Val
210 215 220

Gln Asp Gly Gln Gln Gly Val Ser Ser Ser Thr Ser Thr Glu Asp Pro
225 230 235 240

Val Val Ser Phe Ser Arg Asn Thr Ala Val Glu Phe Asp Gly Asn Val
245 250 255

Ala Arg Val Gly Gly Gly Ile Tyr Ser Tyr Gly Asn Val Ala Phe Leu
260 265 270

Asn Asn Gly Lys Thr Leu Phe Leu Asn Asn Val Ala Ser Pro Val Tyr
275 280 285

Ile Ala Ala Lys Gln Pro Thr Ser Gly Gln Ala Ser Asn Thr Ser Asn
290 295 300

Asn Tyr Gly Asp Gly Gly Ala Ile Phe Cys Lys Asn Gly Ala Gln Ala
305 310 315 320

Gly Ser Asn Asn Ser Gly Ser Val Ser Phe Asp Gly Glu Gly Val Val
325 330 335

Phe Phe Ser Ser Asn Val Ala Ala Gly Lys Gly Gly Ala Ile Tyr Ala
340 345 350

Lys Lys Leu Ser Val Ala Asn Cys Gly Pro Val Gln Phe Leu Arg Asn
355 360 365

Ile Ala Asn Asp Gly Gly Ala Ile Tyr Leu Gly Glu Ser Gly Glu Leu
370 375 380

Ser Leu Ser Ala Asp Tyr Gly Asp Ile Ile Phe Asp Gly Asn Leu Lys
385 390 395 400

Arg Thr Ala Lys Glu Asn Ala Ala Asp Val Asn Gly Val Thr Val Ser
405 410 415

Ser Gln Ala Ile Ser Met Gly Ser Gly Gly Lys Ile Thr Thr Leu Arg
420 425 430

Ala Lys Ala Gly His Gln Ile Leu Phe Asn Asp Pro Ile Glu Met Ala
435 440 445

Asn Gly Asn Asn Gln Pro Ala Gln Ser Ser Lys Leu Leu Lys Ile Asn
450 455 460

Asp Gly Glu Gly Tyr Thr Gly Asp Ile Val Phe Ala Asn Gly Ser Ser
465 470 475 480

Thr Leu Tyr Gln Asn Val Thr Ile Glu Gln Gly Arg Ile Val Leu Arg
485 490 495

Glu Lys Ala Lys Leu Ser Val Asp Ser
500 505

<210> 18

<211> 57

<212> DNA

<213> Chlamydia

<400> 18

aagggcccaa ttacgcagag ctcgagagaa attatgggtc ctcaaggaat ttacgat

57

<210> 19

<211> 20

<212> DNA

<213> Chlamydia

<400> 19

cgctctagaa ctagtggatc

20

<210> 20

<211> 22

<212> DNA

<213> Chlamydia

<400> 20

atgggttcctc aaggaattta cg

22

<210> 21

<211> 19

<212> DNA

<213> Chlamydia

<400> 21

ggtcccccat cagcgggag

19

<210> 22

<211> 1515

<212> DNA

<213> Chlamydia

<400> 22

gaaatcatgg ttccctcaagg aattttacgat ggggagacgt taactgtatc atttccctat 60
actgttatag gagatccgag tgggactact gttttttctg caggagagtt aacattaaaa 120
aatcttgaca attctattgc agctttgcct ttaagttggt ttgggaactt attagggagt 180
tttactgttt tagggagagg aactcgttg actttcgaga acatacggac ttctacaaat 240
ggggcagctc taagtaatat cgctgctgat ggaactgtta ctattgaggg ttttaaagaa 300
ttatcctttt ccaattgcaa ttcattactt gcggtactgc ctgctgcaac gactaataag 360
ggtagccaga ctccgacgac aacatctaca cgtctaatg gtactattta ttctaaaaca 420
gatcttttgt tactcaataa tgagaagttc tcattctata gtaatttagt ctctggagat 480
gggggagcta tagatgctaa gagcttaacg gttcaaggaa ttagcaagct ttgtgtcttc 540
caagaaaata ctgctcaagc tgatggggga gcttgtcaag tagtcaccag tttctctgct 600
atggctaacg aggctcctat tgcctttgta gcgaatgttg caggagtaag agggggaggg 660
attgctgctg ttcaggatgg gcagcaggga gtgtcatcat ctacttcaac agaagatcca 720
gtagtaagtt tttccagaaa tactgcggtg gagtttgatg ggaacgtagc ccgagtagga 780
ggagggattt actcctacgg gaacgttgct ttccctgaata atggaaaaac cttgtttctc 840
aacaatgttg cttctcctgt ttacattgct gctaagcaac caacaagtgg acaggcttct 900
aatacagta ataattacgg agatggagga gctatcttct gtaagaatgg tgcgcaagca 960
ggatccaata actctggatc agtttccttt gatggagagg gagtagtttt ctttagtagc 1020

aatgtagctg ctgggaaagg gggagctatt tatgccaaaa agctctcggt tgetaactgt 1080
 ggccctgtac aatttttaag gaatatcgct aatgatggtg gagcgattta tttaggagaa 1140
 tctggagagc tcagtttatc tgctgattat ggagatatta ttttcgatgg gaattctaaa 1200
 agaacagcca aagagaatgc tgccgatgtt aatggcgtaa ctgtgtcctc acaagccatt 1260
 tcgatgggat cgggagggaa aataacgaca ttaagagcta aagcagggca tcagattctc 1320
 tttaatgac ccatcgagat ggcaaacgga aataaccagc cagcgagtc ttccaaactt 1380
 ctaaaaatta acgatggtga aggatacaca ggggatattg tttttgctaa tggaagcagt 1440
 actttgtacc aaaatgttac gatagagcaa ggaaggattg ttcttcgtga aaaggcaaaa 1500
 ttatcagtga attct 1515

<210> 23

<211> 3354

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
 recombinant expression vector

<400> 23

atgcaaacgt ctttccataa gttctttctt tcaatgattc tagcttattc ttgctgctct 60
 ttaaattggg gggggtatgc agaaatcatg gttcctcaag gaatttacga tggggagacg 120
 ttaactgtat catttcccta tactgttata ggagatccga gtgggactac tgttttttct 180
 gcaggagagt taacgttaaa aaatcttgac aattctattg cagctttgcc tttaagtgtg 240
 tttgggaact tattagggag ttttactgtt ttagggagag gacactcgtt gactttcgag 300
 aacatacga cttctacaaa tggagctgca ctaagtgaac gcgctaatac cgggttattt 360
 actattgagg gttttaaaga attatctttt tccaattgca acccattact tgccgtactg 420
 cctgctgcaa cgactaataa tggtagccag actccgtcga caacatctac accgtctaata 480
 ggtactatct attctaaaac agatcttttg ttactcaata atgagaagtt ctcattctat 540
 agtaattcag tctctggaga tgggggagct atagatgcta agagcttaac ggttcaagga 600
 attagcaagc tttgtgtctt ccaagaaaat actgctcaag ctgatggggg agcttgtcaa 660
 gtagtcacca gtttctctgc tatggctaac gaggctccta ttgcctttgt agcgaatgtt 720
 gcaggagtaa gagggggagg gattgctgct gttcaggatg ggcagcaggg agtgtcatca 780
 tctacttcaa cagaagatcc agtagtaagt ttttccagaa atactgcggt agagtttgat 840
 gggaacgtag cccgagtagg aggagggatt tactcctacg ggaacgttgc tttcctgaat 900
 aatggaaaaa ccttgtttct caacaatgtt gcttctcctg tttacattgc tgctgagcaa 960
 ccaacaaatg gacaggcttc taatacgagt gataattacg gagatggagg agctatcttc 1020
 tgtaagaatg gtgcgcaagc agcaggatcc aataactctg gatcagtttc ctttgatgga 1080
 gagggagtag ttttcttttag tagcaatgta gctgctggga aagggggagc tatttatgcc 1140
 aaaaagctct cggttgctaa ctgtggccct gtacaactct tagggaatat cgctaataat 1200
 ggtggagcga tttatttagg agaactctgga gagctcagtt tatctgctga ttatggagat 1260
 atgattttcg atgggaatct taaaagaaca gccaaagaga atgctgccga tgttaatggc 1320
 gtaactgtgt cctcacaagc catttcgatg ggatcgggag ggaaaataac gacattaaga 1380
 gctaaagcag ggcacagat tctctttaat gatcccatcg agatggcaaa cggaataaac 1440
 cagccagcgc agtcttccga acctctaaaa attaacgatg gtgaaggata cacaggggat 1500
 attgtttttg ctaatggaaa cagtactttg taccaaaatg ttacgataga gcaagggaag 1560
 attgttcttc gtgaaaaggc aaaattatca gtgaattctc taagtcagac aggtgggagt 1620
 ctgtatatgg aagctgggag tacattggat tttgtaactc cacaaccacc acaacagcct 1680

```

cctgccgcta atcagtcgat cacgctttcc aatctgcatt tgtctctttc ttctttgtta 1740
gcaaacaatg cagttacgaa tcctcctacc aatcctccag cgcaagattc tcatcctgca 1800
gtcattggta gcacaactgc tggttctggt acaattagtg ggcctatctt ttttgaggat 1860
ttggatgata cagcttatga taggtatgat tggctaggtt ctaatcaaaa aatcgatgtc 1920
ctgaaattac agttaggggac tcagcccccga gctaatagcc catcagattt gactctaggg 1980
aatgagatgc ctaagtatgg ctatcaagga agctggaagc ttgcgtggga tcctaataca 2040
gcaaataatg gtccttatac tctgaaagct acatggacta aaactgggta taatcctggg 2100
cctgagcggag tagcttcttt gggtccaaat agtttatggg gatccatttt agatatacga 2160
tctgcgcatt cagcaattca agcaagtgtg gatggcgct cttattgtcg aggattatgg 2220
gtttctggag tttcgaattt cttctatcat gaccgcgatg ctttaggtca gggatatcgg 2280
tatattagtg ggggttattc cttaggagca aactcctact ttggatcatc gatgtttggg 2340
ctagcattta ctgaagtatt tggtagatct aaagattatg tagtgtgtcg ttccaatcat 2400
catgcttgca taggatccgt ttatctatct accaaacagg ctttatgtgg atcttatgtg 2460
tttgagatg cgtttattcg tgctagctac gggtttggga atcagcatat gaaaacctca 2520
tatacatttg cagaggagag cgatgtttgt tgggataata actgtctggg tggagagatt 2580
ggagtgggat taccgattgt gattactcca tctaagctct atttgaatga gttgcgtcct 2640
ttcgtgcaag ctgagttttc ttatgccgat catgaatctt ttacagagga aggcgatcaa 2700
gctcgggcat tcaggagtgg acatctcatg aatctatcag ttctgttg agtaaaattt 2760
gatcgatgtt ctagtacaca ccctaataaa tatagcttta tgggggctta tatctgtgat 2820
gcttatcgca ccatctctgg gactcagaca acactcctat cccatcaaga gacatggaca 2880
acagatgcct ttcatttggc aagacatgga gtcatagtta gagggctctat gtatgcttct 2940
ctaacaagca atatagaagt atatggccat ggaagatatg agtatcgaga tacttctcga 3000
ggttatgggt tgagtgcagg aagtaaagtc cggttctaaa aatattgggt agatagttaa 3060
gtgttagcga tgcctttttc tttgagatct acatcatttt gtttttttagc ttgtttgtgt 3120
tcctattcgt atggattcgc gagctctcct caagtgttaa cacctaattg aacctactct 3180
tttaaggggg acgatgttta cttgaatgga gactgcgctt ttgtcaatgt ctatgcaggg 3240
gcagagaacg gctcaattat ctcagcta at ggcgacaatt taacgattac cggacaaaac 3300
catacattat catttacaca ttctcaaggg ccagttcttc aaaattagcc ttca 3354

```

<210> 24

<211> 3324

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
recombinant expression vector

<400> 24

```

atgcaaacgt ctttccataa gttctttctt tcaatgattc tagcttattc ttgctgctct 60
ttaagtgggg ggggggtatgc agcagaaatc atgattcctc aaggaattta cgatggggag 120
acgttaactg tatcatttcc ctatactggt ataggagatc cgagtgggac tactgttttt 180
tctgcaggag agttaacggt aaaaaatctt gacaattcta ttgcagcttt gcctttaagt 240
tgttttggga acttattagg gagttttact gtttttaggga gaggacactc gttgactttc 300
gagaacatac ggacttctac aaatggagct gcaactaagt acagcgctaa tagcgggtta 360
tttactattg agggttttta agaattatct ttttccaatt gcaactcatt acttgccgta 420
ctgcctgctg caacgactaa taatggtagc cagactccga cgacaacatc tacaccgtct 480
aatggtacta tttattctaa aacagatctt ttgttactca ataatgagaa gttctcattc 540

```


<210> 25
<211> 65
<212> PRT
<213> Chlamydia

<400> 25
Pro Tyr Thr Val Ile Gly Asp Pro Ser Gly Thr Thr Val Phe Ser Ala
1 5 10 15

Gly Glu Leu Thr Leu Lys Asn Leu Asp Asn Ser Ile Ala Ala Pro Leu
20 25 30

Ser Cys Phe Gly Asn Leu Leu Gly Ser Phe Thr Val Leu Gly Arg Gly
35 40 45

His Ser Leu Thr Phe Glu Asn Ile Arg Thr Ser Thr Asn Gly Ala Ala
50 55 60

Leu
65

<210> 26
<211> 24
<212> PRT
<213> Chlamydia

<400> 26
Ala Ala Asn Gln Leu Ile Thr Leu Ser Asn Leu His Leu Ser Leu Ser
1 5 10 15

Ser Leu Leu Ala Asn Asn Ala Val
20

<210> 27
<211> 8
<212> PRT
<213> Chlamydia

<400> 27
Gly Tyr Thr Gly Asp Ile Val Phe
1 5

<210> 28
<211> 7
<212> PRT

<213> Chlamydia

<400> 28

Tyr Gly Asp Ile Ile Phe Asp

1 5

<210> 29

<211> 63

<212> PRT

<213> Chlamydera cerviniventris

<400> 29

Gly Tyr Ala Ala Glu Ile Met Val Pro Gln Gly Ile Tyr Asp Gly Glu

1 5 10 15

Thr Leu Thr Val Ser Phe Pro Tyr Thr Val Ile Gly Asp Pro Ser Gly

20 25 30

Thr Thr Val Phe Ser Ala Gly Glu Leu Thr Leu Lys Asn Leu Asp Asn

35 40 45

Ser Ile Ala Ala Leu Pro Leu Ser Cys Phe Gly Asn Leu Leu Gly

50 55 60

<210> 30

<211> 22

<212> PRT

<213> Chlamydia

<400> 30

Met Ala Asn Gly Asn Asn Gln Pro Ala Gln Ser Ser Lys Leu Leu Lys

1 5 10 15

Ile Asn Asp Gly Glu Gly

20

<210> 31

<211> 14

<212> PRT

<213> Chlamydia

<400> 31

Ala Asn Gly Ser Ser Thr Leu Tyr Gln Asn Val Thr Ile Glu

1 5 10

<210> 32

<211> 10

<212> PRT

<213> Chlamydia

<400> 32

Lys Leu Ser Val Asn Ser Leu Ser Gln Thr

1 5 10

<210> 33

<211> 45

<212> PRT

<213> Chlamydia

<400> 33

Val Ile Gly Ser Thr Thr Ala Gly Ser Val Thr Ile Ser Gly Pro Ile

1 5 10 15

Phe Phe Glu Asp Leu Asp Asp Thr Ala Tyr Asp Arg Tyr Asp Trp Leu

20 25 30

Gly Ser Asn Gln Lys Ile Asn Val Leu Lys Leu Gln Leu

35 40 45

<210> 34

<211> 64

<212> PRT

<213> Chlamydia

<400> 34

Val Ile Gly Ser Thr Thr Ala Gly Ser Val Thr Ile Ser Gly Pro Ile

1 5 10 15

Phe Phe Glu Asp Leu Asp Asp Thr Ala Tyr Asp Arg Tyr Asp Trp Leu

20 25 30

Gly Ser Asn Gln Lys Ile Asn Val Leu Lys Leu Gln Leu Gly Thr Lys

35 40 45

Pro Pro Ala Asn Ala Pro Ser Asp Leu Thr Leu Gly Asn Glu Met Pro

50 55 60

[illegible]

```
<210> 36
<211> 458
<212> PRT
<213> Chlamydia
```

Ala Pro Ile Ala Phe Val Ala Asn Val Ala Gly Val Arg Gly Gly Gly
20 25 30

Thr Glu Asp Pro Val Val Ser Phe Ser Arg Asn Thr Ala Val Glu Phe
50 55 60

Val Ala Phe Leu Asn Asn Gly Lys Thr Leu Phe Leu Asn Asn Val Ala
85 90 95

Asn Thr Ser Asn Asn Tyr Gly Asp Gly Gly Ala Ile Phe Cys Lys Asn
115 120 125

Glu Gly Val Val Phe Phe Ser Ser Asn Val Ala Ala Gly Lys Gly Gly
145 150 155 160

28

165	170	175
Phe Leu Arg Asn Ile Ala Asn Asp Gly Gly Ala Ile Tyr Leu Gly Glu		
180	185	190
Ser Gly Glu Leu Ser Leu Ser Ala Asp Tyr Gly Asp Ile Ile Phe Asp		
195	200	205
Gly Asn Leu Lys Arg Thr Ala Lys Glu Asn Ala Ala Asp Val Asn Gly		
210	215	220
Val Thr Val Ser Ser Gln Ala Ile Ser Met Gly Ser Gly Gly Lys Ile		
225	230	235
Thr Thr Leu Arg Ala Lys Ala Gly His Gln Ile Leu Phe Asn Asp Pro		
245	250	255
Ile Glu Met Ala Asn Gly Asn Asn Gln Pro Ala Gln Ser Ser Lys Leu		
260	265	270
Leu Lys Ile Asn Asp Gly Glu Gly Tyr Thr Gly Asp Ile Val Phe Ala		
275	280	285
Asn Gly Ser Ser Thr Leu Tyr Gln Asn Val Thr Ile Glu Gln Gly Arg		
290	295	300
Ile Val Leu Arg Glu Lys Ala Lys Leu Ser Val Asn Ser Leu Ser Gln		
305	310	315
Thr Gly Gly Ser Leu Tyr Met Glu Ala Gly Ser Thr Trp Asp Phe Val		
325	330	335
Thr Pro Gln Pro Pro Gln Gln Pro Pro Ala Ala Asn Gln Leu Ile Thr		
340	345	350
Leu Ser Asn Leu His Leu Ser Leu Ser Ser Leu Leu Ala Asn Asn Ala		
355	360	365
Val Thr Asn Pro Pro Thr Asn Pro Pro Ala Gln Asp Ser His Pro Ala		
370	375	380
Val Ile Gly Ser Thr Thr Ala Gly Ser Val Thr Ile Ser Gly Pro Ile		
385	390	395
Phe Phe Glu Asp Leu Asp Asp Thr Ala Tyr Asp Arg Tyr Asp Trp Leu		
405	410	415
Gly Ser Asn Gln Lys Ile Asn Val Leu Lys Leu Gln Leu Gly Thr Lys		

430

Lys Tyr Gly Tyr Gln Gly Ser Trp Lys Leu
450 455

```
<210> 37
<211> 325
<212> PRT
<213> Chlamydia
```

<400> 37

Leu Lys Ala Thr Trp Thr Lys Thr Gly Tyr Asn Pro Gly Pro Glu Arg
1 5 10 15

Val Ala Ser Leu Val Pro Asn Ser Leu Trp Gly Ser Ile Leu Asp Ile
20 25 30

Arg Ser Ala His Ser Ala Ile Gln Ala Ser Val Asp Gly Arg Ser Tyr
35 40 45

Cys Arg Gly Leu Trp Val Ser Gly Val Ser Asn Phe Phe Tyr His Asp
50 55 60

Arg Asp Ala Leu Gly Gln Gly Tyr Arg Tyr Ile Ser Gly Gly Tyr Ser
65 70 75 80

Leu Gly Ala Asn Ser Tyr Phe Gly Ser Ser Met Phe Gly Leu Ala Phe
85 90 95

Thr Glu Val Phe Gly Arg Ser Lys Asp Tyr Val Val Cys Arg Ser Asn
100 105 110

His His Ala Cys Ile Gly Ser Val Tyr Leu Ser Thr Gln Gln Ala Leu
115 120 125

Cys Gly Ser Tyr Leu Phe Gly Asp Ala Phe Ile Arg Ala Ser Tyr Gly
130 135 140

Phe Gly Asn Gln His Met Lys Thr Ser Tyr Thr Phe Ala Glu Glu Ser
145 150 155 160

Asp Val Arg Trp Asp Asn Asn Cys Leu Ala Gly Glu Ile Gly Ala Gly
165 170 175

Leu Pro Ile Val Ile Thr Pro Ser Lys Leu Tyr Leu Asn Glu Leu Arg
 180 185 190

Pro Phe Val Gln Ala Glu Phe Ser Tyr Ala Asp His Glu Ser Phe Thr
 195 200 205

Glu Glu Gly Asp Gln Ala Arg Ala Phe Lys Ser Gly His Leu Leu Asn
 210 215 220

Leu Ser Val Pro Val Gly Val Lys Phe Asp Arg Cys Ser Ser Thr His
 225 230 235 240

Pro Asn Lys Tyr Ser Phe Met Ala Ala Tyr Ile Cys Asp Ala Tyr Arg
 245 250 255

Thr Ile Ser Gly Thr Glu Thr Thr Leu Leu Ser His Gln Glu Thr Trp
 260 265 270

Thr Thr Asp Ala Phe His Leu Ala Arg His Gly Val Val Val Arg Gly
 275 280 285

Ser Met Tyr Ala Ser Leu Thr Ser Asn Ile Glu Val Tyr Gly His Gly
 290 295 300

Arg Tyr Glu Tyr Arg Asp Ala Ser Arg Gly Tyr Gly Leu Ser Ala Gly
 305 310 315 320

Ser Arg Val Arg Phe
 325

<210> 38

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 38

gggtttggga atcagcacat gaaaacctca tatacatttg c

41

<210> 39

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 39

gcaaatgtat atgaggtttt catgtgctga ttcccaaacc c

41

<210> 40

<211> 55

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 40

aagggcccaa ttacgcagac atatggaaac gtctttccat aagttctttc tttca

55

<210> 41

<211> 80

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 41

aagggcccaa ttacgcagag tctagattat taatgatgat gatgatgatg gaaccggact 60
ctacttctg cactcaaacc 80